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Abstract 
 
Azinomycins A and B are bioactive compounds produced by Streptomyces 
species.  These naturally occurring antibiotics exhibit potent in vitro cytotoxic 
activity, promising in vivo antitumor activity and exert their effect by disruption of 
DNA replication by the formation of interstrand cross-links.  The electrophilic C-10 
and C-21 carbons contained within the aziridine and epoxide moieties are known to 
be responsible for the interstrand cross-links through alkylation of N-7 atoms of 
guanine bases.  The naphthoate moiety (3-methoxy-5-methyl-naphthoate) is believed 
to play a role in the azinomycins’ biological activity through hydrophobic interactions 
in the DNA major groove.  In this study, precursor directed biosynthesis (PDB) has 
been investigated for the production of unnatural azinomycin analogues.  A series of 
naphthoic acid analogues were fed to the azinomycin producing bacteria 
(Streptomyces sahachiroi ATCC 33158).  LCMS analyses revealed that 1-naphthoic 
acid, 4-fluoro-1-naphthoic acid, 4-methyl-1-naphthoic acid and 3-methoxy-1-
naphthoic acid were successfully incorporated into the azinomycin A biosynthesis 
pathway and resulted in the development of novel azinomycin A analogues.  These 
novel products were isolated and purified using preparative HPLC and were 
characterised by diode array detection and electrospray tandem mass spectrometry. 
NMR characterisation and biological studies could not yet be conducted due to the 
low production levels (~100 µg in 500 mL fermentation broth) and the persistence of 
some impurities in these novel azinomycin A analogues.  
In the course of this work, additional metabolites were found in the 
fermentations.  LCMS analysis revealed that a range of naphthoic acids were 
biotransformed into primary amides.  Column chromatography has been carried out 
towards purification of all the produced amides.  As consequence, 1-naphthoic amide 
and 4-fluoro-1-naphthoic amide were successfully purified and characterised by NMR 
and LCMS.  Further amides were so far only characterised by LCMS, as impurities 
hampered NMR analysis.  Antibacterial and antifungal tests were carried out to 
investigate the biological activity of the purified amide.  The results revealed that they 
were inactive against the tested microorganisms. 
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IC50    Half maximal inhibitory concentration 
ISC   Interstrand cross-link 
ISCs   Interstrand cross-links 
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MDP   Maduropeptin 
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CHAPTER 1:  Introduction     
  
1.1 Microbial secondary metabolites  
 
1.1.1 Definition and history of secondary metabolites 
 
Secondary metabolites, also known as natural products (Williams et al., 1989), are 
products of metabolism that are not essential for normal growth, development or 
reproduction of an organism. These substances are cited by many authors as 
molecules that are synthesized by living organisms but are not required for essential 
functions like cell division and metabolism (Carmichael, 1992; George et al., 1993).  
Alternatively, other opinions consider secondary metabolites either as playing a key 
role in fixing beneficial genetic characteristics within the producing organism or as 
having a strong connection with the primary metabolism at molecular and cellular 
levels (Roze et al., 2011).   
 
In comparison to secondary metabolites, primary metabolites (such as nucleic acids, 
carbohydrates, lipids and proteins) are common for all biological organisms and vital 
for their growth and multiplication (Barrios-Gonzales et al., 2005). 
It is well established that many types of living systems (both prokaryotes and 
eukaryotes) are producers of secondary metabolites.  However, the major 
contributions are found within Streptomyces bacteria (Bérdy, 2005). 
Since early times, secondary metabolites were mainly known as plant natural 
products.  Microorganisms, and more specifically their secondary products, were used 
in food conservation and production of wine, bread, cheeses and other fermented milk 
products even before the discovery of the microorganisms.  For example, as a method 
of preservation, yogurt was produced by the acidic fermentation of lactose sugar 
present in the milk (Zourari et al., 1992). 
The first antibiotic secondary metabolite to be isolated and crystalized was a 
mycophenolic acid produced by Penicillium glaucum and published by Gosio in 1896 
(Birkinshaw et al., 1948; Muth et al., 1975; Bérdy, 2005).  The structure of the 
compound is shown in Figure 1.1. 
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Figure 1.1: Structure of mycophenolic acid 
 
The secondary metabolites produced by microbes that show signs of either 
antimicrobial (antibacterial, antifungal, antiprotozoal), antitumor and/or antiviral 
activities, used to be named antibiotics (Bérdy, 2005).  Antibiotics were also defined 
as “…chemical compounds produced by actinomycetes, fungi, or bacteria that 
interfere with some essential bacterial structure or process with no effects on the 
eukaryotic host having the infectious agents” (Hiroshi and Ryoichi, 2006).  These 
classical definitions of antibiotics were extended by Bérdy, to include all secondary 
metabolites controlling the growth routes, duplication processes, and affecting the life 
cycle of prokaryotic and eukaryotic cells at the biomolecular level, at low 
concentration. 
 
1.1.2 Streptomycetes secondary metabolites 
 
Streptomyces is a genus of filamentous Gram-positive bacteria occurring naturally in 
soil and also present in aquatic habitats (Moran et al., 1995).  Members of the 
streptomyces genus are known to possess two growth phases during their 
developmental cycle: a vegetative and a reproductive phase (Manteca et al., 2005).  
During the first stage and once the growth conditions are favourable (availability of 
nutrients for example), a streptomyces spore germinates into a germ tube that 
elongates into a branched vegetative mycelium.  Then, and probably due to nutrient 
reduction, aerial branches emerge from the soil and start growing to form aerial 
hyphae.  The second phase of the growth is marked by the formation of compartments 
in the branches of the aerial hyphae resulting in the development of the prespore 
segments that are transformed subsequently into mature spores (Figure 1.2) 
(Hopwood, 1999 review). 
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Figure 1.2: Schematic representation of the developmental life cycle of Streptomyces 
coelicolor (Edited from original source: Osmialowska et al., 2006). (A): vegetative 
phase. A spore from aerial hyphae germinates into a germ tube that grows into 
vegetative hyphae. (B): Reproductive phase. Development of aerial hyphae (from the 
vegetative one) and formation of a spore compartments which differentiate into 
mature spores. 
 
Streptomyces species have been and continue to be an important source of bioactive 
natural products.  Members of this group produce more than 7,600 known active 
metabolites.  That represents about 33% of all known bioactive microbial natural 
products (Olano et al., 2009).  These natural products have various biological 
activities such as antibiotics (tetracyclines, cephalosporins, aminoglycosides, 
macrolides for example) (Bérdy, 2005), anticancer drugs (such as anthracyclines: 
aclarubicin, daunomycin, adriamycin and doxorubicin for example) (Olano et al., 
2009) or as immunosuppressive agents (rapamycin for example) (Gummert et al., 
1999) (Figure 1.3). 
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Figure 1.3: Examples of medicinally important natural products. 
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1.1.3 Streptomycetes secondary metabolites containing naphthoic 
acid moiety 
 
The antitumor natural products azinomoycins A 3 and B 4 and some members of the 
enediyne natural products such as neocarzinostatin (NCS) 5, kedarcidin 6, and 
N1999A2 7 are examples of secondary metabolites containing naphthoic acid (NA) 
moiety (Figure 1.4A).   
A detailed discussion about the biological activity, mode of action and biosynthesis of 
azinomycins A 3 and B 4 is outlined in section 1.6.  As to the role of the 
azinomycins’ NA component in the inhibition of DNA synthesis, it was found (Zang 
and Gates, 2000; Coleman et al., 2002) that its intercalates into DNA and hence 
positioning the azinomycins into the major groove enabling the formation of 
interstrand cross-links (ISCs) which, are accompanied by alkylation of DNA 
(Terawaki and Greenberg, 1966a; Lown and Majumdar, 1977).  As consequence, 
DNA synthesis is inhibited.  
 
The enediyne natural products NCS 5, kedarcidin 6, and N1999A2 7 belong to the 
nine-membered enediyne family of antitumor antibiotics, which are of great interest 
as potent anticancer agents. They possess a reactive enediyne core (in black in Figure 
1.4) that is able to induce DNA damage and eventually cell death.  Enediynes are 
capable of undergoing Bergman (or Myers-Saito) cyclization to form 1,4-benzenoid 
diradicals, which abstract hydrogen atoms from the sugar backbone of the DNA 
molecule resulting in single and double strand lesions (Shen et al., 2003).  This high 
reactivity against DNA makes enediynes very toxic, limiting their use in clinical 
applications.  However, their potent activity may be beneficial if used as modified 
enediynes to target the DNA of cancerous tumors specifically.  For example, the 
conjugation of NCS with poly(styrene-co-maleic acid) (SMA) has significantly 
reduced the toxicity of NCS 5 and as result, the SMANCS derivative has been used to 
treat heptoma in Japan since 1994 (Galm et al., 2005).  The enediynes compounds 5 
and 6 are members of the 9-membered enediyne chromophore natural products also 
known as chromoproteins as they are non-covalently associated with an apo-protein 
(N1999A2 7 lacks the apo-protein).  The apo-protein is known to play a key role in 
protecting, carrying and delivering the biologically active enediyne chromophore to 
its DNA target (Shen et al., 2003; Galm et al., 2005; Luo et al., 2008; Lohman et al., 
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2013).  A brief discussion regarding the biosynthesis of NCS 5 and kedarcidin 6 is 
outlined in section 1.3.2.  
 
The elucidation of NCS chromophore 5 was established in 1985 (Edo et al., 1985) and 
was initially isolated from the culture filtrate of Streptomyces carzinostaticus by 
Ishida and co-workers in 1965 (Ishida et al., 1965).  Structurally, NCS chromophore 5 
is characterised by a nine membered enediyne core (black), a deoxyaminosugare 
(green), a fucosamine fragment (red) and a NA moiety (blue).  The latter plays a 
significant role in the action of NCS 5 bioactivity.  Indeed, NA moiety is an important 
element in binding the NCS 5 chromophore to its apoprotein NcsA.  Furthermore, it 
aids in positioning the chromophore 5 into the minor groove by intercalating into 
DNA (Luo et al., 2008). 
 
The chromoprotein antitumor antibiotic kedarcidin 6 was isolated from broth filtrate 
of Streptoalloteichus sp. ATCC 5365 (formerly actinomycete L585-6) in 1992 by Leet 
and co-workers and its structure was elucidated on the basis of extensive 
spectroscopic analysis and chemical degradation (Leet et al., 1992).  The original 
structural proposal was revised firstly in 1997 by Hirama and co-workers (Kawata et 
al., 1997) and secondly in 2007 by Myers and co-workers (Ren et al., 2007) with the 
final structure shown in Figure 1.4A (Lohman et al., 2013).  In addition to the 
enediyne core (black), kedarcidin 6 possesses two peripheral moieties, a (R)-2-aza-3-
chloro--tyrosine (red) and an iso-propoxy-bearing 2-naphthonate moiety (blue), as 
well as two deoxysugars (green).  In a manner similar to NCS 5, the NA moiety of 
kedarcidin 6 plays significant role in the biological activity by intercalating into DNA 
and therefore placing the chromophore 6 into the minor groove (Luo et al., 2008).   
    
The nonprotein enediyne N1999A2 (NA2) 7, isolated (in a stable form) from a culture 
supernatant of Streptomyces sp. AJ9493 (Ando et al., 1998), possesses a naphthoic 
acid moiety (blue) and an enediyne core (black) (Figure 1.4A).  The chemical 
structure of NA2 7 is analogous to the NCS chromophore 5 but differ in that 
compound 7 lacks the C10 amino-sugar residue and C13-C14 carbonate.  In a manner 
similar to NCS 5, the naphthoic acid moiety of NA2 7 binds into DNA through 
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intercalative mechanism and therefore aids in placing the chromophore 7 in the minor 
groove (Luo et al., 2008). 
 
 
 
Figure 1.4: Examples of naphthoic acid moiety (highlighted in blue) containing 
natural products.  (A): Azinomycin A 3, azinomycin B 4, neocarzinostatin 5, 
N1999A2 7 and kedarcidin 6.  (B): Structure of the NCS enediyne form and the 
proposed aromatised form (Galm et al., 2005).  
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1.2 DNA and DNA binding secondary metabolites 
  
As a genetic material of all cellular organisms, deoxyribonucleic acid (DNA) provides 
the chemical basis for storing and encoding genetic information (Kennard, 1993). The 
DNA double helix was identified by Watson and Crick in 1953 as the fundamental 
structure for DNA (Russel, 2002). 
The bases in DNA are monocyclic or bicyclic structures and are referred to as 
pyrimidines (cytosine and thymine) or purines (guanine and adenine) respectively. 
DNA consists of two right handed helical chains running in opposite directions to 
form a double helix (Figure 1.5A).  Each strand is a series of nucleotides, and each 
nucleotide is composed of a sugar-phosphate compound attached to one of four 
nitrogen-containing bases.  The sugar-phosphate compounds link together to form the 
backbone of the strand.  The base pairs are responsible for holding two strands 
together and it is the sequence of bases in DNA that encodes the genetic information 
of the molecule. 
There are three helical forms of DNA (A, B and Z) that vary with respect to a range of 
constraints that depict their three-dimensional structure.  B-form DNA is the most 
biologically relevant as it persists under physiological conditions. 
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Figure 1.5: (A): Double strand DNA structure showing the presence of minor and 
major grooves (Picture taken from Brenno and Alexandre, 2009).  (B): DNA base-
paring: cytosine pairs with guanine and adenine pairs with thymine (original source: 
Wojciechowski and Leumann, 2011).  
  
The space across the helix between each of the deoxyribose-base glycosidic bonds is 
about 10.8 Å and a purine-pyrimidine base pair fits perfectly within this space, 
whereas two pyrimidine bases would be too far away from each other to allow 
hydrogen bonding.  The rotation angle made by the base pairs with respect to each 
adjacent pair is 36
o
 resulting in exact 10 base pairs per helical turn.  Furthermore, the 
distance separating two base pair is precisely 3.4 Å (Reddy et al., 2001).  As can also 
be seen from Figure 1.5A, two obvious grooves arise from this structure; the larger is 
known as the major groove, the narrower as the minor groove.  Within the major 
groove, a large portion of the base is exposed and this is where most protein-DNA 
interactions occur whereas small molecules including many antibiotics, mostly bind in 
the minor groove, in many cases because they have complementary shape to it.  
Binding can be reversible, e.g. non-covalent minor groove binders netropsin and 
distamycin, or irreversible, e.g. covalent minor groove binders including anthramycin. 
Some ligands interact with specific bases, e.g. anthramycin interacts with guanine in 
the minor groove and azinomycin B reacts also with guanine bases but in the DNA 
major groove.  This is important because they can be used in areas where there are 
known to be lots of guanine bases.  As it is normally vacant, the minor groove 
represents a susceptible site of attack by anthramycin (Reddy et al., 2001) and the 
major groove an ideal alkylation site for azinomycins (Armstrong et al., 1992).  
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1.3 Polyketide natural products 
 
1.3.1 Introduction to polyketides 
 
Polyketides (PKs) represent a large class of structurally diverse and complex natural 
products, found in microbes and plants (Minow et al., 2007).  Many clinically 
important drugs such as radicicol, rifamycin and lovastatin (Figure 1.6) are of 
polyketide origin. 
 
 
 
Figure 1.6: Polyketide structures. 
 
It has been more than 100 years since J. N. Collie, an organic chemist, first introduced 
the term polyketide (PK) following the discovery of aromatic compounds produced 
while conducting organic synthesis studies on pyrones (Collie and Myers, 1893).  In 
1907, Collie rightly proposed that a triketone 8 was an intermediate molecule in the 
production of the aromatic compound, orcinol 9 following the treatment of pyrone 10 
with water and strong alkali (Figure 1.7) (Collie, 1907).  He also proposed that 
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polyketone compounds are intermediate metabolites formed by living cells during the 
production of many natural phenolic compounds.  Collie also noted that the suggested 
polyketone intermediates could be hypothetically considered as polymers of ketenes 
11.  Hence, he coined the terms ketides and polyketides.  Sadly, his ideas and the 
polyketide field were not developed for more than half a century (Staunton and 
Weissman, 2001). 
 
 
 
Figure 1.7: Synthesis of orcinol 9 from dehydroacetic acid 10. 
 
In the mid-1950s, Birch extended Collie’s idea and suggested that the proposed 
polyketones might arise in living cells from acetate units by repeated condensation 
reactions (Birch et al., 1955).  At that time the isotope tracer technique including 
carbon-14 was well established which enabled Birch to test his acetate hypothesis.  
Based on series of experiments involving the feeding of [1-
14
C]-acetate 12 to the 
fungus Penicillium patulum that produces 6-methylsalicylic acid (6-MSA) 13, he was 
able to confirm his biosynthetic proposal as described in Figure 1.8.  
 
 
 
Figure 1.8: Feeding experiment showing that 6-MSA 13 is derived from four [1-
14
C]-
acetates. 
 
The search in the field of natural products has thrived since the decade of the 1950s 
and as a consequence, there has been a sharp increase in the number and diversity of 
PK structures (Staunton and Weissman, 2001; Hertweck, 2009).  Some highly 
renowned aromatic and aliphatic compounds are illustrated in Figure 1.6.  
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Birch had benefited from the advanced knowledge and carried out more acetate 
feeding studies to many organisms known to produce secondary metabolites.  The 
results of these experiments established that both aromatic and non-aromatic 
compounds were biosynthetised from acetate units.  Hence, Birch was able to produce 
a unified hypothesis known as "Collie-Birch polyketide hypothesis" (Staunton and 
Weissman, 2001).  Birch’s findings were based on mechanistic reasoning and on the 
fact that fatty acids were well known to be derived from acetates (Bentley and 
Bennett, 1999).  The relationship between fatty acid biosynthesis and that of PKs 
continues to influence thinking in the PK field to this day.  Therefore it is appropriate 
to give a brief illustration of the fundamental pathways employed in fatty acid 
biosynthesis.  Figure 1.9 elucidates detailed steps used in the fatty acid biosynthesis.   
37 
 
 
   
Figure 1.9: Fatty acid biosynthesis.  (A): Synthesis of malonyl-CoA by the action of 
acetyl-CoA carboxylase.  Biotin is a required as cofactor.  (B): Detailed steps of fatty 
acid biosynthesis.  
 
During the first step of fatty acid synthesis (Figure 1.9B), the acetyl group (starter 
unit) gets transferred from CoA to ACP by acetyl CoA-ACP transacylase (acetyl 
transacylase).  The acetyl (acyl) group next gets transferred to the KS arm of FAS.  
Then the starter substrate bound to the KS active-site cysteine is condensed with the 
chain extender substrate (malonyl moiety), which has been transferred to the 
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phosphopantetheine thiol attached to the serine hydroxyl group on the ACP (the 
phosphopantetheinylation of ACP is illustrated in Figure 1.10).  The resulting -
ketoacyl moiety produced is fully processed by stepwise ketoreductase (KR)-, 
dehydratase (DH)-, and enoyl reductase (ER)-catalysed reactions prior to the next 
elongation step.  Repeated cycles are carried out by the same enzymes until the 
correct length chain has been formed.  At that stage, the fatty acid is cleaved from the 
ACP by a thioesterase (TE) enzyme.  
 
 
 
Figure 1.10: Phosphopantetheinylation of the acyl carrier protein (ACP). 
  
The period from the 1950s through the 1980s saw few biochemical studies made in 
the area of polyketides since the main emphasis at that time was the development of 
new synthetic routes in organic chemistry (Smith and Tsai, 2007).  The development 
of nuclear magnetic resonance (NMR) and mass spectrometry (MS) during the 1960s, 
as powerful new spectroscopic techniques, enabled the chemists and biochemists to 
accomplish several structural and elucidation studies of complex compounds within 
relatively short period of time (weeks or even days) rather than years as it used to be 
before (Staunton and Weissman, 2001).  As consequence, several spectacular total 
syntheses of polyketides such as erythromycin 14 (Figure 1.3), toralactone and 
rifamycin (Figure 1.6) were completed.  The period did see also the first successful 
isolation and characterization of the 6-methylsalicylic acid 13 synthase from 
Penicillium patulum (Smith and Tsai, 2007). 
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During the 1980s and with the advancement of genetic and molecular biology 
techniques, the way was opened towards the discovery of genes and their equivalent 
proteins involved in polyketide biosynthesis (Staunton and Weissman, 2001).  The 
Hopwood group was a pioneer to study the genetics of Streptomyces coelicolor, a 
bacterium known to biosynthesise the aromatic PK actinorhodin 15 (Figure 1.11).  
Over a number of years of carefully designed experiments and thorough scientific 
research, the authors were able to sequence the genes coding for the enzymes of 
actinorhodin biosynthesis and established the primary sequence of the equivalent 
proteins.  Further comparison studies between the discovered proteins and various 
known protein sequences, showed a strong homology with numerous enzymes of fatty 
acid synthases.  The similarities were shown mainly at the active sites of enzymes 
such as KS, ACP and KR.  The actinorhodin PKS was found to be type II dissociable 
system similar to FAS of bacteria.  The scientific community was motivated by the 
important achievement in the genetic field and since then a wealth of new PKS 
systems were discovered (Malpartida and Hopwood, 1984; Hopwood and Sherman, 
1990; Hopwood, 1997).   
    
 
 
Figure 1.11: Structure of antibiotic actinorhodin produced by S. coelicolor. 
 
1.3.2 Polyketide biosynthesis   
 
Polyketides (PKs) are made by enzymes called polyketide synthases (PKSs).  PKSs 
operate in a similar fashion to fatty acid synthases (FASs):  they share common 
chemical mechanisms involved in chain extension and are alike in building a carbon 
backbone from simple acyl precursors, such as acetyl and malonyl units.  Both PKSs 
and FASs assemble their products (PKs and fatty acids respectively) by successive 
rounds of decarboxylative Claisen condensation between an acyl thioester and an -
carboxythioester (Figure 1.12).  However, PKSs diverge from FASs in that PKSs use 
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optional reductive steps to process the β-keto group, thus giving rise to a more 
complex pattern of functionalities and that FASs catalyse a full reductive cycle after 
each elongation cycle.  Additional factors such as the broad spectrum of starting 
biosynthetic precursors (e.g. acetyl-, ethyl-, propionyl-, and butyryl-CoA) and the 
chain length control further expand the variability of the chemical structure of PK 
natural products compared to the relative simple structure of fatty acids.  An 
additional aspect that set the PK chain apart from simple fatty acid chain is that the 
resulting polyketide, which is cleaved from the PKS system, can be subjected to 
tailoring modification reactions (Hertweck, 2009). 
 
 
 
Figure 1.12: Generic reaction scheme for the biosynthesis of both fatty acids and 
polyketides (PKs).  In fatty acid biosynthesis the β-ketoacyl unit produced after each 
chain elongation is completely reduced to a saturated carbon prior to the next 
condensation reaction.  In PK biosynthesis, the reductive steps of the β-ketoacyl 
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moiety are optional: they can be partly or fully omitted before the next elongation 
cycle. 
 
The biosynthesis of polyketides is initiated by decarboxylative Claisen condensation 
between an activated simple acyl starter unit attached to the ketosynthase (KS) active 
site with an extender unit, which is initially derivatised as thioester using active thiol 
group at the active site of acyl carrier protein (ACP).  Before any condensation step, 
the ACP domain is first posttranslationally modified at the active site serine by 
attaching phosphopantetheine to the hydroxyl in fashion similar to fatty acids 
synthesis (Figure 1.10) (Fischbach and Walsh, 2006).  Following each chain 
extension of the polyketide backbone, the β-ketoacyl thioester intermediate may retain 
its β-CO group or can be selectively reduced by ketoreductase (KR), dehydratase 
(DH), and enoyl reductase (ER) tailoring domains.  The elongation cycles are 
repeated until the defined PK chain lengths are obtained, and the thioester-bound 
products are cleaved from PKS systems.  Further post-PKS modifications such as 
cyclisation, methylation and glycosidation are very common (Bentley and Bennett, 
1999; Hertweck, 2009).  
  
By analogy to FASs, PKSs can be classified into three different classes (type I, type II 
and type III) based on their architectures and catalytic mechanisms, (Hopwood, 1997; 
Staunton and Weissman, 2001; Hertweck, 2009): type I PKSs consist of one or more 
large multifunctional proteins containing covalently linked function domains which 
are organised into modules.  Based on the number of elongation cycles catalysed by 
KS domain, type I PKSs can be further subdivided into two groups, modular (non-
iterative) and iterative systems (these particular groups of PKSs will be detailed in the 
next paragraphs).   
 
Type II PKS systems are composed of individual enzymes that carry a single set of 
iteratively acting activities.  These protein systems are responsible for the biosynthesis 
of numerous bacterial aromatic polyketides such as actinorhodin 15 (Figure 1.11), 
tetracenomycin 16 and doxorubicin 17 (Figure 1.13).  The minimal PKS needed for 
chain synthesis consists of two KS-like enzymes (KS and KS) and an ACP to 
anchor the growing PK chain.  Additional proteins such as cyclases, aromatases and 
ketoreductases are required for a controlled cyclisation and aromatisation.  Finally, 
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the polyphenols are tailored by oxygenases, glycosyl and methyl transferases (Flores-
Sanchez and Verpoorte, 2009).   
  
 
 
Figure 1.13: Structure of the aromatic polyketides tetracenomycin C 16 and 
doxorubicin 17. 
 
Type III PKSs are simple homodimers of ketosynthases (KSs) and act in an iterative 
manner.  Their single active site in each monomer is used to carry out all 
decarboxylation, condensation, cyclisation and aromatisation reactions.  Additional 
enzymes such as oxidoreductases, cyclases or glycosyl-transferases often modify the 
complete polyketide structure to generate the mature, biologically active polyketide 
natural product.  In contrast to type I and type II PKSs that utilise substrates bound to 
an ACP, type III PKSs act on CoA thioesters directly.  Despite their structural 
simplicity, type III PKSs produce a wide array of compounds such as chalcones, 
pyrones, stilbenes and resorcinolic lipids.  Type III PKSs have been found in bacteria 
and fungi, as well as plants (Hertweck, 2009). 
 
In modular type I PKS systems, which are found mainly in bacteria and recently in 
protozoans (Zhang et al., 2013), each catalytic domain catalyses a single chemical 
reaction and each module is responsible for the addition and modification of a single 
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building block to the growing polyketide chain that remains covalently attached to an 
acyl carrier protein domain.  The modular system is best exemplified by 6-
Deoxyerythronolide B synthase (6-DEBS) that catalyse the assembly of 6-
deoxyerythronolide B 18 (6-DEB), the macrocyclic core of macrolide antibiotic 
erythromycin A 14 produced by Saccharopolyspora erythraea (Donadio and Katz, 
1992) (Figure 1.14).  6-DEBS consists of three giant proteins designated DEBS 1, 
DEBS 2 and DEBS 3, organised into six catalytic modules.  Each module harbours at 
least a set of 3 core domains (ketosynthase (KS), acyl transferase (AT), and acyl 
carrier protein (ACP)), satisfying the minimal requirement for each chain elongation 
(Khosla et al., 2007).  All six modules harbour the ketoreductase domain for the 
subsequent reduction process of the newly generated -ketone.  Only module 4 carries 
dehydratase (DH) and enoyl-reductase domains that further modify the product of KR 
domain.  At the front of DEBS 1 is an additional loading didomain (Load) that primes 
the KS of module 1 with propionyl-CoA.  At the end of module 6, there is a 
thioesterase (TE) domain (denoted End in Figure 1.14) and responsible for the release 
and cyclisation of the completed PK chain.   
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Figure 1.14: Modular organisation of the 6-deoxyerythronolide B synthase (DEBS) 
and putative intermediates.   
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In iterative type I PKSs, the same module repeatedly catalyses chain elongation and 
modification (Staunton and Weissman, 2001).  Iterative type I PKSs such as 6-
methylsalicylic acid 13 (6-MSA) synthase and lovastatin 19 (Figure 1.6) synthase 
were initially known to be found exclusively in fungi (Staunton and Weissman, 2001; 
Chan et al., 2009) until recent discovery of these enzymes in bacteria as well (Zhang 
et al., 2013).  Figure 1.15 illustrates the involvement of the iterative type I PKS in the 
biosynthesis of 6-MSA 13.  Indeed this PKS does not contain a distinct module for 
each round of chain extension; the single module of 6-methylsalicylic acid synthase is 
used iteratively. 
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Figure 1.15: The biosynthetic pathway for 6-methylsalicylic acid 13 (6-MSA).  The 
polyketide 13 is assembled from one acetyl-CoA entity and three units of malonyl-
CoA catalysed by 6-MSA synthase.  
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Bacterial iterative type I PKSs catalyse relatively simple (mono- or bicyclic) aromatic 
polyketide products (Figures 1.4A and 1.16) compared to the complex and 
multicyclic aromatic PKs produced by bacterial iterative type II PKSs (actinorhodin 
15 and tetracenomycin 16 for example) (Zhang et al., 2013).  The first clone of an 
iterative type I PKS for bacterial PK biosynthesis was achieved by Bechthold and co-
workers in 1997 (Gaisser et al., 1997).  The authors cloned successfully the 
avilamycin 20 PKS (AviM) that catalyses the biosynthesis of the orsellinic acid 21 
moiety (Figure 1.17) produced by Streptomyces viridochromogens Tü57. 
 
 
 
Figure 1.16: Example of bacterial natural products containing simple aromatic 
polyketide moieties (highlighted in red) catalysed by iterative type I PKSs.     
 
Five years later, a second successful clone of a bacterial iterative type I PKS was 
achieved by Thorson and co-workers (Ahlert et al., 2002).  This PKS (CalO5) is 
responsible for the biosynthesis of the orsellinic acid 21 moiety of calicheamicin 22 
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compound.  Amazingly, CalO5 and AviM PKSs share high sequence homology and 
exhibit identical domain organisation (KS, AT, DH and ACP). It is worth to mention 
that both PKSs completely omit the KR function. 
 
 
 
Figure 1.17: Biosynthesis of orsellinic acid 21.  (A): Identical domain organisation of 
bacterial aromatic iterative type I PKSs AviM and CalO5.  KS, -ketoacyl synthase; 
AT, acyl transferase; DH, dehydratase; ACP, acyl carrier protein. (B): Biosynthesis of 
21 catalysed by AviM or CalO5. 
 
In 2005, Shen and co-workers reported the cloning and sequencing of the NCS 5 
biosynthetic gene cluster from Streptomyces carzinostaticus ATCC15944 (Liu et al., 
2005).  The authors revealed the identification of two distinct type I PKSs, NcsE and 
NcsB (and other tailoring enzymes) catalysing the biosynthesis of the enediyne core 
and the naphthoic acid entity respectively.  In addition, it was proposed that the deoxy 
aminosugar moiety is likely to be derived from D-mannose-1-phosphate.  Based on 
mechanistic analogy and sequence homology with recently cloned and characterised 
enediyne PKSs, C-1027 (Liu et al., 2002) and CalO5 (Ahlert et al., 2002), Shen and 
co-workers proposed that NcsE catalyses the formation of the nascent linear PK 
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intermediate from one acetyl CoA and seven malonyl CoAs in an iterative process.  
Subsequently and upon other enzyme activities (NcsE1-E11 and epoxide hydrolases 
F1 and F2), the linear polyunsaturated chain is desaturated and cyclased to form the 
enediyne core (Figure 1.18D).  On the basis of genetic analysis, It was also proposed 
that the biosynthesis and the incorporation of the naphthoic acid moiety into the 
enediyne core of 5 is catalysed by the iterative type I PKS NcsB and four other 
tailoring enzymes NcsB1, NcsB2, NcsB3 and NcsB4 (Figure 1.18A-C).  The 
biosynthetic steps towards the napthoic acid moiety were predicted (Cooke et al., 
2007; Luo et al., 2008) as follow: First, NcsB catalyses the condensation of one 
acetyl-CoA with 5 malonyl-CoA units to form 2-hydroxy-5-methyl-1-naphthoic acid 
23  as free intermediate, followed by the hydroxylation of the naphthoic acid 23 at 
position C7.  The hydroxylation step is catalysed by the cytochrome P-450 
hydroxylase NcsB3 generating the 2,7-dihydroxy-5-methyl-1-naphthoic acid 24 
product.  The generated acid 24 is subsequently methylated at C7 hydroxy group by 
O-methyltransferase NcsB1 to afford 2-hydroxy-7-methoxy-5-methyl-1-naphthoic 
acid 25.  Then the ATP-dependent CoA ligase (NcsB2) catalyses the activation of 25 
into 26a via the acyl-AMP 26b as an intermediate.  This later reaction was 
demonstrated in vitro by liu et al. (2005) and Cooke et al. (2007).  As final step, the 
ester 26a is incorporated into NCS 5 by the NcsB4 acyltransferase.     
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Figure 1.18: Proposed biosynthetic pathway for NCS chromophore 5 (Liu et al., 
2005; Luo et al., 2008).  (A): Genes encoding the enzymes NcsB, NcsB1, NcsB2, 
NcsB3 and NcsB4 for the biosynthesis and the incorporation of the naphthoic acid 
moiety 25 into 5. (B): Domain organizations of NcsB.  KS, ketoacylsynthase; AT, 
acyltransferase; DH, dehydratase; KR, ketoreductase; ACP, acyl carrier protein. (C): 
The biosynthesis of 26 and its incorporation into 5. (D): Biosynthesis of the enediyne 
core.    
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In 2013, the biosynthetic gene cluster of kedarcidin 6 (ked) was cloned from 
Streptoalloteichus sp. ATCC 53650 and sequenced (Lohman et al., 2013).  Based on 
bioinformatics analysis and comparative studies between ked gene cluster and the 
formerly cloned and characterised gene clusters of some of the 9- and 10-membered 
enediynes such as NCS 5 (Liu et al., 2005) and calicheamicin 22 (Ahlert et al., 2002), 
the authors revealed the identification of kedE, a gene in the cluster encoding for 
enediyne PKS and others (kedE1-kedE11, kedM, kedS, kedL, kedJ, kedD2, kedF) 
encoding accessory enzymes for enediyne core biosynthesis (Figure 1.19C).  The 
identity of this cloned gene cluster was partly corroborated by the co-expression of 
kedEkedE10 in E. coli leading to the formation of a signature heptaene product 
previously implicated in enediyne core biosynthesis (Liu et al., 2002; Ahlert et al., 
2002; Liu et al., 2005). 
 
The disclosure of genes encoding for 2-aza--tyrosine moiety were sort of mystery for 
the authors as no biosynthetic work on 2-aza--tyrosine had been reported yet.  
Fortunately and upon comparative studies between the ked gene cluster with the 
biosynthetic clusters of enediynes C-1027 and maduropeptin (MDP), the authors 
revealed the presence of seven conserved genes (kedY, kedY1 - kedY5 and kedE6).  
Inspired by these findings, Shen and co-workers proposed a biosynthetic pathway for 
(R)-2-aza-3-chloro--tyrosine initiating from 2-aza-L-tyrosine in a manner similar to 
the biosynthesis pathway of L-tyrosine derived components in C-1027 and MDP 
(Figure 1.19A).   
 
Insights into the biosynthesis of the iso-propoxy-bearing 2-naphthoic acid moiety 
were also based on comparative analysis between the ked cluster and the enediynes 
NCS 5 and MDP which naphthoate and benzoate moieties are biosynthesised by the 
iterative type I PKSs, NcsB (Liu et al., 2005) and MdpB (Van Lanen et al., 2007), 
respectively.  A close examination of ked cluster revealed the presence of genes 
encoding for iterative type I PKS with a similar domain organisation as NcsB and 
MdpB.  As consequence, Shen and co-workers proposed a role of type I PKS in the 
biosynthesis of the 2-naphthonate moiety.  However, this proposal is awaiting 
validation as all experimental attempts carried by the authors to establish the exact 
biosynthetic origin of 2-naphthoic acid moiety failed.   
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The comparative analysis of ked cluster to NCS 5 and MDP also unveiled the 
identification of five genes, denoted KedN1-N5 and displaying high sequence 
homology with enzymes responsible for the biosynthesis of 1-naphthoic acid moiety 
in NCS 5.  These findings led the authors to propose the intermediacy of 3,6,8-
trihydroxy-2-naphthoic 27 acid in kedarcidin biosynthesis (Figure 1.19B). 
The biosynthetic steps towards the iso-propoxy-bearing 2-naphthoic acid moiety were 
proposed as illustrated in Figure 1.19B.  The compound 27 is first hydroxylated at 
position C7 by the cytochrome P-450 monoxygenase KedN3 generating compound 
28.  Catalysed by O-methyltransferase KedN1, the acid 28 is then triply O-methylated 
to produce compound 29.  In order to furnish the isopropoxy group, Shen and co-
workers proposed double C-methylation of 29 by the radical S-Adenosyl methionine 
(SAM) methyltransferase KedN5 producing 3-hydroxy-7,8-dimethoxy-6-isopropoxy-
2-naphthoic acid 30.  Lastly, the acid 30 is activated by KedN2 as a naphthonyl-CoA 
31 and joined to the enediyne core via an amide linkage to the (R)-2-aza-3-chloro--
tyrosine entity by the acyltransferase KedN4. 
 
In regard to the biosynthesis of the two deoxysugars and their incorporation, Shen and 
co-workers proposed a D-glucose-1-phosphate as a common precursor and that both 
finally modified sugars are coupled to the enediyne core by two glycosyltransferases 
denoted KedS6 and KedS10. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
 
 
Figure 1.19: The kedarcidin chromophore 6 biosynthetic pathway (Lohman et al., 
2013).  (A): Biosynthetic pathway of (R)- 2-aza--tyrosine moiety from 2-aza-L-
phenylalanine.  (B):  Biosynthetic pathway of naphthoic acid 30 from 3,6,8-
trihydroxy-2-naphthoic 27 (C): Acetate origin of the enediyne core and its 
incorporation (in addition to the other moieties) into the chromophore 6. 
 
1.4 Nonribosomal peptide natural products 
 
1.4.1 Introduction  
 
Nonribosomal peptides (NRPs) represent a large family of structurally diverse natural 
products produced in the secondary metabolism of microorganisms such as bacteria 
and fungi (Fischbach and Walsh, 2006; Strieker et al., 2010).  A vast majority of these 
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natural products exhibit important biological activities, such as antibiotics penicillin 
(Ozcengiz et al., 2013), immunosuppressive agent cyclosporine (Shu, 1998) and 
antitumor agent bleomycin (Glam et al., 2005) (Figure 1.3).  
  
1.4.2 Biosynthesis 
 
NRPs are biosynthesised by large multidomain enzymes, the nonribosomal peptide 
synthetases (NRPSs), which link many simple amino acids (both proteinogenic and 
non-proteinogenic) building blocks by a cascade of condensation reactions (Fischbach 
and Walsh, 2006).  NRPSs are organised into modules and each module catalyses one 
round of polypeptide chain elongation and associated functional group modifications. 
NRPSs could also function iteratively by using more than one module at a time during 
chain elongation (Fickers, 2012).  A typical NRPS module consists of a least three 
core domains (C-A-PCP) catalysing a specific reaction for the incorporation of a 
monomer.  The adenylation domain (A) selects the amino acid and activates it, by 
ATP-hydrolysis, as amino acyl adenylate.  The activated amino acid is then 
transferred to the peptidyl carrier protein domain (PCP) (also known as a thiolation 
domain (T)) where it is covalently tethered to its 4-phosphopantetheine (4-PP) 
cofactor as thioester.  The transfer of this cofactor to the conserved serine residue of 
PCP is catalysed by dedicated phosphopantetheinyl transferases (Fischbach and 
Walsh, 2006) (Figure 1.20).  
  
 
 
Figure 1.20: Postranslational modification of PCP domains by phosphopantetheinyl 
transferases. 
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The condensation domain (C) catalyses the formation of the peptide bond between the 
activated amino acids from two adjacent modules.  A sketch of the fundamental 
activities of C-A-PCP core domains is illustrated in Figure 1.21.    
 
 
 
Figure 1.21: Core domains of NRPSs and their basic enzymatic reactions:  (A): 
Recognition and activation of amino acid by the adenylation domain (A1).  (B): 
Transfer of the aminoacyl adenylate to the PCP domain where it is covalently tethered 
to its 4-phosphopantetheine (4-PP) cofactor as thioester.  (C): An amide bond-
forming condensation reaction between amino acyl substrates bound to PCPs of 
adjacent modules: the C domain catalyses the nucleophilic attack of the amine of the 
acceptor substrate onto the electrophilic thioester of the donor substrate.  
 
Besides the core domains, each NRPS contains tailoring domains and two additional 
modules dedicated for chain-initiation and termination.  The tailoring domains are 
supplementing the core domains and are involved in the diversification of the growing 
peptidyl chain by catalysing useful chemical modifications.  For example, the 
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transformation of the thiazoline ring into thiazole during bleomycin biosynthesis is 
catalysed by an Oxidase (Ox) domain.  Epimerase (E) domain alters the 
stereochemistry of  positions of aminoacyl groups.  The initiation module is a two-
domain A-C module involved in the activation and incorporation of the first amino-
acid of the NRP.  The most common termination domain in the last NRPS module is a 
thioesterase (TE) catalysing the release of the nascent aminoacyl chain (from the final 
PCP) by direct nucleophilic cleavage of the thioester.  The product can then be 
released from the assembly line by two different mechanisms (Fischbach and Walsh, 
2006): intermolecular hydrolysis as in vancomycin biosynthesis and intramolecular 
macrocyclisation affording macrolactones as in the biosynthesis of the core ring of 
rapamycin.  In some PKS/NRPS hybrids, the TE domain of the final module is 
replaced by a reduction domain (R) as in azinomycin B biosynthesis (Zhao et al., 
2008).  
 
1.5 Similarities and differences between PKSs and NRPSs  
 
Although NRPSs and PKSs catalyse two distinct classes of natural products (NRPs 
and PKs respectively), striking structural and catalytic similarities exist between 
NRPSs and type I PKSs.  Both systems are multifunctional megasynthases organised 
into repeated functional units known as modules and assemble their products by 
sequential condensation of simple monomeric building blocks (amino acids and acyl-
CoAs, respectively).  Each module is responsible for catalysis of one cycle of PK 
(type I modular PKSs) or NRP chain elongation and associated functional group 
modifications.  In both systems, carrier proteins (PCP for the NRPS and ACP for 
PKS) which bear a covalently attached 4-phosphopantetheinyl prosthetic group are 
used to tether the monomers and the nascent polymers as thermodynamically 
activated thioesters.  In addition to carrier protein domains PCP and ACP, each 
module consists of two more core catalytic domains denoted adenylation (A) and 
condensation (C) for NRPS and ketosynthase (KS) and acyltransferase (AT) for PKS.  
The three core domains are responsible for the central chain-building reactions of PK 
or NRP biosynthesis.  Both PKSs and NRPSs share, in general, a dedicated 
thioesterase (TE) termination domain.  In some NRPSs, the C-terminal TE domains 
are replaced by NADH-dependent reductase domains (saframycin for example) (Cane 
et al., 1998; Fischbach and Walsh, 2006; Walsh and Fischbach, 2010). 
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NRPSs and type I PKSs diverge in regard to monomer activation before being 
tethered into the modified carrier proteins.  In PK biosynthesis, the monomers are 
activated as acyl-CoA thioesters and in NRP biosynthesis as aminoacyl-AMP.  The 
two enzyme systems also diverge in respect to their fundamental building blocks:  
PKSs use a small number of simple acyl monomers however, NRPSs use more than 
500 proteinogenic and nonproteogenic amino acids (Walsh and Fischbach, 2010).  In 
regard to the mechanisms of biosynthesis, PKSs use KS domain to catalyse 
decarboxylative Claisen-like condensation to form C-C bond between the growing 
polyketide chain and the extender unit compared to NRPSs that use condensation 
domain (C) to catalyse the formation of amide linkage between two amino acids.  The 
ultimate state of the modified intermediates is determined by combination of optional 
tailoring domains (KR, DH and ER) for PKSs and by different auxiliary domains 
(epimerisation (E), N-methylation (M) and cyclisation (Cy)) in the case of NRPSs.  
 
1.6 The secondary metabolites Azinomycins (A and B)  
 
1.6.1 Discovery and biological activities of azinomycins (A and B) 
 
Azinomycins A 3 and B 4 (Figures 1.4 and 1.22) are naturally occurring bioactive 
compounds produced by Streptomyces species.  Hata and co-workers were the first to 
isolate azinomycin B from Streptomyces sahachiroi and named it carzinophilin (Hata 
et al., 1954) however, its structure remained elusive until 1986, the time when Yokoi 
and co-workers determined the structures of azinomycins A 3 and B 4.  Based on 
spectroscopic and chemical properties, the authors were able to determine the 
molecular weights of metabolites 3 and 4 as 595 and 623 for molecular formulas of 
C30H33N3O10 and C31H33N3O11, respectively (Yokoi et al., 1986).  In this work, 
natural products 3 and 4 were isolated from Streptomyces griseofuscus (Nagaoka et 
al., 1986; Yokoi et al., 1986) with three additional related metabolites 32, 33 and 34 
(Figure 1.22) that were found to be biologically inactive (Yokoi et al., 1986).  About 
two decades later, it was found that the amide 32 exhibited cytotoxic activity against 
P388 murine leukemia cell line (Hashimoto et al., 2003).  Early bioactivity tests have 
revealed that the azinomycins (A and B) possess in vitro cytotoxic activity when 
subjected to a cytotoxicity assay employing L5178Y tumor cells.  It was found that 
the IC50 (the concentration for 50% inhibition of cell growth) for compound 3 was 
0.07 µg mL
1
 and 0.11 µg mL
1
 for compound 4 showing that azinomycin A is more 
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potent than azinomycin B.  Furthermore, antimicrobial activity studies have shown 
that 3 and 4 are active against Gram-positive and Gram-negative bacteria but inactive 
against yeast and fungi (Nagaoka et al., 1986).  Additional in vivo studies on 
bioactivities of azinomycin A and B against various murine tumors showed that 
azinomycin B was more potent than azinomycin A (Ishizeki et al., 1987).  Further in 
vivo studies reported by Kelly and co-workers showed the biological activity of 
azinomycin B against yeast cells.  Experiments with fluorescence imaging and 
oligonucleotide microarrays demonstrated DNA damage as consequence of covalent 
bonding with azinomycin B (Kelly et al., 2006).   
 
 
 
Figure 1.22: Structures of Azinomycin A 3 and B 4 and additional related metabolites 
(32, 33 and 34) produced and isolated from S. sahachiroi and S. griseofuscus. 
 
1.6.2 Mode of action of azinomycins (A and B) 
 
The background surrounding the mode of action of azinomycins goes well back to the 
antibiotic activity studies done by Terawaki and Greenberg in 1966.  They were first 
to indicate that azinomycin B inhibited DNA synthesis but had no inhibition effect 
over RNA or protein synthesis when tested against Escherichia coli strain B0 and 
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Bacillus subtilis (Terawaki and Greenberg, 1966a).  Moreover, the authors established 
the formation of the interstrand cross-links (ISCs) between azinomycin B and DNA of 
E. coli strain B0 and B. subtilis and that this ISC was not irreversible (Terawaki and 
Greenberg, 1966b).  Further studies based on ethidium fluorescence assays conducted 
by Lown and Majumdar showed that azinomycin B caused in vitro DNA damage as 
result of ISC formation accompanied by alkylation of DNA.  These observations were 
detected experimentally by the reduction of ethidium fluorescence.  Also the 
incubation of DNA with the intercalating dye prior to addition of azinomycin B 
inhibited the cross-linking (Lown and Majumdar, 1977).  The authors also determined 
the basic nature of the reactive sites of azinomycin B requiring protonation to be 
active.  In fact, both ISC and alkylation to DNA were shown to be pH-dependent and 
favoured lower pH.  These findings shed more light on the tumor targeting of 
azinomycin B since the acidity in tumor cells is known to be lower than normal cells.     
Further studies on the specific nature of the interstrand cross-links (ISCs) formed by 
azinomycin B were carried out by Armstrong and co-workers.  It was found that 
azinomycin B alkylated guanine and either guanine or adenine two bases removed 
from one another on the opposite DNA strands.  The authors reached this conclusion 
by incubating azinomycin B with 
32
P-labelled synthetic DNA duplexes and following 
the cross-linking formation by denaturing polyacrylamide gel electrophoresis 
(Armstrong et al., 1992). 
The first confirmation of the direct implication of the aziridine and epoxide moieties 
in the double alkylation of DNA was achieved by Saito et al. (Fujiwara and Saito, 
1999).  By following the incubation of both azinomycin B and its derivative 4-O-
methyl-azinomycin with the DNA duplex d(TAGCTA)2 and also through monitoring 
the reactions by HPLC analysis in association with mass spectrometry, the authors 
observed initial formation of a monoadduct corresponding to monoalkylation at the 
aziridine moiety, followed by interstrand cross-linked material indicating alkylation at 
the epoxide moiety.  As consequence of these observations as well as the thermolysis 
of both alkylated adduct products (that resulted in depurination) the authors suggested 
that the second DNA alkylation (at guanine N-7) at the epoxide fragment was 
facilitated by the initial reaction between N-7 of adenine with the aziridine moiety 
(Figure 1.23).  These findings seemed to contradict Armstrong’s previous 
conclusions.   
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Figure 1.23: DNA alkylation by azinomycin B.  (A): The interstrand cross-link is 
initiated by alkylation of adenosine (nitrogen N-7) by the aziridine C10 carbon, 
followed by a second alkylation of guanine (nitrogen N-7) by the epoxide carbon at 
C21.  (B): Azinomycin B spanning over 3 base pairs and forms interstrand cross-links 
between purine bases on opposite strands two base pairs apart. 
 
Further details in respect to the role of aziridine and epoxide moieties towards DNA 
cross-linking were revealed by Shipman and co-workers (Hartley et al., 2000).  Using 
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plasmid DNA and synthetic epoxyaziridine analogues, they found that compound 35 
(containing the epoxide and aziridine parts)  shown in Figure 1.24 triggered 
significant DNA cross-linking in contrast to compounds 36 and 37 (lacking the 
epoxide or aziridine moieties).  
 
 
Figure 1.24: Structures of epoxyaziridine analogues 35, 36 and 37. 
 
In vivo cross-linking and double alkylation of azinomycin B was further evaluated in 
a series of assays using yeasts as target organisms (Kelly et al., 2006).  The results 
were consistent with the previous conclusions reached by the authors mentioned 
earlier in this section. 
 
1.6.3 Biosynthesis of the azinomycins   
 
A considerable amount of research has been carried out by a number of chemists and 
biochemists to understand the cytotoxicities, the antitumor activities and the mode of 
action of the azinomycins since the discovery of carzinophilin/azinomycin B in 1954.  
Despite all these decades of research efforts, no biosynthetic work on the azinomycins 
had been reported till the year 2004, when Lowden and co-workers reported the first 
biosynthetic studies on azinomycin B and established the polyketide origin of the 
naphthoate fragment (Corre and Lowden, 2004a).  Isotope-labelled experiments based 
on feeding C1-, C2- and doubly labelled acetates to S. sahachiroi cultures and 
13
C-
NMR analyses, showed the incorporation of the labelled acetates into the azinomycin 
naphthoate fragment (Figure 1.25A).  The results are consistent with the polyketide 
origin of the naphthoate fragment.  Upon these findings, it was suggested that 5-
methyl-1-naphthoic acid 41 (Figure 1.26) was the first enzyme-free intermediate in 
the azinomycin biosynthesis that has been formed on the basis of the condensation of 
62 
 
one molecule of acetyl-CoA with 5 of malonyl-CoA.  The condensation reactions 
were mediated by a polyketide synthase (PKS) leading to the formation of a linear 
hexaketide chain that was subject to further modifications (reduction, cyclization, and 
dehydration/aromatization) by the PKS to form 5-methyl-1-naphthoic acid 41.  
Moreover, it was suggested that metabolite 41 was then hydroxylated and methylated 
before incorporation into azinomycin B.  By feeding methyl-
13
C-labelled methionine 
to the azinomycin producer, a significant labelling (43%) was incorporated into only 
the methoxy carbon of the naphthoate fragment establishing the source of methyl 
group.  Further isotopic labelling studies were conducted by Corre et al. to test the 
possibility that 41 is an intermediate metabolite and also to investigate the exact 
timing of the incorporation of the methoxy group (Corre et al., 2004b).  Feeding 
synthetic deuterated naphthoate intermediates 38-40 (Figure 1.25B) to S. sahachiroi 
resulted in an efficient incorporation of deuterium from the feeding compounds into 
azinomycin B as revealed by 
2
H-NMR analyses.  The results demonstrated that 3-
methoxy-5-methyl-NPA 43 was fully synthesised before elaboration into azinomycin 
B.  Additional results of the acetate labelling experiments showed that 
13
C-labelled 
acetates were incorporated in 5 carbons (C6-C7, C8 and C12-C13) of the aziridine 
moiety and 4 carbons (C1-C4) of the enol fragment.  As consequence, it was proposed 
that the enol chain was of threonine origin with threonine in turn derived from 
oxaloacetate.  Also it was proposed that -ketoglutarate was the origin of the labelled 
carbons seen in the aziridine moiety after the subsequent metabolism of the labelled 
acetates through the Krebs cycle.  In fact, any of the -ketoglutarate derived amino 
acids (glutamate, glutamine, arginine and proline) would give the same results 
(Foulke-Abel et al., 2011a).   
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Figure 1.25: Studies on the azinomyicin naphthoate fragment based on feeding 
isotope labelled compounds to S. sahachiroi.  (A): Schematic illustrations of the 
labelling patterns of azinomycin B subsequent to feeding labelled acetates to S. 
sahachiroi.  (B): Structures of naphthoic acids in deuterium-labelled form. 
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Figure 1.26: Pathway suggesting early stages to production of 3-methoxy-5-methyl-
NPA 43 before incorporation into the azinomycin backbone.  (i): Condensation 
reaction mediated by polyketide synthase (PKS).  (ii): Reduction followed by 
cyclisation/aromatisation.  (iii): Possible hydroxylation mediated by cytochrome P-
450.  (iv): Involvement of S-adenosylmethionine (SAM) in the methylation of 42. 
 
Further in vitro biosynthetic studies on azinomyicin B were conducted by Liu and co-
workers using cell-free extracts of S. sahachiroi.  The authors were able to 
reconstitute all the stages involved in the azinomycin biosynthetic pathway by 
identification of substrates and cofactors involved in the biosynthesis of azinomycin B 
(Liu et al., 2006).  Results from enzyme assay using radiolabelled malonyl-CoA, 
acetyl-CoA and cofactors (NADPH, SAM and FAD) showed the significant 
importance of the NADPH and SAM in the azinomycin B biosynthesis.  Other 
experiments using cerulenin (inhibitor of fatty acid synthase/polyketide synthase 
(FAS/PKS)) and miconazole (a cytochrome P-450 hydroxylase inhibitor) revealed the 
important role of PKS and cytochrome P-450 in azinomycin biosynthesis.  Further 
enzyme assays using radiolabelled amino acid substrates (valine, threonine, glycine 
and ornithine) showed the positive incorporation of all the amino acids involved in the 
azinomycin B biosynthesis supporting the biosynthetic origin of azinomycin B.  
During these isotope-tracer experiments, ornithine was proposed as the precursor of 
the aziridine moiety.  However, the details of the aziridine formation remain obscure.  
 
Other biosynthetic studies were conducted by Kelly et al. in order to investigate the 
origin of the terminal enol fragment of azinomycin B (Kelly et al., 2008).  The 
authors developed first a new optimised culture method allowing a reliable and 
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consistent supply of azinomycins A and B.  The optimised method involved culturing 
S. sahachiroi on dehydrated plates, followed by multiple step seed culture and 
subsequent fermentation of the strain in nutrient limited medium.  The development 
of the new culture method was a necessity for biosynthetic studies as the continuous 
production of azinomycins by S. sahachiroi was unreliable following the available 
literature protocols (Nagaoka et al., 1986; Yokoi et al., 1986; Corre et al., 2004a; 
Corre et al., 2004b).  The authors started their investigations by feeding [U-
13
C]-
threonine followed by synthetic potential substrates 44-46 (Figure 1.27).  It was 
found that threonine was incorporated into azinomycin B and gave labelling patterns 
at the carbons C1-C4 but no labelling was detected in azinomycin B after feeding [U-
13
C]-compounds 44-46.  Hence, it was suggested that a nonribosomal peptide 
synthetase (NRPS) had incorporated the advanced precursor threonine with further 
chemical modification occurring after peptide assembly to construct the terminal 
(enol) fragment of azinomycin B.  
 
 
 
Figure 1.27: Investigation of the origin of the enol fragment of azinomyicin B.  (A): 
Structure of the [U-
13
C]-labelled synthetic compounds evaluated for incorporation 
into azinomycin B.  (B): Schematic representation of [U-
13
C]-threonine illustrating it 
incorporation into the terminal fragment of azinomycin B subsequent to feeding 
studies.   
66 
 
Azinomycin A, on the other hand, has a ketoamine as a terminal fragment and lacks 
the enol part within its structure.  Based on a series of experiments involving the 
feeding of 
15
N and 
13
C labelled aminoacetone, threonine and glycine, it was proposed 
that the aminoacetone 50 was the last precursor of the first three carbons C1-C3 of 
azinomycin A and resulted from either glycine 47 or threonine 48 as described in 
Figure 1.28.  The authors also proposed that the terminal aminoacetone moiety is 
fully constructed before being tethered to the NRPS (Sharma et al., 2009).  
 
 
 
Figure 1.28: Proposed biosynthetic pathway of aminoacetone 50 and its incorporation 
into azinomycin A.  
 
Sharma et al. (2009) suggest the action of threonine dehydrogenase or 2-amino-3-
ketobutyrate coenzyme A ligase on threonine 48 and glycine 47, respectively.  In both 
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cases the amino acid 49 was the product and reacted by spontaneous decarboxylation 
to give precursor 50.   
 
Whole cell feeding studies, using 
13
C-labelled potential substrates (such as valine and 
epoxyvaline) were carried out to investigate the biosynthetic origin of the epoxide 
moiety and the timing of its incorporation into the azinomycin backbone.  These 
studies revealed that much of the valine tailoring occurs prior to being loaded onto the 
NRPS machinery.  It was also revealed that neither of the epoxyvaline precursors 
showed incorporation into the natural product likely to their instability in aqueous 
medium.  As consequence, the precise timing of the formation of the azinomycin 
epoxide moiety could not be revealed.  Additionally, results from 
13
C NMR analyses 
showed that amongst the nine [1-
13
C]-valine derivatives utilised in this study, only 
precursors 51-54 were incorporated into the azinomycin epoxide leading the authors 
to suggest the biosynthetic route illustrated in Figure 1.29 (Sharma et al., 2008).   
 
 
 
Figure 1.29: Evaluation of biosynthetic origin of the azinomycin epoxide moiety. 
Formation of -hydroxyvaline 52 by oxidation of L-valine 51, followed by 
transamination to give -keto acid 53 and dehydration to produce 3-methyl-2-
oxobutenoic acid 54.     
 
The entire azinomycin B biosynthetic gene cluster azi, was cloned and sequenced by 
Zhao et al. (2008) facilitating the identification of numerous genes involved in the 
construction of individual fragments of azinomycin B.  However, many other genes 
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are still of unidentified function and details of the biosynthetic formation of the 
aziridine moiety remain a mystery. 
The sequencing of the azinomycin B gene cluster (azi) in conjunction with 
bioinformatic analysis helped to identify aziB, the gene encoding for the enzyme 
AziB, a type I iterative PKS responsible for the production of 5-methyl-NPA 41 by 
iterative decarboxylative condensation of one molecule of acetyl-CoA with 5 
molecules of malonyl-CoA (Figure 1.30).  In regard to the post modifications of 5-
methyl-NPA to form 3-methoxy-5-methyl-NPA, Zhao et al. identified the genes aziB1 
and aziB2 (within the azi gene cluster) encoding for AziB1 and AziB2 respectively, 
and proposed their involvement in the step wise addition of the methoxy group at 
carbon C3’ of the naphthoate fragment.  The authors suggested the role of cytochrome 
P-450 hydroxylase (AziB1) in the introduction of hydroxyl functional group at C3’, 
followed by methylation catalysed by S-adenosylmethionine (SAM)-dependent O-
methylransferase AziB2. Confirmation of their predictions was achieved by 
construction of an S. albus recombinant strain containing the genes aziB, aziB1 and 
aziB2, followed by culturing the strain and detecting the metabolite 3-methoxy-5-
methyl-NPA from the culture medium.   
 
Further in vitro studies were conducted by Ding and co-workers (2010) to investigate 
the role of enzymes AziB1 and AziB2 in their respective hydroxylation and 
methylation of 5-methyl-NPA at carbon C3.  Overexpression of the two enzymes in 
E. coli and their separate incubations with 5-methyl-NPA confirmed that AziB1 
catalysed the C3 hydroxylation and AziB2 was responsible for 3-O-methylation of the 
free naphthoic acid.  Additional investigations using an ATP-[
32
P]-PPi exchange 
assay were carried out to determine the substrate specificity of AziA1.  It was found 
that the substrates 3-methoxy-5-methyl-NPA, 5-methyl-NPA and 3-hydroxy-5-
methyl-NPA were activated by AziA1 with a preference for the first naphthoic acid 
(Ding et al., 2010).  Inspired by the apparent flexibility of the AziA1 active sites, the 
authors tested a range of commercially available naphthoic acid analogues in addition 
to 6-methylsalicyclic acid and orsellinic acid using ATP-[
32
P]-PPi exchange assay.  
The results showed the activation of only compounds with a naphthalene ring.  The 
findings suggested the requirement of a naphthalene ring for substrate recognition and 
activation by the adenylation domain of AziA1.   
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Figure 1.30: 3-methoxy-5-methyl-NPA biosynthesis.  (A): Genes encoding the 
enzymes AziB, AziB1 and AziB2 for the biosynthesis of 3-methoxy-5-methyl-NPA.  
(B): Domain organizations of 3-methoxy-5-methyl-NPA.  KS, ketoacylsynthase; AT, 
acyltransferase; DH, dehydratase; KR, ketoreductase; ACP, acyl carrier protein.  (C): 
Pathway for 3-methoxy-5-methyl-NPA synthesised by AziB, AziB1 and AziB2. 
 
The azi sequencing enabled likewise the identification of five modular nonribosomal 
peptide synthetase (NRPS) genes, aziA1-aziA5 involved in the assembly of the 
azinomycin fragments as illustrated in Figure 1.31.  Zhao et al. (2008) predicted a 
dual role of AziA1 that is composed of acyl-CoA ligase (A) and peptidyl carrier 
protein (PCP) domains.  The (A) domain (also known as adenylation domain) is 
responsible for the recognition, incorporation and activation of the free 3-methoxy-5-
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methyl-NPA before being transferred to the PCP domain and then to AziA2 for 
starting the assembly of azinomycin fragments.  The condensation (C) domains allow 
the formation of amide bonds.  The AziA3 module was proposed to activate the acid 
55, transfer it to its PCP domain and then reduce the ketone using the KR domain to 
form intermediate 56.  The adenylation domain (A) of AziA4 recognises and activates 
the aziridino[1,2a]pyrolidinyl compound 57 (or a partially processed intermediate 
amino acid) and then transfers it to the PCP domain.  At the end of the four domain 
enzyme AziA5, there is a reductase (RE) domain responsible for the release of the 
final metabolite as an aldehyde for further functionalization. 
  
 
 
Figure 1.31: Proposed assembly of azinomycin B 4 building blocks by NRPS 
enzymes AziA1-AziA5.  NRPS domains are: AL, acyl-CoA ligase; PCP, peptidyl 
carrier protein; C, condensation domain; KR, ketoreductase domain; A, adenylation 
domain; RE, reductive release domain. 
 
Additional genes encoding for proteins required for tailoring reactions (such as 
acetylation, oxidations and methylation) were also identified by Zhao and co-workers 
(2008).  Validation of the functional role of AziB in the azinomycin biosynthesis 
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pathway was accomplished by cloning and expressing the aziB gene into the 
expression host S. albus that was cultivated followed by characterisation of the 
metabolite 5-methyl-NPA formed in the fermentation culture.   
Subsequent to genome sequencing of S. sahachiroi, an azinomycin B resistance 
protein was identified and characterised as AziR (Foulke-Abel et al., 2011b).  The 
protein was overexpressed in the heterologous hosts S. lividans and E. coli and then 
its resistance effect was tested against azinomycin B.  It was found that AziR 
exhibited protective effect against azinomycin B as the number of surviving cells was 
enhanced.  In vitro protein assay revealed a reasonable binding between AziR and 
azinomycin B.  
 
1.7 Other natural products containing aziridine moiety 
 
There are only a small number of aziridine-containing natural products that have been 
identified compared to the tens of thousands ( 100,000) of natural products that have 
been characterized up to 2010 (Foulke-Abel et al., 2011a).  Examples include 
mitomycins, ficellomycin, azicemicins, mirazidine and maduropeptin compounds 
(Figure 1.32).  A discussion on the discovery, biological activity, mode of action and 
biosynthesis of mitomycins (mainly mitomycin C 58), ficellomycin 59 and azicemicin 
A 60 and B 61 will be covered in this section.   
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Figure 1.32: Structure of the aziridine-containing natural products mitomycins (A, B, 
C 58 and E), ficellomycin 59, azicemycins (A 60 and B 61), maduropeptin and 
miraziridine A. 
 
The mitomycins are potent antibiotics that belong to the family of antitumor quinone.  
In 1956, Hata and co-workers isolated mitomycins A and B (Figure 1.32) from 
Streptomyces caespitosus (Hata et al., 1956a; Hata et al., 1956b) and shortly 
thereafter mitomycin C 58 was discovered from the same strain (Wakaki et al., 1958). 
Few years after their discovery, Webb and co-workers established the absolute 
structure of the mitomycins (Webb et al., 1962a; Webb et al., 1962b).  Further 
analysis by high-resolution X-ray crystallography (Shirahata and Hirayama, 1983) 
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and chemical studies (Hornemann and Heins, 1985) proved to be critical in resolving 
the final stereochemical structures of the mitomycins.  
Mitomycin C 58, which is widely used for the treatment of solid tumors (Begleiter, 
2000), was found to cause diverse biological effects such as selective inhibition of 
DNA synthesis, mutagenesis, induction of DNA repair, sister-chromatid exchange, 
signal transduction and induction of apoptosis (Tomasz and Palom, 1997).  Early 
investigations to understand and explain the mode of action of mitomycins revealed 
the ability of these natural products to form both inter- and intrastrand DNA cross 
links in the minor groove with a sequence specificity favouring 5-CG-3, and that 
these alkylation processes were the cause of the biological activities of these 
compounds (Iyer and Szybalski, 1963; Iyer and Szybalski, 1964).  Also, it has been 
shown that the resulting alkylated mitomycin C-DNA complexes are not due to direct 
reaction between mitomycin C 58 and DNA, but require prior reductive activation of 
the quinone system by enzymatic (Suresh et al., 1997) or chemical means (Paz, 2009).  
Intensive work has been carried out by many researchers in order to establish the 
mechanisms of the reductive activation and the chemical steps leading to the 
formation of mitomycin C-DNA complexes and Figure 1.33 illustrates the accepted 
mechanism of DNA cross-linking by reductive activation of mitomycin C 58 (Schiltz 
et al., 1993; Tomasz and Palom, 1997; Suresh et al., 1997).   
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Figure 1.33: Proposed pathway of reductive activation of mitomycin C 58 and the 
mechanism of DNA cross-linking by the activated form of 58. 
 
The hydroquinone 62 is formed by two-electron reduction (or may be by two stepwise 
one-electron reduction) of the quinone moiety of 58.  Then the elimination of the 
methoxy group from the C9a position affords iminium ion 63, which quenches itself 
via deprotonation/tautomerisation to afford net elimination of methanol from 62 and 
yielding intermediate leuco-aziridinomitosene 64.  The reactive intermediate methide 
65 is formed next prior to aziridine-ring opening due to electron donation from the 
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hydroquinone indole core of 64.  The methide 65 can now alkylate DNA at the 
exocyclic nitrogen of guanine (N-2) at the C1 position to form species 66, which can 
then produce the iminium intermediate 67 by elimination of the carbamate.  Since a 
second alkylating site is been revealed now, a subsequent alkylation by a second 
guanine N-2 takes place leading to the formation of the final cross-linked adduct 68. 
 
Early biosynthetic studies on mitomycins (A, B and C) and porfiromycin were carried 
out in the laboratories of Kirsch (Kirsch and Korshalla, 1964), Vining (Bezanson and 
Vining, 1971) and Hornemann (Hornemann and Cloyd, 1971).  Based on feeding 
[methyl-
14
C]-L-methionine to Streptomyces verticillatus, it was established that the O- 
and N-methyl functionalities (but not the C6-methyl groups) of these mitomycins 
were derived from methionine.  Additional incorporation experiments with 
radiolabelled precursors [guanidino-
14
C]-L-arginine (Hornemann and Cloyd, 1971) 
and [ureido-
14
C]-L-citrillune (Hornemann et al., 1974a) showed that the C10 
carbamoyl groups originate from L-arginine or L-citrillune.  These results are 
summarised for mitomycin C 58 in Figure 1.34.   
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Figure 1.34: Biosynthetic origin of the O-methyl groups of mitomycin C 58. 
 
Further precursor incorporation experiments using [1-
14
C]-, [1-
14
C, 
15
N]-, [1-
13
C, 
15
N]- and [6-
14
C]-D-glucosamine followed by degradative studies and MS analyses 
(Hornemann and Cloyd, 1971; Hornemann and Aikman, 1973; Hornemann et al., 
1974a) demonstrated that D-glucosamine can provide the nitrogen atome of the 
aziridine ring,  the non-quinone C6 chain, the C10 of the carbamoyl group and can 
also fully incorporate into mitomycins as illustrated for mitomycin C 58 in Figure 
1.35.  Further feeding experiments using 
14
C-labelled D-glucose and D-ribose showed 
an efficient incorporation into mitomycins, with ribose labelling the quinone ring 
(Hornemann and Cloyd, 1971).  It was also demonstrated that C6a and C6 of 
mitomycin C 58 were originated from labelled pyruvate and D-glucose suggesting an 
early branch from shikimate pathway (Hornemann et al., 1974b).  Since attempts to 
incorporate labelled shikimic acid and 3-dihydroquinic acid were unsuccessful, the 
authors proposed the intermediary of a “C7N unit” via 4-amino-3,4-dideoxy-D-
arabino-heptulosonic acid 7-phosphate subsequent to the condensation between 
pyruvic acid and erythrose-4-phosphate (E4P) .  Additional studies showed that the 
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C7 unit of the mitomycins can be formed from [4-
14
C]-D-erythrose and C5 from [3-
14
C]-pyruvate subsequent to the incorporation of labelled erythrose and pyruvate into 
the mC7N unit of mitomycin C (Hornemann et al., 1980). These results are 
summarised for mitomycin C 58 in Figure 1.35.  
 
 
 
 
Figure 1.35: Radiolabelled precursors to the carbon skeleton of mitomycin C 58. 
   
Shortly afterwards, it was established that the quinone ring of the mitomycins is 
derived from 3-amino-5-hydroxybenzoic acid (AHBA) (Anderson et al., 1980), which 
is also a precursor of the mC7N unit of ansamycin antibiotics (Kibby et al., 1980).  
Later work has repeatedly confirmed the intermediary role of AHBA in the 
biosynthesis of a range of natural products containing mC7N structural fragment (Wu 
et al., 1987; Lee et al., 1994; Komoda et al., 2007).  It was also established that the 
mitosane skeleton of mitomycins is originated from the coupling of AHBA and D-
glucosamine (Hornemann et al., 1974a; Anderson et al., 1980).   
More details regarding the biosynthesis of mitomycins have been revealed since the 
intensive work on genetics and enzymology of mitomycin C 58 carried by Sherman’s 
group (Sherman et al., 1999) and extensive studies about AHBA biosynthesis (Kibby 
et al., 1980; Kim et al., 1996).  The Sherman group have cloned and sequenced the 
gene cluster for biosynthesis of mitomycin C 58 in Streptomyces lavendulae.  They 
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identified genes mitA and mitB related to AHBA synthases (MitA) and a group of 
glycosyltransferases (MitB).  The group also identified homologues of seven genes 
(rifG -H, -J, -K, -I, -M, -N) which are necessary and sufficient for AHBA formaton in 
rifamycin producer Amycolatopsis mediterranei (Kim et al., 1998).  Moreover, the 
Sherman’s group identified a number of tailoring genes necessary for complete 
assembly of mitomycin C 58.  Examples include identification of three SAM-
dependent methyltransferases that might be involved in the addition of O- and N-
methyl groups and also identification of a putative carbamoyltransferase. 
Based on what is known about AHBA biosynthesis (Kibby et al., 1980; Kim et al., 
1996) and Sherman’s findings, a representation of mitomycin C 58 biosynthesis is 
depicted in Figure 1.36.    
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Figure 1.36: Summary of the biosynthetic pathway of mitomycin C 58. 
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Beginning with the conversion of erythrose-4-phosphate (E4P) into imino-E4P, in 
which the ammonia is incorporated from the amide nitrogen of glutamine, the 
formation of 4-amino-3,4-dideoxy-D-arabino-heptulosonic acid 7-phosphate (amino-
DAHP) is ensued via the coupling of imino-E4P and PEP (phosphoenolpyruvate).  
Then, amino-DAHP is processed through aminodehydroquinic acid (amino-DHQ) 
and aminodehydroshikimic acid (amino-DHS), which is then aromatised by the 
enzyme, AHBA synthase.  The biosynthetic pathway proceeds then via the coupling 
of AHBA and D-glucosamine and also through a number of tailoring enzyme to 
furnish the final structure of mitomycin C 58 (Figure 1.36). 
 
Because no biosynthetic genes were assigned an exact role in respect to the precise 
cyclisation and formation of aziridine ring, a hypothesis that cyclisation occurs 
through an SN2 reaction might be a possibility.  The carbons C2 and C3 from 
glucosamine might act as nucleophilic and electrophilic centres, respectively prior to 
the substitution of the glucosamine C3 hydroxy group with a good leaving functional 
group (such as halogen atoms).       
 
Comparison between the mode of action of mitomycin C 58 and azinomycin B 4 
shows that compound 58 requires bioreductive activation prior to DNA alkylation and 
cross-linking in contrast to compound 4 where the reactive sites (aziridine and 
epoxide rings) do not require such activation.  Compounds 58 and 4 also diverge in 
that the first one forms both inter- and intrastrand DNA cross-links in the minor 
groove whereas the latter forms interstrand DNA cross-links in the major groove.  
Regarding the biosynthetic origin of the aziridine moiety it was shown that D-
glucosamine was the precursor of the aziridine ring of mitomycin C 58 while either 
ornithine or glutamate derivative is the precursor of the aziridine moiety in 
azinomyicin B 4.  
 
The second aziridine-containing natural product ficellomyicin 59 was isolated from a 
culture broth of Streptomyces ficellus in 1976 by Argoudelis and co-workers at 
Upjohn Research Laboratories (Argoudelis et al., 1976).  It is the only natural product 
known to share the 1-azabicyclo[3.1.0]hexane ring system with the azinomycins 
(Foulke-Abel et al., 2011a).  The compound 59 displays high in vitro activity against 
Staphylovoccus aureus infections in mice and inhibits the growth of Gram positive 
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bacteria in vivo.  It is inactive against Gram negative bacteria, viruses and a variety of 
fungi.  In 1989, Kuo and co-workers elucidated the structure of ficellomycin 59 based 
on NMR, MS and derivatisation studies (Kuo et al., 1989).  However, the absolute 
stereochemistry of the compound remains undetermined.  
Studies on the mode of action of ficellomycin 59 were carried by Reusser and co-
workers (1977).  It was found that compound 59 selectively impairs semiconservative 
DNA replication in Eschirichia coli, and this was found not to be due to direct 
inhibition of DNA polymerase.  It was also found that 59 triggered the accumulation 
of DNA population of a mean size of 34S.  In the light of these results, it was 
suggested that ficellomycin 59 may exert its biological activity by alkylation of DNA, 
possibly in similar manner to azinomycins.  In 2011, Foulke-Abel research group 
revealed parts of an unpublished work on S. ficellus genome aiming at cross-
comparing the biosynthetic pathways between azinomycins and ficellomycin (Foulke-
Abel et al., 2011a).  Despite the promising anti-cancer potential of ficellomycin 59, 
no complete biosynthetic work had been published yet.   
 
Azicemicins A 60 and B 61, the third group of aziridine-containing natural products 
to be discussed in this section, were isolated in 1993 from Amycolatopsis sp. MJ126-
NF4 (lately known as Kibdelosporangium sp. MJ126-NF4 (Ogasawara and Liu, 
2009)) and shown to exhibit moderate activity against Gram positive bacteria and 
mycobacteria.  Azicemicins 60 and 61 did not show any signs of toxicity when 
administrated to mice at a dose of 150 mg/Kg and 75.5 mg/Kg, respectively (Tsuchida 
et al., 1995a; Tsuchida et al., 1995b; Tsuchida et al., 1993).  Structurally, antibiotics 
60 and 61 contain an angucycline core (in black) and unprecedented aziridine moiety 
(in red) (Figure 1.32), though their mode of action has not been investigated yet.  
Meanwhile, biosynthetic studies on these compounds have been published by 
Ogasawara and Liu in 2009.  Starting with feeding [1-
13
C]- and [1, 2-
13
C2]acetates to 
the azicemicins producing organism, it was shown that the angucycline core of 
Azicemicin A 60 is of a decaketide origin and that its carbon skeleton is assembled by 
a type II polyketide synthase (PKS).  Also it was suggested, based on results from 
labelling patterns seen on C1, C2 and C3 of compound 60 (Figure 1.37), that the 
acetate derived amino acid 77 might be the starter unit of azicemicin A 60 
biosynthesis.  The authors conducted further isotope tracing experiments in order to 
82 
 
investigate the azicemicins’ biosynthetic pathway.  The choice of amino-acids to be 
fed was based on the fact that the labelling of the acetate 69 and intermediates of TCA 
(tricarboxylic acid) cycle subsequently generate the labelling of the amino-acids 
originating from -ketoglutarate and oxaloacetate 70 (Den Hollander et al., 1981; 
Glawischnig et al., 2001).  Then deuterium-labelled amino-acids D-alanine, D,L-
serine and D,L-aspartate were fed to the azicemicins producing strain and results 
showed that aspartic acid 71 is the precursor of the aziridine moiety since it was the 
sole amino-acid showing incorporation of deuterium into C1 of azicemicin A 60 
(Figure 1.37).  The labelling patterns (from the same amino-acid) shown on the O- 
and N-methyl groups of 60 were justified by the conversion of amino-acid 71 to 
glycine 72 and subsequent transfer of deuterium through a series of steps, from 71 to 
73 passing by 72.  Then finally deuterium was incorporated into the O- and N-methyl 
groups of 60 by means of the S-adenosyl-L-methionine (SAM)-dependent 
methyltransferase 74 (Figure 1.37).  Results from deuterium-labelling experiments 
also showed the absence of deuterium in C2 indicating that only one deuterium atom 
from aspartic acid 71 reached the finally constructed aziridine moiety and that the 
remaining two deuteria were washed away during the formation process.  As 
consequence, it was suggested that the deuterium seen in C1 in azicemicin A 60 
could be derived either from - or from -deuterium and that the absence of 
deuterium in C2 depended on the biosynthetic faith of 71 during the biosynthetic path 
a or b shown in Figure 1.37.   
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Figure 1.37: Incorporation of 
13
C-labelled acetate and deuterium in aziridine starter 
unit 77 in azicemicin A 60. 
 
Ogasawara and Liu (2009) have made great advances in understanding of the genetics 
and enzymology of azicemicins’ production.  They have cloned and sequenced the 
azicemicin (azic) gene cluster and assigned functions to genes on the basis of 
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sequence comparison with known genes from the databank.  In addition to genes 
encoding for type II PKS, the cluster harbours also two genes azicM and azicV 
encoding for two adenylyl transferases AzicM and AzicV, respectively.  The authors 
investigated the substrate specificity of these enzymes based on gene expression 
experiments and enzyme activity assays and results showed that AzicM has 
preference for aspartate 71 (L and D forms).  They concluded that AzicM catalyses 
the activation of L- or D-aspartate 71 by ATP-hydrolysis, as amino acyl adenylate.  
Additional genes contained in the cluster are a decarboxylase AzicN, that may play a 
role in the formation of the starter unit 77 by catalysing the decarboxylation of 80, and 
an acyl carrier protein AzicP that tether the activated aspartate to it 4-
phosphopantetheine cofactor.  The cluster also contains several oxygenase genes 
(azicO1, azicO2 and azicO6) encoding for enzymes involved in 
oxidation/hydroxylation reactions during the biosynthesis of the starter unit 81.  
Additional oxygenase genes (azicO3, azicO4, azicO5 and azicO6) involved in the 
oxidation/hydroxylation of the angucycline core were also found contained in the 
cluster.  The azic gene cluster reveals as well the presence of azicT gene encoding for 
AzicT enzyme that has sequence homology with numerous phosphopantetheinyl 
transferases and may play a role in the activation of AzicP during azicemicin 
biosynthesis.  Unfortunately, all genetic manipulation efforts carried by the authors to 
verify the functions of these genes were unsuccessful and therefore they relied mainly 
on isotope labelling experiments and enzymatic studies, previously discussed, to 
propose the biosynthetic pathway for the formation of the aziridine carboxylate starter 
unit 83 in azicemicin A 60 (Figure 1.38).   
 
85 
 
 
 
Figure 1.38: Aziridine carboxyl 83 formation in azicemicin A 60 biosynthesis. 
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During the first step of the formation of the aziridine carboxyl 83 (Figure 1.38), 
aspartate 71 (L or D) is activated by AzicM as amino acyl adenylate 84 before being 
transferred and tethered to the 4-phosphopantetheine (4-PP) cofactor of the carrier 
protein AzicP.   The transfer of 4-PP cofactor to the conserved serine residue of 
AzicP is catalysed by the phosphopantetheinyl transferase AzicT.  Then, a 
decarboxylation reaction catalysed by AzicN led to the formation of AzicP-tethered 
-alanine 81 from 80.  After a series of oxidation reactions catalysed by AzicO2, 
AzicO1 or O6 followed by cyclisation, compound 81 generated the AzicP-tethered 
isoserine 82 followed by the formation of the aziridine carboxyl starter unit 83, 
respectively.    
 
Although the mode of action of azicemicins A 60 and B 61 has not been studied yet, a 
reasonable hypothesis is that the antimicrobial activities of these compounds could be 
attributed to the aziridine moiety by analogy to the reactivity of the aziridine 
functional groups in azinomycins A 3 and B 4 and in several other aziridine-
containing natural products (Ismail et al., 2009). 
  
Comparison between the biosynthetic pathways of azinomycin B 4 and azicemicins A 
60 and B 61 shows disparate strategies to generate the aziridine moieties.  As matter 
of fact, feeding experiments and cloning and sequencing of gene clusters established 
that either ornithine or glutamate derivative is the precursor of the aziridine moiety in 
azinomyicin B 4 while aspartic acid 71 is found to be the precursor of the aziridine 
moiety in azicemicins’ biosynthesis.  Genetics efforts were unsuccessful in 
identifying the enzyme/enzymes catalysing the cyclisation of the aziridine moieties in 
both cases but succeeded to identify the origin of carbons C1 and C2 in azicemicins.  
Much remains to be discovered about the origin of carbons C10 and C11 of the 
aziridine ring in azinomycins.    
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1.8 Significance and definition of precursor-directed 
biosynthesis 
 
Natural products from micro-organisms have traditionally played a significant role in 
clinical practice. These secondary metabolites with a broad spectrum of structural 
diversity cover a wide scope of biological activities ranging from antibiotics to 
immunosuppressants and from cytostatic to
 
antitumor properties.  Throughout 
thousands of years with continuous genetic mutations and environmental impacts, the 
devoted functions of these natural products were naturally enhanced and optimised.   
Furthermore, natural products present promising new scaffolds on which future drug 
development efforts can be focused (Grünewald and Mohamed, 2006).    
However, natural products are not fully effective for the expected objective and 
generally do not exhibit optimum potency when tested against specific targets.  In 
addition, they have the potential to cause unpleasant side-effects.  The application of 
synthetic (or semi-synthetic) chemistry or combination of chemical and biological 
approaches (mutasynthesis and precursor-directed biosynthesis) to modify bioactive 
natural product leads are often seen as good solutions for problems such as increasing 
desired activity, or minimising toxic side effects.  
  
Strategies and methods developed by organic chemists allowed the chemical synthesis 
of complicated natural product molecules such as vitamin B12 and chlorophyll a and 
also played a crucial role in the development of numerous medicinal drugs such as the 
antibiotic vancomycin and the anticancer agent epothilone (Nicolaou et al., 2000).  
However, organic synthesis has limitations in applicability for complex natural 
compounds that contain for example highly reactive groups such as azinomycin B 4. 
 
The semi-synthetic approach can be used as an alternative to develop new drugs with 
enhanced activity compared to the native natural compound.  Some successful 
examples of drugs developed by this approach are the medically approved 
antibacterial drug tigecycline (analogue of tetracycline) and glycopeptide antibiotics 
that are in an advanced phase of clinical development.  Furthermore, the combination 
of chemical and enzymatic tools proved to be a powerful technique to generate new 
lead drugs with improved activity such as analogues of epothilone and vancomycin 
(Lam, 2007). 
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Another important technique to generate novel drug leads from natural product 
producing organisms is through the mutasynthesis approach which developed from 
precursor-directed biosynthesis (see next paragraph).  This technique is based on the 
cellular uptake of modified biosynthetic precursors that are fed to genetically 
engineered/mutant organisms which are blocked in various steps of the natural 
product biosynthesis pathway (Kennedy, 2008).  One example of mutasynthesis was 
the production of the new bioactive compounds nikkomycins Lx and Lz (Figure 1.39) 
by the mutant of the wild type Streptomyces tendae Tü901.  The mutant was obtained 
by inserting a kanamycin resistance gene in the nikkomycin biosynthesis gene nikF 
encoding a cytochrome P-450 monooxygenase.  The new antibiotic compounds, 
which lack the oxygen atom of the pyridyl residues, are respective derivatives of the 
natural antibiotics nikkomycins X and Z (Figure 1.39) that are produced by S. tendae 
Tü901.  Studies on the stability of nikkomycins Lx and Lz at various pH values using 
nikkomycins X and Z as references, showed that they were more stable under various 
condition than the reference compounds.  Additional work on the biological activity 
of nikkomycins Lx and Lz showed a slightly lower or similar activity to nikkomycins 
X and Z when tested against a variety of fungi microorganisms (Bormann et al., 
1999). 
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Figure 1.39: Structures of the natural antibiostics nikkomycins X and Z and the 
corresponding derivatives Lx and Lz. 
 
PDB can also be used to generate natural product analogues by adding enzyme 
inhibitors (to the culture media), which are able to block a particular biosynthetic 
pathway biochemically.  This approach has been used by Ritacco and co-workers 
(2005) to generate new rapamycin analogues by incorporating unusual analogues of 
the normal amino acid, L-pipecolate, into the rapamycin 85 compound.  Rapamycin 
85 is a polypeptide-polyketide natural product produced by Streptomyces 
hygroscopicus ATCC 29253 and exhibits potent immunosuppressive and anticancer 
activities which are useful properties to generate novel drug leads.  Also compound 85 
is known to involve several features in its biosynthesis and of particular note the 
enzyme lysine cyclodeaminase which is encoded by the gene rapL and known to 
catalyse the cyclisation and conversion of the amino acid L-lysine to L-pipecolate 
(Nancy et al., 1993; Khaw et al., 1998) (Figure 1.40).  
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Figure 1.40: Lysine cyclodeaminase catalysing the cyclisation and conversion of L-
lysine to L-pipecolate. 
 
Another biosynthetic feature in rapamycin biosynthesis is the pipecolate-incorporating 
enzyme that is encoded by the rapP gene and recognised for its catalytic 
incorporation of L-pipecolate as well as the pre-rapamycin ring closure (Molnár et al., 
1996).  Based on the knowledge about the biosynthetic assembly of rapamycin 85 
natural product, Ritacco and co-workers (2005) carried out feeding experiments using 
pipecolate analogues (1,4-thiazane-(3S)-carboxylic acid 86 and 1,3-thiazane-(4S)-
carboxylic acid 87) in the presence of racemic ()-nipecotic acid 88 (inhibitor of L-
pipecolate biosynthesis) (Figure 1.41).  Results showed incorporation of the two 
sulfur-containing analogues of L-pipecolate into the rapamycin 85 molecule yielding 
the new rapamycin analogues 20-thiarapamycin 89 and 15-deoxo-19-
sulfoxylrapamycin 90, respectively (Figure 1.41).  Structurally, the product 89 was 
identical to rapamycin 85 except for the presence of a sulfur atom on the 
pipecolate/thiazane ring while the second product 90 showed a new sulfoxide group 
which was derived from the oxidation of the thiazine sulfure and also revealed an 
absence of the C15 carbonyl indicating a possible disruption in the activity of the 
downstream cytochrome P-450 monooxygenase. 
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Figure 1.41: Structures of the fed precursors used in the study and their 
corresponding products. (A): Structures of ()-nipecotic acid 88, 1,4-thiazane-(3S)-
carboxylic acid 86 and 1,3-thiazane-(4S)-carboxylic acid 87. (B): Structures of 
rapamycin 85, 20-thiarapamycin 89 and 15-deoxo-19-sulfoxylrapamycin 90. 
 
Bioactivity assays were carried by Ritacco et al. (2005) and results revealed that 
rapamycin analogues 89 and 90 were weaker binders to FKBP12 compared to the 
natural product rapamycin 85 and that 90 showed the least binding activity as 
consequence to the lack of the C15 carbonyl group.    
One more powerful, attractive and easy approach toward trying to generate novel 
microbial natural product derivatives is precursor-directed biosynthesis (PDB).  PDB 
involves the addition of biosynthetic precursor analogues to the culture broth of the 
producing organism.  In order to become incorporated into the organism’s metabolic 
92 
 
pathway and produce novel metabolites, the added precursor has to be channelled 
from the growth medium into the producing organism cells and accepted by the 
biosynthetic enzymes (Timothy et al., 2000).  Thiericke has defined precursor-
directed biosynthesis as “the derivatisation of a secondary metabolite by feeding the 
biosynthetic precursor analogues to the fermentation broth of producing organisms” 
(Thiericke and Rohr, 1993).  The secondary metabolite biosynthetic enzymes often 
show a certain degree of flexibility as to what substrates they accept.  Amide 
synthases and non-ribosomal peptide synthetases (NRPSs) are some examples of 
secondary metabolite biosynthetic enzymes exhibiting broad substrate specificity 
(Thiericke and Rohr, 1993; Kleinkauf and Von. Doeren, 1996).  Over many years, a 
number of new lead compounds have been developed by the PDB approach (Goss et 
al., 2012).  The lipopeptide antibiotic A54145 (Figure 1.42) is one example.  This 
antibiotic which inhibits Gram positive bacteria is a complex of eight lipopeptide 
compounds [A, A1, B, B1, and C to F] produced by Streptomyces fradiae (Thiericke 
and Rohr., 1993).  The similarities between the antibiotic A54145 components include 
four peptide cores that diverge by only few amino acids.  Another feature of the 
A54145 complex is the diversity of the fatty acid side chains which form an amide 
bond with the N-terminus of the peptide nucleus.  In an attempt to produce antibiotic 
analogues or to improve the biosynthesis of certain native metabolites, a range of fatty 
acid precursors (from acetate to oleate lipids) were fed to Streptomyces fradiae (strain 
NRRL 18158).  New derivatives of the A54145 complex, containing previously 
undiscovered C6, C8 and C9 acyl units resulted from feeding hexanoate, caprylate and 
nonaoate, respectively.  The produced compounds were detected and isolated from the 
culture media (Thiericke and Rohr, 1993). 
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Figure 1.42: Illustration of the A54145 complex (Adapted from Thiericke and Rohr, 
1993). 
 
Another example of the application of PDB is the generation of jadomycin analogues 
91 (Figure 1.43) through amino acids feeding experiments.  Jadomycin family of 
natural products are angucycline polyketides exhibiting potent antibacterial, anti-
tumour, antiviral and Aurora-B kinase inhibitory activity.  It is assumed that the 
addition of L-isoleucine and also amino acids 92 with the polyketide core 93 (Figure 
1.43) is likely to be a non-enzymatic reaction (Rix et al., 2004).  Cottreau and co-
workers (2010) carried out their experiments by feeding a series of proteinogenic and 
non-proteinogenic amino acids to the producing bacteria Streptomyces Venezuelae 
ISP5230.  Results revealed the production of jadomycin analogues which were then 
assessed for their DNA-cleaving profiles in the presence of metal catalysts.  
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Incorporation of alternative amino acids, in place of the natural L-isoleucine, into the 
metabolite resulted in modifications to the natural oxazolone ring.  The unnatural 
amino acid starting units were processed with no racemisation at the -carbon.  These 
studies provided deeper insight into the flexible nature of the glycosyltransferase 
JadS, which acts upon the natural product following oxazolone formation.  Cytotoxic 
assays reveal that the activity of these compounds increases in proportion to the 
polarity of the side chains (Syvitski et al., 2006; Borissow et al., 2007). 
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Figure 1.43: Biosynthesis of jadomycins A and B and related analogues 91.  
Analogues were generated through feeding various natural and unnatural amino acids 
(in blue).  A wide variety of natural and non-proteinogenic amino acids combine with 
the polyketide core 93 and it is postulated that this step is non-enzymatic (Rix et al., 
2004).  The enzyme JadS is involved in installing the L-digitoxose sugar unit onto 
jadomycin B. 
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1.9 The use of fluorine compounds in PDB   
 
During the last two decades fluorine-containing compounds have widely spread into 
medicinal chemistry and new highly effective drugs have emerged since then (Hans-
Joachim et al., 2004; Iwao, 2004).  The introduction of fluorine into molecules has 
been an important concept for many reasons.  Firstly, fluorine atom(s) are introduced 
into the organic compounds to circumvent the low metabolic stability of the drug.   
Secondly, fluorine affects the physicochemical properties of the fluorinated molecule.  
Being a highly electronegative atom, fluorine vastly affects the acidity and basicity of 
the neighbouring functional groups by varying their dissociation constant (pKa).  As a 
consequence, the binding affinity of the molecule is affected by this pKa change.  
Also, it has been shown that the binding affinity of the molecule increases by the 
effect of the fluorine on the lipophilicity of the molecule.  Finally, a change towards a 
preferable molecular conformation can be triggered by the introduction of fluorine 
into the target molecule.  For example, the substitution of the methoxy group of 
methoxybenzenes without ortho substituents with the trifluoromethoxy group (OCF3) 
leads to a twist in the favoured planar conformation by many degrees (Hans-Joachim 
et al., 2004).  
   
Natural products are considered as biologically validated lead structures, and a lot of 
research has been done to develop new fluorine compounds with novel or enhanced 
biological properties.  Fluorinated natural compounds are considered rare compared to 
other halogenated compounds (Vaillancourt et al., 2006).  However, precursor-
directed biosynthesis (PDB) is one among many biotechnological approaches that can 
be used to generate novel fluorinated metabolite analogues.  For example, Kawashima 
and co-workers prepared fluorinated derivatives of the antibiotic vulgamycin (Figure 
1.44) that is produced by Streptomyces hygroscopicus (Kawashima et al., 1985).  As 
the aromatic part of vulgamycin antibiotic is derived from benzoic acid, the authors 
used fluorobenzoic acids as precursors for directed biosynthesis.  To the culture broth 
of S. hygroscopicus, they added fluorinated precursors such as ortho-, meta-, and 
para- fluorobenzoic acids at a concentration of 100 µg ml
1
 and the cultivation was 
continued for 120 hrs.  The identity of the fluorinated analogues, produced in the 
culture media, was elucidated by 
19
F NMR spectroscopy.  The results showed a very 
significant (70%) incorporation of the added compounds.  
1
H and 
13
C NMR analysis 
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were used to determine the structures of the isolated fluorovulgamycins.  The 
antibacterial activities of the isolated fluoro-compounds were then tested and results 
indicated that they were not effective against the test organisms except for 
Micrococcus luteus ATCC 9341 and that para-fluorovulgamycin showed stronger 
activity than vulgamycin against this organism. 
 
 
 
Figure 1.44: Structures of vulgamycins and fluorovulgamycins (Figure adapted from 
Kawashima et al., 1985). 
 
The second example of the application of fluorinated compounds in PDB is the 
generation of soraphen A 96 analogues by Hill and Thompson (2003).  Soraphen A 96 
polyketide natural product was originally isolated from the culture broth of 
Sorangium cellulosum, a soil dwelling myxobacterium and exhibited inhibition 
activity against fungal growth (Gerth et al., 1994; Vahlensieck et al., 1994).  The 
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complete biosynthetic gene cluster for the synthesis of soraphen A 96 was cloned and 
sequenced and results (Figure 1.45) revealed that 96 is biosynthesised by a type I 
PKS and that the first module in the soraphen PKS recognises and processes a rare 
benzoyl CoA as starter unit (Ligon et al., 2002).  Hill and co-workers (2003) 
investigated the scope of the soraphen PKS-substrate flexibility by feeding various 
fluorinated forms of phenylalanine, cinnamate and benzoate to the wild type 
organism.  Analysis of the crude broths by 
19
F NMR and LC-MS showed the 
production of novel fluorine-containing soraphens (Figure 1.45) for the cultures fed 
meta and para substituted phenylalanine and cinnamate and that no production of 
soraphen analogues was seen in the other cultures.  Also higher cell counts and 
soraphen titres were observed for cultures administered with meta and para-
fluorocinnamates compared to phenylalanine.  Additional feeding experiments were 
carried out by the authors to investigate whether chlorinated and brominated starter 
units (4-chloro and 4-bromocinnamate) could be recognised and loaded by the 
soraphen PKS starting domain.  LC-MS analyses revealed the presence of chlorinated 
and brominated soraphen analogues in the crude extracts.  
Biological activity tests were carried out against the fungus Botrytis cinerea using 3-
fluoro soraphen A and 4-fluoro soraphen A and results showed that these novel 
compounds were less active than the natural soraphen A 96.  
These results showed that the soraphen starting domain can accept and process some 
non-natural starter units.  However, production relative to soraphen A 96 itself was 
low, probably due to the preference of the PKS for the natural starter moiety, and 
none of the tested analogues exhibited a better bioprofile compared to 96. 
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Figure 1.45: Generation of soraphen A analogues by feeding cinnamate analogues to 
the producing bacteria Sorangium cellulosum.    
 
1.10 General aims of the present study 
   
The aim of this project was to investigate the scope of precursor-directed biosynthesis 
for the production of novel azinomycin metabolites by feeding commercially 
available and synthetic analogues of the naphthoate moiety. These new azinomycins 
might have improved anticancer activity, and results of this study will give insight 
into the substrate specificity of the azinomycin biosynthetic enzymes. 
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Chapter 2: Materials and Methods 
 
2.1 Materials  
 
2.1.1 Reagents 
 
Reagents used for the feeding experiments were purchased from Sigma-Aldrich or 
Acros Organics unless otherwise stated and were used as received (purity: 97-99.5%).  
3-Methoxy-1-naphthoic acid 97 (Figure 2.1) was a generous gift from Cyrille 
Landreau, a post doc in Exeter and 3-Fluoro-1-naphthoic acid 98 (Figure 2.1) was 
supplied by Mike Shipman who was Dr in Exeter, then was promoted to Prof at the 
University of Warwick, Coventry.  Culture media were purchased from Oxoid or 
BDH.  Commercial solvents were used as received from Sigma-Aldrich, Fisher 
Scientific, VWR or Acros Organics.  Solvents used for LCMS (Liquid 
chromatography/mass spectrometry) experiments were of LCMS grade.  Solvents 
used for all other experiments were of HPLC (High Performance Liquid 
Chromatography) grade unless otherwise stated.  Flash column chromatography Silica 
60A (40-63 micron) was purchased from Fisher Scientific.  Thin-layer 
chromatography (TLC) aluminium sheets (20  20 cm) with 0.20 mm silica gel 60 
was purchased from Alugram
®
 or MERCK.  Ultrafiltration filters (Millipore) were 
purchased from Fisher Scientific.    
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Structure of compounds 97 and 98. 
 
Feeding experiment reagents 
 
All reagents used for fermentation feeding experiments are commercially available 
except reagents 97 and 98. 
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2.1.2 Bacterial strains 
 
Streptomyces sahachiroi (ATCC 33158) was used in this study and was obtained from 
the American Type Culture Collection (ATCC).  
Escherichia coli K1 and K12 strains used in disk diffusion assay (DDA) and spot 
culture growth inhibition assay (SCGIA) (Evangelopoulos and Bhakta, 2010) were 
provided by Dr. Parissa Mortavazi.  Other bacterial strains used in DDA, SCGIA and 
bioactivity tests are Escherichia coli, Micrococcus luteus, Bacillus subtilis, Bacillus 
megaterium, Pseudomonas diminutus and Staphylococcus epidermis.  Fungi used in 
disk diffusion assay and bioactivity tests are Trichoderma harzianum, Pyrenophora 
avenae, Rhizoctonia solani and Fusarium oxysporum.   
Both bacteria strains and fungi were obtained from the general stock in the 
Microbiology Research Laboratory at Birkbeck College.   
 
2.1.3 Growth Media 
 
All growth media were sterilised by autoclaving at 121
 o
C for 18 minutes and at 1.1 
bar pressure in a Priorclave (Biocote Ltd) machine. 
 
Glucose, Yeast extract and Maltose extract (GYM) 
 
GYM agar medium contained the following components per litre of tap water: 5 g 
glucose monohydrate (BDH), 5 g yeast extract (Oxoid), 10 g malt extract (Oxoid), 2 g 
CaCO3 (BDH) and 12 g agar (Oxoid).  GYM liquid medium was made the same way 
except that CaCO3 and agar were omitted.  Both media were adjusted to pH 6.8 with 1 
M NaOH and sterilised by autoclaving. 
 
Pharmamedia and Starch (PS5) 
 
PS5 liquid medium contained the following ingredients per litre of tap water: 5 g 
Pharmamedia (yellow cotton seed flour) (Traders Protein, Southern cotton oil 
company, USA) and 5 g soluble starch (BDH).  The medium was adjusted to pH 7.0 
with 1 M NaOH and sterilised by autoclaving.   
 
  
102 
 
Nutrient Agar (NA)  
 
NA medium contained the following components per litre of distilled water (dH2O): 
1 g ‘Lab-lemco’ powder (Oxoid), 2 g yeast extract (Oxoid), 5 g peptone (Oxoid), 5 g 
NaCl (Oxoid) and 5 g agar (Oxoid).  The medium was adjusted to pH 6.8 with 1 M 
NaOH and sterilised by autoclaving.   
   
Potatoes Dextrose Agar (PDA)  
 
PDA medium contained the following components per litre of dH2O: 
4 g potato extract (Oxoid), 20 dextrose (Oxoid) and 15 g agar (Oxoid).  The medium 
was adjusted to pH 5.6 ± 0.2 with 1 M NaOH and sterilised by autoclaving.   
 
Trypticase Soy Agar (TSA) 
 
TSA medium contained the following components per litre of dH2O: 
15 g tryptone (Oxoid), 5 g soytone (Oxoid),  5 g NaCl (Oxoid) and 15 g agar (Oxoid). 
 
Streptomyces refuineus Agar (SRA) 
 
5 g NZ amine (casein hydrolysate) (Sigma), 2 g yeast extract (Oxoid), 2 g soytone 
(soya peptone) (Oxoid), 1 g soluble starch (BDH), 5 g D-mannitol (BDH), 15 mg 
FeSO4.7H2O (BDH) and 20 g agar (Oxoid) were weighed and dissolved in 1 litre 
dH2O.  The medium was adjusted to pH 7.0 with 1 M NaOH and sterilised by 
autoclaving.     
 
2.2 Methods 
 
2.2.1 Chemistry  
 
Extraction and evaporation 
 
As cited on the literature (Hata et al., 1954; Nagaoka et al., 1986; Kelly et al., 2008), 
Liquid-liquid or solvent extraction technique was used in this study to separate the 
desired compounds (azinomycin A, azinomycin A analogues and other novel 
additional metabolites) from the bacterial supernatants subsequent to centrifugation.   
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In fact S. sahachiroi’s fermentation broths were centrifuged for 10 min at 6000  g at 
4 
o
C in a Beckman Avanti J-26XP centrifuge machine then supernatants were 
extracted with an equal volume of chloroform.  The organic layers were dried over 
MgSO4 and concentrated using a rotary evaporator. 
Since the metabolites of interest were relatively small organic compounds (relative 
molecular weight (MW): 170-700 MW), they were expected to partition mainly into 
the organic layer.  The expectation was not only based on literatures (Hata et al., 
1954; Nagaoka et al., 1986) but was supported by the experimental work as well 
(Chapter 4).  
 
Separation by High Performance Liquid Chromatography (HPLC or LC) 
 
During HPLC separation methods, HPLC (Agilent 1100 LC system) was equipped 
with diode array detector (DAD) that recorded UV/VIS spectra up to six different 
wavelengths.  Chromatograms were recorded at 350 nm.  The system was also 
coupled to mass spectrometry (MS), a Bruker Esquire 3000 mass spectrometer with 
electrospray ionization (ESI) source operating on either positive () or negative () 
ionization mode.  The instrument was operated with Agilent ChemStation and Bruker 
Esquire Control software, data was processed using Bruker Data Analysis software. 
 
Preparative HPLC (prep HPLC) 
 
Throughout chromatographic processes, separation was done with a pre-degassed 
mobile phase consisting of a mixture of water and methanol (45:55).  Throughout the 
isolation process, C18 column (ACE5 250  21.2 mm) was used, the flow rate was of 
5 mL min
1
 and the injection volume of extract was 100 µl.  The amount of sample 
injected was around 4-6 mg. Isolation and purification was processed by manual 
fraction collection based upon the online signal plot and mass-based identification.  
The signal plot was generated from DAD (using detection at 350 nm) and displayed 
by the instrument.  The mass identification was based on the fact that the molecular 
mass of the compound of interest (azinomycin A or its analogues) was known and the 
detection mode was based on the ionization process used by the MS with the ESI 
source.  The MS was operating on a positive ionization mode: ESI () with a 
nebulizer = 2 psi, a dry gas = 6 l min
1
 and dry temperature = 330 
o
C. 
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Once the identified fraction was collected in a 50 mL Falcon tube, it was concentrated 
in a rotary evaporator, redisolved in methanol (0.5 mL) and LCMS analyses were 
done for confirmation of purity.   
 
Analytical HPLC 
 
Through chromatographic procedures, separation was done with a pre-degassed 
mobile phase consisting of a mixture of water and methanol (45:55).  The separation 
was developed using either C8 microbore column (ACE3, 100  2.1mm) or C18 
analytical column (ACE5, 250  4.6mm).  The flow rate was 0.2 mL min1 and the 
injection volume of extract was 5 µl when using C8 microbore column.  The C18 
analytical column was deployed when the flow rate and injection volume were 
increased (1 mL min
1
 and 20 µl respectively).  The amount of sample injected each 
time was very small (2-15 µg) in order not to exceed the column capacity.  The target 
compounds were detected by DAD and mass-based identification.  
 
Structure elucidation 
 
MS and tandem mass spectrometry (MS/MS) were the main techniques used to 
elucidate and characterize the structures of purified azinomycin A 3 and its analogues 
(Chapter 4).  NMR characterisation could not yet be conducted because of the low 
yields and the persistence of some impurities in the native azinomycin A 3 and its 
analogues.  Attempt to characterise azinomycin A 3 by 
1
H-NMR was unsuccessful as 
shown in Figure 2.2 (Appendix one).  
The MS, one and two dimensional NMR and infra-red (IR) spectrometry techniques 
were used to characterize the structures of purified 1-naphthoic amide 99a and 4-
fluoro-1-naphthoic amide 100a.  The remaining purified compounds (4-methyl-1-
naphthoic amide 101a, 2-methyl-1-naphthoic amide 102a, 2-methoxy-1-naphthoic 
amide 103a, 3-methoxy-1-naphthoic amide 97a and 3-fluoro-1-naphthoic amide 98a) 
were characterized by MS only as NMR analysis was hampered by impurities.  
Additionally, the apparent new compound resulting from feeding hydrazine 
dihydrochloride 111 was not identified yet and can be characterized by one and two 
dimensional NMR.  Finally, melting points (m.p.) were determined for all purified 
compounds except azinomycin A analogues because of the low production levels. 
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All MS/MS were performed using a Bruker (Bruker Esquire 3000 mass spectrometer) 
with helium as collision gas.  The first analyzer was used to isolate the precursor ion 
(parent ion) of chosen m/z ratio.  By increasing the activation energy inside the 
spectrometer, collision between helium gas and the selected ion resulted in a 
fragmentation process generating product ions.  Then a second mass spectrometer 
analyzed the product ions.  
NMR spectra for naphthoic amides 99a and 100a were recorded on an AMX Bruker 
300 MHz spectrometer while the apparent NMR spectrum for azinomycin A (Figure 
2.2, Appendix one) was done on a Bruker AV600 spectrometer.  One-dimensional 
(1D) NMR and two-dimensional (2D) NMR were performed at room temperature.  
Chemical shifts are given in ppm (δ) relative to CDCl3 (7.26 ppm for 
1
H NMR and 
77.2 for 
13
C NMR) and coupling constants (J) are reported in Hertz (Hz).  Signals are 
designated as follows: s, singlet; d, doublet; t, triplet; q, quadruplet; m, multiplet; br s, 
broad singlet.  
IR spectra were recorded using a Satellite FTIR Thermo Mattson spectrometer.  
  
2.2.2 Microbiology 
 
The following paragraphs describe the techniques and procedures used for the growth, 
conservation and maintenance, biological activity tests and feeding experiments of 
bacteria.  This section also illustrates the antifungal activity tests used during this 
study. 
 
Bacterial maintenance  
 
Streptomyces sahachiroi K-534 (ATCC 33158) cultures were maintained by transfer 
onto GYM agar prepared plates.  The plates were grown at 30 
o
C in a Scientific 
Isotemp. incubator for 5-7 days then kept at room temperature.  New plates were 
spread every two weeks.  
 
Spore suspensions Spore stocks:  
 
5 mL of sterile distilled water were added to a fresh plate culture of Streptomyces 
sahachiroi.  The surface of the culture was scraped with a sterile inoculating loop to 
suspend the spores.  All the suspension was removed, pipetted into a 50 mL Falcon 
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tube and then centrifuged for 10 min at 4000  g.  The pellet (spores) was 
resuspended in 500 µL of 20% sterile glycerol, transferred to a 2 mL screw tap vial 
tube, flash frozen, and stored at – 80 oC. 
 
Streptomyces sahachiroi batch cultures   
 
First stage culture.  One loopful of aging spores from a culture grown on a GYM agar 
plate at room temperature for 3-6 months was used to inoculate 50 mL of GYM liquid 
medium in a 250 mL Erlenmeyer flask containing a 30 cm spring to disperse spores.  
The culture was incubated in an orbital shaker at 30 
o
C for 24 h at 200 rpm.   
Second stage culture.  An aliquot (2 mL) from the first stage culture was used to 
inoculate 50 mL of PS5 medium in a 250 mL Erlenmeyer flask containing a 30 cm 
spring.  The culture was incubated in an orbital shaker at 30 
o
C for 24 h at 200 rpm. 
Fermentation cultures.  20 mL of the second stage culture were inoculated into 2 L 
Erlenmeyer baffled flasks containing 500 mL of PS5 medium.  The culture was 
incubated at 30 
o
C for 64 h at 200 rpm. 
 
 
 
 
Figure 2.2: Sequence of fermentation system: (a) GYM spores. (b) First stage culture. 
(c) Seed culture. (d) Fermentation broth. 
 
Streptomyces sahachiroi growth curve 
 
One loopful of aging spores from a culture grown on a GYM plate at room 
temperature for 3-6 months was used to inoculate 50 mL of GYM medium in a 250 
mL Erlenmeyer flask containing a 30 cm spring.  The culture was incubated in an 
orbital shaker at 30 
o
C for 24 h at 200 rpm.  Samples (3  2 mL) were used to 
inoculate a triplicate 50 mL of PS5 medium in a 250 mL Erlenmeyer flask.  The 
culture was incubated at 30 
o
C for 80 h at 200 rpm.  Aliquots containing 0.1 mL were 
taken every 4 h (for 80 h), serially diluted in sterile saline solution (NaCl at 0.8 g %) 
and were subcultured in triplicate on GYM agar plates.  The cultures were incubated 
at 30 
o
C for 48 h and the number of viable cells was determined by colony forming 
a dcb
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units (CFU) using the formula: Number of colonies  dilution factor  10 cells /mL).  
The number of viable bacteria cell per mL was measured over time and was plotted as 
a graph of average log10 viable cell number per mL against time.  
 
Time course of the production of azinomycin A 
 
One loopful of aging spores from a culture grown on a GYM solid plate at room 
temperature for 3-6 months was used to inoculate 50 mL of GYM liquid medium in a 
250 mL Erlenmeyer flask containing a 30 cm spring.  The culture was incubated in an 
orbital shaker at 30 
o
C for 24 h at 200 rpm.  Samples (3  10 mL) were used to 
inoculate a triplicate 250 mL of PS5 medium in a 1 L Erlenmeyer flask.  The culture 
was incubated at 30 
o
C for 80 h at 200 rpm.  Aliquots containing 2 mL were taken 
every 4 h, transferred to a 15 mL Falcon tubes and stored in the freezer at 20 oC.  
Then cultures were centrifuged for 10 min at 6000  g at 4 oC in a Beckman Avanti J-
26XP centrifuge machine.  The cell pellets were discarded and the supernatants 
extracted with the same volume of chloroform (1).  The organic layers were 
collected, concentrated in a HOWE Gyrovap centrifuge and redisolved in the 
minimum amount of chloroform.  LCMS samples were prepared by mixing 50 µL 
from each sample with 950 µL of LCMS solvents system (water:methanol in the ratio 
of 65:35).  The time course of azinomycin A production was followed by measuring 
the peak area for each HPLC chromatogram and then plotted as a graph of peak area 
against time.  
 
Disk diffusion Assay (DDA) 
 
Antibacterial test 
 
A loopful of each bacterial culture (section 2.1.2) was used to inoculate nutrient agar 
plates.  The cultures were incubated for 24-48 h at 37 
o
C.  Using a sterile loop, a 
colony from each plate was emulsified in a sterile 15 mL Falcon tube containing 1 mL 
sterile saline solution (NaCl 0.8 g %), mixed thoroughly until no solid material from 
the colony was visible.  The procedure was repeated until the solution became cloudy.  
The turbidity of the bacterial suspension was then adjusted to a prepared 0.5 
McFarland turbidity standard.  It was prepared by adding 0.5 mL of a 1.175% (w/v) 
barium chloride dihydrate (BaCl2.2H2O) solution to 99.5 mL of 1% (v/v) sulphuric 
acid.  The turbidity standard aliquots (1 mL) were then transferred to a sterile 15 mL 
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Falcon tubes, sealed tightly with parafilm and stored in the dark at room temperature. 
Aliquots (100 µL) from bacterial suspension were then transferred to agar plates and 
spread evenly using a sterile glass spreader.  Sterile Whatman antibiotic disks (Tong 
et al., 2011) were inoculated in triplicate with 10 µL of S. sahachiroi fermentation 
crude extracts or purified compounds (dissolved in methanol) at different 
concentrations (a range of concentrations from 120 to 5 mg mL
-1 
for crude extracts 
and 2 to 1 mg mL
-1 
for pure compounds).  In some agar plates, two different 
compounds were used where each of them was inoculated in duplicate.  In every 
plate, a control disk was used and was inoculated with 10 µL of methanol only.  
Using sterile forceps, the disks were applied to the plates at equal distances (4 or 5 
disks per plate, of which one was used as control), gently pressed onto the surface of 
the agar, taking care not to press them into the agar and the plates were inverted and 
incubated for 24 hours at 37 
o
C.  
 
Antifungal test 
 
A disk of each precultured fungus colony (section 2.1.2) was cut with a cork-borer (5 
mm diameter), and the trimmed colony disk was placed in the centre of the PDA 
media.  The procedure of applying and inoculating the disks was the same as the one, 
described previously for antibacterial test except that the plates were not inverted and 
were incubated for 3-5 days at 25 
o
C. 
 
Spot culture growth inhibition assay (SCGIA) 
 
The assay was established for mycobacterial cultures (Evangelopoulos and Bhakta, 
2010) and was used (with the following modifications: 2.5 mL was used in each well 
instead of 5 mL to increase the concentration of each tested compound) in this study 
towards determination of the minimum inhibitory concentration (MIC) of purified 
compounds against the tested Gram

 and Gram

 bacteria (section 2.1.2).  Compounds 
were dissolved in methanol and two duplicated dilutions (2 mg mL
1
 and 0.2 mg 
mL
1
) of each compound were made in 2 mL eppendorf tubes.  After that, a small 
volume (2  5 µL) of each compound was transferred into a duplicated wells of a six 
well plate.  Then 2.5 mL of nutrient agar medium (NA) which was kept at 50 
o
C (in 
order not to solidify) was poured into each well.  The final dilutions of each 
compound were 4 and 0.4 µg mL
1
 respectively (dilution factor = 1/500).  The 
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remaining duplicate wells were used as positive control where 5 µl of methanol was 
poured in each one (no compound was added).  Bacterial cultures were prepared as 
described in disk diffusion test section.  A small bacterial inoculum (a drop of 5 µL) 
was transferred (spotted) in the middle of each well. The plates were carefully 
horizontally shacked and incubated at 37 
o
C up to 48 hours after being sealed with 
Parafilm. The minimum concentration of compound where there is no visual growth 
of bacteria was defined as MIC.  
 
General feeding conditions for Streptomyces sahachiroi 
 
One millimolar (1 mM) of each precursor compound (Table 3.1, Chapter 3) was 
solubilised in dimethyl sulfoxide (DMSO) solvent and was fed into the fermentation 
culture after 24 h growth of Streptomyces sahachiroi.  Initially, a multiple small scale 
fermentation feeding experiments were carried out using each time 50 mL of GYM 
medium in a 250 mL Erlenmeyer flask containing a 30 cm spring.  In fact, by 
repeating each feeding process at least 3 times, the consistence of the reproducibility 
of products of interest (azinomycin analogues or naphthoic amides for example) was 
checked.  Afterward, a scale up feeding experiments were proceeded using for each 
compound a 2 L flask containing 500 mL fermentation broth as was described 
previously in section 2.2.2 (Streptomyces sahachiroi batch culture).  The culture 
was harvested after 64 h incubation (at 30 
o
C at 200 rpm) and the fermentation 
products were extracted and isolated following the methods described in section 
2.2.1.     
The same process was followed for the commercial compounds shown in Table 3.4; 
chapter 3 except that sterile distilled water was used instead of DMSO. 
 
Separation and purification by chromatography 
 
Once TLC plates were developed, the visualisation of different spots was done at 250 
nm using a UV/VIS SPECTROLINE cabinet, MODEL ENF-260C/FE Lamp.  Then 
flash chromatography (FC) separation technique was used to isolate the following 
produced amides: 1-naphthoic amide 99a, 4-fluoro-1-naphthoic amide 100a, 3-fluoro-
1-naphthoic amide 98a, 4-methyl-1-naphthoic amide 101a, 2-methyl-1-naphthoic 
amide 102a, 3-methoxy-1-naphthoic amide 97a and 2-methoxy-1-naphthoic amide 
103a.  FC was also used in an attempt to isolate the natural product azinomycin A 3 
but the product had degraded due to the acidic nature of the stationary phase (silica 
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gel) of the column.  A second attempt using fresh crude extract and base-washing 
silica with 1% triethylamine was also unsuccessful.  However, azinoycin A was 
isolated by prep HPLC as mentioned in section 2.2.1 (Prep HPLC).  During each FC 
run, the mass of each bacterial crude extract used was in the range of 40 to 200 mg 
which was extracted from 500 mL fermentation broth.  In addition, the adsorbent 
material (stationary phase) remained unchanged while the mobile phase consisted of 
ethyl acetate (40-60): petroleum ether at different ratios (Table 2.1). 
 
Compound Ethyl acetate (40-60):petroleum ether ratios 
1-naphthoic amide  50:50 
4-fluoro-1-naphthoic amide 60:40 
3-fluoro-1-naphthoic amide 60:40 
4-methyl-1-naphthoic amide 70:30 
2-methyl-1-naphthoic amide 70:30 
3-methoxy-1-naphthoic amide  70:30 
2-methoxy-1-naphthoic amide 70:30 
 
Table 2.1 Naphthoic amide compounds and the corresponding solvent system ratios 
used during FC isolation. 
 
2.3 Data 
 
Characterization of azinomycin A 3  
 
 
 
 
 
Whitish plates (45:55 water: methanol) 
Molecular formula: C30H33N3O10 
Molecular Weight: 595 g.mol
-1
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m/z (ESI) 596. 
m.p. 144-151 
o
C.  (lit. 140
 o
C) (Nagaoka et al., 1986). 
 
Characterization of azinomycin B 4  
 
 
 
Molecular formula: C31H33N3O11 
Molecular Weight: 623 g.mol
-1
 
m/z (ESI) 624. 
m.p. 190 
o
C (from lit.) (Nagaoka et al., 1986). 
 
Characterization of 3-methoxy-1-naphthoic amide 97a 
 
 
 
 
Light-grey amorphous residue (50:50 ethyl acetate/40-60: petroleum ether)  
Molecular formula: C12H11NO2 
Molecular Weight: 201 g.mol
-1
 
m/z (ESI) 202. 
m.p. 206-218 
o
C (lit. Not found). 
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Characterization of 3-fluoro-1-naphthoic amide 98a 
 
 
 
 
Beige needles (50:50 ethyl acetate/40-60: petroleum ether)  
Molecular formula: C11H8NFO 
Molecular Weight: 189 g.mol
-1
 
m/z (ESI) 190. 
m.p. 225-233 
o
C (lit. Not found). 
 
Characterization of 1-naphthoic amide 99a 
 
 
 
 
 
 
 
Beige amorphous needles (50:50 ethyl acetate/40-60: petroleum ether) δH (300 MHz, 
CDCl3) 5.98 (2 H, br s, NH2), 8.43 (1 H, d, J7,8 5.04, H-8), 7.95 (1 H, d, J3,4 5.01, H-
4), 7.89 (1 H, d, J5,6 5.07, J5,7 0.70, H-5), 7.72 (1 H, d, J2,3 4.35, H-2), 7.59 (1 H, ddd, 
J6,7 5.43,  J7,8 4.92,  J5,7 0.75, H-7), 7.54 (1 H, ddd, J5,6 5.01,  J6,7 4.14,  J6,8 0.75, H-6), 
7.48 (1 H, dd, J2,3 4.32, J3,4 4.95, H-3).  
13
C NMR (300 MHz, CDCl3)  171.67, 
133.84, 133.08, 131.34, 130.11, 128.46, 127.40, 126.60, 125.50, 125.46, 124.69.  IR 
(cm
-1
) (KBr) 3150, 3080, 3030, 1680. 
Molecular formula: C11H9NO 
Molecular Weight: 171 g.mol
-1
 
m/z (ESI) 172. 
m.p. 198-207 
o
C (lit. 200-202
 o
C) (http://www.matrixscientific.com/1-naphthamide-
mfcd00014314-2243-81-4-c11h9no.html). 
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Characterization of 4-fluoro-1-naphthoic amide 100a 
 
 
 
 
 
 
 
 
white-beige needles (60:40 ethyl acetate/40-60: petroleum ether) δH (300 MHz, 
CDCl3) 5.97 (2 H, br s, NH2), 8.48 (1 H, d, J7,8 4.86, H-8), 8.15 (1 H, d, J5,6 4.77, H-
5), 7.69 (1 H, dd, J2,3 4.62, J2,F 3.21, H-2),  7.64 (1 H, ddd, J5,6 4.62, J6,7 4.17,  
J6,8 0.45, H-6), 7.60 (1 H, d, J7,8 4.86, H-7), 7.13 (1 H, dd, J3,F 6,  J2,3 4.86, H-3).
  13
C 
NMR (300 MHz, CDCl3)  170.55, 159.50, 132.01, 128.40, 126.10, 121.40, 108.48.  
IR (cm
-1
) (KBr) 3190, 3100, 3025, 1733. 
Molecular formula: C11H8NFO 
Molecular Weight: 189 g.mol
-1
 
m/z (ESI) 190. 
m.p. 229-237 
o
C (lit. Not found). 
 
Characterization of 4-methyl-1-naphthoic amide 101a 
 
 
 
 
light-grey amorphous residue (70:30 ethyl acetate/40-60: petroleum ether)  
Molecular formula: C12H11NO 
Molecular Weight: 185 g.mol
-1
 
m/z (ESI) 186. 
m.p. 187-192 
o
C (lit. 193
 o
C) (Frenzel et al., 1993). 
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Characterization of 2-methyl-1-naphthoic amide 102a 
 
 
 
Brownish needles (50:50 ethyl acetate/40-60: petroleum ether)  
Molecular formula: C12H11NO 
Molecular Weight: 185 g.mol
-1
 
m/z (ESI) 186. 
m.p. 102-111 
o
C (lit. 83.5-84.5
 o
C) (Dozen and Fujishima, 1972). 
 
Characterization of 2-methoxy-1-naphthoic amide 103a 
 
 
 
Brownish amorphous residu (50:50 ethyl acetate/40-60: petroleum ether)  
Molecular formula: C12H11NO2 
Molecular Weight: 201 g.mol
-1
 
m/z (ESI) 202. 
m.p. 185-194 
o
C (lit. 189
 o
C) (IG Farben Industrie AG, 1927). 
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Chapter 3: Novel Biotransformations of Naphthoic 
Acids by Streptomyces sahachiroi 
 
3.1 Introduction 
 
During the course of this study, we attempted to generate new azinomycin analogues 
through feeding analogues of the naphthoic acid intermediate (Table 3.1).  A range of 
naphthoic acids were added to S. sahachiroi fermentations.  As well as several 
unnatural azinomycin analogues (Chapter 4), additional metabolites were produced 
in the culture media.  The fermentation crude extracts carrying the additional 
metabolites were further investigated in order to isolate and characterize these novel 
substances.  Firstly, analytical samples were prepared, analysed by LCMS and then 
the additional metabolites were detected by ESI-MS.  After that, scaled up 
fermentations were conducted, followed by LCMS separation and detection.  Then 
flash chromatography (FC) was used for separation and purification purposes.  The 
identity of the novel metabolites as naphthoic amide analogues was suggested by 
electrospray mass spectrometry.  Further NMR characterisation was carried out for 1-
naphthoic amide and 4-fluoro-1-naphthoic amide.  Finally, antibacterial and 
antifungal activity studies were carried out in order to test the purified compounds for 
any potential biological activities.   
 
These novel biotransformation reactions are of interest for the following reasons.  On 
one hand, they may shed light on the flexibility of the azinomycin biosynthetic 
enzymes to unnatural substrates as well as on the mechanism of naphthoate activation 
and transfer to nucleophiles.  On the other hand, the discovered biotransformation 
reactions could be extended to further carboxylic acid substrates to test if there is any 
useful chemo- and/or regioselectivity.  
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3.2 Results  
 
3.2.1 Feeding experiment compounds 
 
In order to assess the ability of S. sahachiroi’s enzymatic system to process unnatural 
substrates, a series of commercial and synthetic precursors (97-114) were fed to the 
bacterial fermentation culture after 24 h incubation at 30 
o
C and at 200 rpm (Chapter 
2). 
 
Feeding of naphthoic acid precursors  
 
A variety of naphthoic acid compounds (97-109) were fed to S. sahachiroi.  Some 
acids were biotransformed into primary amides.  The results of the feeding 
experiments are shown in Table 3.1. 
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Compound  
 
Expected 
amide 
Result 
 
3-methoxy-1-naphthoic 
acid  
 
~2 mg of light-grey 
amorphous residue of 3-
methoxy-1- naphthoic 
amide (purification from 
43 mg of crude extract).  
 
 
 
3-fluoro-1-naphthoic 
acid 
 
~14 mg beige needles of 3-
fluoro-1- naphthoic amide  
(purification from 97 mg 
of crude extract). 
 
1- naphthoic acid  
 
~8 mg beige amorphous 
needles of 1-naphthoic 
amide (purification from 
74 mg of crude extract).  
 
4-fluoro-1-naphthoic 
acid  
 
~24 mg white-beige 
needles of 4-fluoro-1- 
naphthoic amide  
(purification from 150 mg 
of crude extract).  
 
4-methyl-1-naphthoic 
acid  
 
~5 mg of light-grey 
amorphous residue of 4-
methyl-1-naphthoic amide 
(purification from 180 mg 
of crude extract). 
 
 
2-methyl-1-naphthoic 
acid  
 
~3 mg of brownish needles 
of 2-methyl-1- naphthoic 
amide (purification from 
74 mg of crude extract). 
 
 
2-methoxy-1-naphthoic 
acid  
 
~20 mg of grey- brownish 
amorphous residue of 2-
methoxy-1-1naphthoic 
amide (purification from 
80 mg of crude extract).  
 
 
 
 
Table 3.1: Evaluation of naphthoic acid analogues for biotransformation into naphthoic 
amides after 64 h incubation of S. sahachiroi fermentation culture.  1 mM of each 
compound was added into a 500 mL culture broth after 24 h incubation. 
97 
97a 
99 
99a 
100 
100a 
101 
101a 
98 
98a 
102 
102a
a 
103 
103a 
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Compound  
 
Expected 
amide 
Result 
 
 
1,4-
naphthalenedicarboxylic 
acid 
 
No production. 
 
8-bromo-1-naphthoic acid 
 
No production. 
 
2-ethoxynaphthoic acid 
 
No production. 
 
1-hydroxy-2-naphthoic 
acid  
 
No production. 
 
2-hydroxy-1-naphthoic 
acid  
 
No production. 
 
1,8-naphthalaldehydic 
acid 
 
No production. 
 
Table 3.1: Evaluation of naphthoic acid analogues for biotransformation into 
naphthoic amides after 64 h incubation of S. sahachiroi fermentation culture.  Each 
compound was added to a final concentration of 1 mM into a 500 mL culture broth 
after 24 h incubation. 
 
  
108 
107 
109 
107a 
108a 
109a 
106 
106a 
105 
105a 
104 
104a 
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The results from Table 3.1, LCMS figures and 1D and 2D NMR data (for amides 99a 
and 100a) show the production and purification of naphthoic amides subsequent to 
feeding naphthoic acids 97-103 to the fermentation cultures.   
 
Isolation and purification of 1-naphthoic amide 99a 
 
The isolation and purification steps are summarised in chap. 2 (section: separation 
and purification by chromatography) and are as follows.  TLC analysis of the 
CHCl3 extract of the culture using 50:50 ethyl acetate/40-60: petroleum ether showed 
a strong blue fluorescence spot with Rf = 0.33.    Flash chromatography (FC) was used 
to isolate the target product using the same solvent system.  The purified compound 
was identified as 1-naphthoic amide 99a by LCMS (Figure 3.1), 1D and 2D NMR 
(Figures 3.2 and 3.4-3.10) and IR analyses (Figure 3.11).  Figures 3.2, 3.6 and 3.11 
are shown in the Appendix one. 
8 mg of the amide was isolated from 74 mg of crude extract, a yield of 9% relative to 
the added acid. 
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LCMS data of 1-naphthoic amide 99a: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: LCMS of purified 1-napthoic amide.  (X1): LCMS chromatograms.  
(Y1): Positive ion electrospray mass spectrum for peak at Rt = 2.2-2.3 min.  
 
Figure 3.1 shows a clear alignment between the HPLC total ion chromatogram (TIC), 
the base peak chromatogram (BPC) and extracted ion chromatogram (EIC) for 
naphthoic amide ion (m/z 172).  EIC peaks for m/z of 155, 145 and 129 superimpose 
perfectly with EIC 172 indicating that these peaks are fragments of m/z 172.   
A small impurity peak at 3.2 min could be seen in (X1) and some impurities also 
found in 
1
H-NMR data (Figure 3.2).  1-naphthoic amide was identified by LCMS 
(Figure 3.1), 1D and 2D NMR (Figures 3.2 and 3.4-3.10) and IR analyses (Figure 
3.11).  The fragmentation patterns shown in Figure. 3.1 can be explained by the 
fragmentation mechanisms described in scheme 3.1.  
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Scheme 3.1: Possible mechanisms of the fragmentation of 1-naphthoic amide.   
 
The fragment with m/z 155 is produced after loss of ammonia from the protonated 
ion.  The fragment with m/z 129 could be the result of a loss of acetylene (C2H2) from 
the naphthoyl fragment (m/z 155).  The fragment with m/z 145 could be the result of a 
loss of CNH from the molecular ion after an internal rearrangement of hydrogens 
between the amine and the carbonyl functional groups.   
 
1D and 2D NMR data of 1-naphthoic amide 99a 
 
An overview of the 
1
H-NMR spectrum of 99a in CDCl3 is displayed in Figure 3.2 
(Appendix one).  Expansions of different parts of the spectrum are represented in 
Figures 3.4 and 3.5. 
 
Assignment of  protons and carbons of 99a 
 
In order to assign all naphthoic amide protons and carbons, 1D 
1
H-NMR (Figures 3.2, 
3.4 and 3.5), 1D 
13
C-NMR (Figures 3.6 (Appendix one) and 3.7), and 2D NMR 
(COSY, HMQC and HMBC, Figures 3.8-3.10) were performed.  It is possible to 
identify all 7 protons (H2-H8) of the naphthoic amide 99a based on the COSY 
spectrum (Figure 3.8).  The HMQC heteronuclear experiment was used to correlate 
directly bonded 
1
H and 
13
C peaks.  The HMBC heteronuclear technique was used to 
connect 
1
H and 
13
C peaks separated by 2 or 3 bonds.  It is clear from the
 1
H-
1
H COSY 
NMR spectrum of amide 99a that protons   7.72 and  7.48 are interrelated but  
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7.72 and  7.95 are not correlated because the meta coupling was not resolved.  
Moreover,  7.95 and  7.48 are shown to be interrelated.  From HMBC spectrum 
(Figure 3.10),  7.72 (1 H d) corresponds to 171.67 carbon (CONH2) and is assigned 
to H2 that is also interrelated with 130.63 carbon (C1).  Therefore, proton  7.48 is 
assigned to H3 and  7.95 to H4.  
1
H-
1
H COSY NMR also reveals that protons  8.43 and  7.59 are coupled to each 
other and that  8.43 is not coupled to  7.54.  On the other hand  7.59 and  7.54 are 
coupled to each other.  The ortho coupling between neighbouring protons is shown in 
1
H-NMR spectrum but the meta coupling was not fully resolved (Figure 3.4).  
Furthermore  7.88 is correlated to   7.54 and not interrelated with  7.59.  
Therefore, proton  8.43 (1 H d) is assigned to H8,  7.59 (1 H ddd) is assigned to H7, 
 7.54 (1 H ddd) is assigned to H6 and proton  7.88 (1 H d) is assigned to H5.   
HMQC spectrum of naphthoic amide 99a (Figure 3.9) revealed all the 7 cross-peaks 
that correlate directly bonded 
1
H and 
13
C peaks.  Consequently all the 7 carbons (C2-
C8) were assigned as shown in the assignment table in Figure 3.9.  
HMBC spectrum (Figure 3.10) shows (in addition to the interrelation between proton 
H2 and carbons C1 and CONH2) that H8, giving the signal at  8.43 is coupled to 
C8a, giving the signal at  133.84.  Also, this experiment shows the interrelation 
between  7.88 and  133.08 that is the coupling between H5 and carbons C4a over 2-
bond length. 
The summary of proton and carbon assignment of 1-naphthoic amide 99a is illustrated 
in Figure 3.3 and Table 3.2. 
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Figure 3.3: COSY, HMQC and HMBC correlations for 99a.  Black arrows highlight 
1
H-
1
H COSY correlations, blue arrows show 
1
H-
13
C HMBC correlations and red 
arrows represent 
1
H-
13
C HMQC correlations.  
1
H-NMR chemical shifts (in ppm) are 
displayed next to each respective proton.  
 
 
Position 1-naphthoic amide 99a 
1
H-NMR 
 (in ppm) 
13
C

-NMR 
 (in ppm) 
1 - 130.11 
2 7.72 125.46 
3 7.48 124.69 
4 7.95 131.34 
4a - 133.08 
5 7.88 128.46 
6 7.54 126.60 
7 7.59 127.40 
8 8.43 125.50 
8a - 133.84 
CONH2 - 171.67 
 13C-NMR data deduced from HMQC and HMBC spectra. 
  
Table 3.2: 
1
H-NMR and 
13
C-NMR data of 1-naphthoic amide 99a. 
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Figure 3.4:
 1
H-NMR in CDCl3 of 1-naphthoic amide 99a (expanded view of Figure 3.2, 
region 7.84-8.48).  
 
1
H-NMR spectrum in Figure 3.4 exhibited only ortho couplings between H8 and H7, H4 
and H3 and H5 and H6.  The meta and the para couplings were not revealed by the 
experiment as the peaks were not fully resolved.  The spectrum also shows the persistence 
of some impurities.    
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Figure 3.5:
 1
H-NMR in CDCl3 of 1-naphthoic amide 99a (expanded view of Figure 3.2, 
region 7.16-7.78).  
 
1
H-NMR spectrum in Figure 3.5 shows the ortho couplings between H3 and both 
neighbouring protons H2 and H4.  Furthermore, the proton H6 and H7 reveal meta 
couplings with H8 and H5 respectively, even if the peaks are not fully resolved.  
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Figure 3.7: 
13
C-NMR in CDCl3 of 1-naphthoic amide 99a (expanded view of Figure 
3.6, Appendix one) and assignment of the 11 carbon atoms. 
 
13
C-NMR analysis of 1-naphthoic amide 99a reveals clear signals for all the 11 
carbon atoms constructing the skeleton of compound 99a.  The seven larger signals 
are assigned to the C2-C4 and C5-C8 carbons.  The three smaller signals are assigned 
to C1, C4a and C8a because carbon atoms without attached hydrogen atoms relax 
very slowly when the delay time used is not very large.  The amide carbon (CONH2) 
appears downfield at  171.51. 
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Figure 3.8: 
1
H-
1
H COSY NMR in CDCl3 of 1-naphthoic amide 99a.   
 
The experiment presents a two-dimensional contour map, each dimension 
representing proton chemical shifts and the contours representing signal intensity.  
The diagonal (running bottom left (H8, H7) to top right (CDCl3)) shows peaks that 
correspond to the 7 protons (H2-H8) of 1-napthoic amide 99a.  The off-diagonal 
peaks (cross-peaks) represent a coupling between the protons that are correlated by 
the cross-peak and are represented in Figure 3.8 by solid perpendicular lines (in 
tangerine colour).  The spectrum is symmetrical about the diagonal as a coupling from 
proton 8 to 7 will always be matched with one from 7 to 8.  Based upon 
1
H-
1
H COSY 
experiment, we could identify coupling between protons H2 and H3, H3 and H4, H5 
and H6, H6 and H7 and between H7 and H8.   
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Figure 3.9: HMQC-NMR in CDCl3 of 1-naphthoic amide 99a.  The spectrum shows 
the correlation between directly bonded 
1
H and 
13
C peaks and provides carbon 
assignment (Table on the right). 
 
As seen in the simulated spectrum above (Figure 3.9), assignment is made by 
drawing two lines (in green) at a right angle from the 
1
H spectrum to the 
13
C spectrum 
through the cross-peak. Thus, in the spectrum above, C8 is directly attached to H8.  In 
a similar fashion, C2, C3, C4, C5, C6 and C7 are directly correlated and bonded to 
H2, H3, H4, H5, H6 and H7, respectively.  This experiment provides assignment of 
carbons C2-C8 as illustrated in the joined Table in Figure 3.9.  
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Figure 3.10: HMBC-NMR in CDCl3 of 1-naphthoic amide 99a.  The spectrum shows 
the correlation between 
1
H and 
13
C peaks, mostly over 2-3 bond length. 
 
Most of the peaks in Figure 3.10 are consistent with the two- and three-bond 
couplings expected for molecule 99a.   
The cross-peak labelled CP2 shows coupling between carbon C8a and proton H6 over 
four-bond length which is possible in conjugated systems.  Similarly, the cross-peak 
CP3 shows connectivity between C8a and proton H3 over four-bond length.  
Furthermore, cross-peaks CP1 and (H4, C3) are situated in the same horizontal line 
suggesting a possible coupling between H6 and the more distant C3.  The cross-peak 
subtended by the horizontal and vertical dashed lines such as H8, C8a shows that H8, 
giving the signal at  8.43 is coupled to C8a, giving the signal at  133.84 over two-
bond length.  Similarly, proton H8 is connected to C6, giving the signal at  126.60 
over three-bond length.  Additionally, the cross-peak (H2, C1) reveals coupling 
between H2, at  7.72 and C1, at  130.11 over two-bond length.  The remaining 
cross-peaks show couplings between respective protons and carbons over either two- 
or three-bond and could be explained in similar fashion as the cross-peaks (H8, C8a) 
and (H8, C6). 
130 
 
IR data of 1-naphthoic amide 99a 
 
The IR spectrum of the amide 99a is shown in Figure 3.11 (Appendix one).  The 
spectrum exhibits absorption band at about 1680 cm
-1
 which may be indicator of C=O 
stretching.  The NH stretching of the NH2 group of 1-naphthoic amide was not strong 
(may be because of the low concentration of the sample) and shows 2 distinct bands 
between 3080 and 3150 cm
-1
.  The spectrum also shows an absorption peak at 
approximately 3030 cm
-1 
and corresponds to CH stretching. 
 
 
 
Isolation and purification of 4-fluoro-1-naphthoic amide 100a 
 
Isolation and purification of 4-fluoro-1-naphthoic amide was achieved similarly to 1-
naphthoic amide 99a with the following changes:  
The flash column chromatography was run with 60:40 ethyl acetate/40-60 petroleum 
ether and the product had an Rf of 0.23.   
24 mg was purified from 150 mg of crude extract, a yield of 25% relative to the added 
acid. 
 
LCMS data of 4-fluoro-1-naphthoic amide 100a: 
 
 
Figure 3.12: LCMS of purified 4-fluoro-1-naphthoic amide.  (X2): LCMS 
chromatograms.  (Y2): Positive ion electrospray mass spectrum for the new peak at Rt 
= 2.5-2.6 min.  
  
131 
 
Figure 3.12 shows a clear alignment between the HPLC total ion chromatogram 
(TIC), the base peak chromatogram (BPC) and extracted ion chromatogram (EIC) for 
the MH
+
 ion for 4-fluoro-1-naphthoic amide ion (m/z 190).    EIC peaks for m/z 173, 
163 and 147 superimpose perfectly with EIC 190 indicating that these peaks are 
fragments of m/z 190.   
4-fluoro-1-naphthoic amide was characterized by LCMS (Figure 3.12), 1D and 2D 
NMR methods (Figures 3.13 and Figures 3.15-3.21) and IR analyses (Figure 3.22).  
Figures 3.13, 3.17 and 3.22 are presented in the Appendix one.  The fragmentation 
pattern is similar to that shown in Figure 3.1 and the mechanisms could be explained 
in a similar fashion to that of 1-naphthoic amide in scheme 3.1.  
 
1D and 2D NMR data of 4-Fluoro-1-naphthoic amide 100a: 
 
An overview of the 
1
H-NMR spectrum of 100a in CDCl3 is displayed in Figure 3.13 
(Appendix one).  Expansions of different parts of the spectrum are represented in 
Figures 3.15 and 3.16. 
 
Assignment of protons and carbons of 100a 
 
1
H-
1
H COSY NMR spectrum of amide 100a (Figure 3.19) shows only 4 protons.  
Protons  7.60 and  8.48 do not appear within the data.  Protons  8.15 and  7.64 are 
interrelated to each other and  7.13 and  7.69 are interrelated to each other as well.  
From HMBC spectrum (Figure 3.21),  7.69 (1 H dd) corresponds to 170.55 carbon 
(CONH2) and is assigned to H2 that is also interrelated with 132.01 and 159.5 
carbons.  Therefore, proton  7.13 (1 H dd) is assigned to H3,  132.01 to C1 and  
159.5 to C4.  Carbons C1 and C4 were assigned by analogy to 1-naphthoic amide 99a.  
HMBC spectrum did not show much data for further analysis.  Furthermore, carbons 
giving signals at  126.10,  108.48,  121.40 and  128.40 were assigned as C2, C3, 
C5 and C6, respectively based on HMQC analysis.  The assignment of the remaining 
protons (H5-H8) could be deduced from comparison to amide 99a.  Proton  8.48 (1 
H d) is assigned to H8 and proton  8.15 (1 H d) is assigned to H5.  From COSY 
experiment,  8.15 and  7.64 (1 H ddd) are interrelated to each other and therefore  
7.64 is assigned to H6.  Finally, the proton  7.60 (1 H d) is assingned to H7.  The 
summary of proton and carbon assignment of amide 100a is illustrated in Figure 3.14 
and Table 3.3. 
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Figure 3.14:
 1
H-
1
H COSY, HMQC and HMBC correlations for 100a. 
 
Green arrows 
show 
1
H-
1
H COSY correlations, red arrows represent HMBC correlations and blue 
arrows highlight HMQC coupling.  
  
 
Position 4-fluoro-1-naphthoic amide 100a 
1
H-NMR 
 (in ppm) 
13
C

-NMR 
 (in ppm) 
1 - 132.01 
2 7.69 126.10 
3 7.13 108.48 
4 - 159.50 
4a - - 
5 8.15 121.40 
6 7.64 128.40 
7 7.60 - 
8 8.48 - 
8a - - 
CONH2 - 170.55 
 13C-NMR data deduced from HMQC and HMBC spectra. 
  
Table 3.3: 
1
H-NMR and 
13
C-NMR data of 4-fluoro-1-naphthoic amide 100a. 
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Figure 3.15: 
1
H-NMR in CDCl3 of 4-fluoro-1-naphthoic amide 100a (expanded view 
of Figure 3.13, region 7.90-8.74). 
 
The proton spectrum shown in Figure 3.15 exhibits two peaks resolved as doublets 
and giving signals at  8.48 and  8.15.  The peaks are assigned H8 and H5, 
respectively.  The two signals appear as doublets because the meta and the para 
couplings were not revealed by the experiment as the peaks were not fully resolved.   
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Figure 3.16:
 1
H-NMR in CDCl3 of 4-fluoro-1-naphthoic amide 100a (expanded view 
of Figure 3.13, region 6.80-7.84). 
 
Figure 3.16 shows 4 protons giving signals at  7.69,  7.64,  7.60 and  7.13 and 
assigned H2, H6, H7 and H3, respectively.  The proton H3 is shown as double doublet 
revealing couplings with fluorine F4 and H2.  As well as ortho couplings, protons H2 
and H6 reveal also meta couplings with F4 and H8, respectively.  Furthermore, the 
spectrum shows that H7 was just partially resolved.  
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Figure 3.18: 
13
C-NMR in CDCl3 of 4-fluoro-1-naphthoic amide 100a (expanded view 
of Figure 3.17, region 107-129 ppm).  Peaks shown with  could not be assigned yet. 
 
The spectrum in Figure 3.18 shows only 8 peaks among the 11 carbon atoms 
contained in compound 100a.  The absence of the remaining peaks might be due to 
the low concentration of the purified sample.  Furthermore, only carbons C3, C2 and 
C6 giving signals at  108.48,  126.10 and  128.40 respectively, could be assigned 
due to the insufficient data collected from HMQC and HMBC experiments (Figures 
3.20 and 3.21 respectively).  As consequence, peaks shown with  in Figure 3.18 
remained unassigned.   
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Figure 3.19:
 1
H-
1
H COSY NMR in CDCl3 of 4-fluoro-1-naphthoic amide 100a.   
 
The COSY experiment was used to analyse the coupling protons in compound 100a. 
The diagonal (running bottom left (H5, H6) to top right (H3, H2)) shows only 4 peaks 
that correspond to protons H5, H2, H6 and H3. The cross-peaks show coupling 
between protons H5 and H6 and also between H2 and H3.  Solid perpendicular lines 
(in red, Figure 3.19) represent coupling between H2 and H3.  Protons H7 and H8 
could not be detected by this experiment.  
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Figure 3.20:
 
HMQC-NMR in CDCl3 of 4-fluoro-1-naphthoic amide 100a. The 
spectrum shows the correlation between directly bonded 
1
H and 
13
C peaks and 
provides assignment of C2, C3, C5 and C6 carbons. 
  
The cross-peaks revealed in the spectrum above (Figure 3.20) show the correlation 
between directly bonded 
1
H and 
13
C peaks.  The carbon assignment could be deduced 
from HMQC spectrum in a similar fashion to that of 1-naphthoic amide in Figure 3.9.  
Hence, carbon giving signal at  126.10 is assigned C2,  108.48 as C3,  121.40 as 
C5 and  128.40 as C6.  It is noteworthy to mention that C5 giving the signal at  
121.40 in HMQC spectrum was not shown in the carbon spectrum as shown by the 
red arrow.  Also the peaks highlighted with  in the carbon spectrum could not be 
assigned yet. 
 
 
 
 
  
138 
 
An outline of HMBC-NMR of 100a in CDCl3 is presented in Figure 3. 21.   
 
 
Figure 3.21: HMBC-NMR in CDCl3 of amide 100a. 
 
Proton  7.69 (1 H dd) is correlated to 170.55 carbon that correspond to the amide 
group (CONH2).  Therefore  7.69 was assigned to H2.  Also Figure 3.21 shows the   
interrelation of proton  7.69 with 132.01 and 159.5 carbons.   132.01 could be 
assigned to C1 in analogy to amide 99a and  159.5 could be assigned either C4 or 
C8a and not C3 as the latter gives signal at  108.48 (Figure 3.21).  Comparison with 
carbon assignment of amide 99a (Table 3.2) shows that  159.5 is further downfield 
compared to C8a ( 133.84).  Furthermore, the presence of a highly electronegative 
substituent (fluorine atom) at C4 could explain clearly the appearance of the peak 
further downfield.  As consequence,  159.5 is assigned to C4.  The region of the 
carbon spectrum projected in F1 dimension (Figure 3.21) did not reveal any of the 
carbon peaks (C1, C4 and CONH2) highlighted by the HMBC-NMR experiment.   
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IR data of 4-fluoro-1-naphthoic amide 100a 
 
The IR spectrum of the amide 100a is shown in Figure 3.22 (Appendix one).  The 
spectrum shows absorption band at about 1733 cm
-1
 which may be indicator of C=O 
stretching.  The NH stretching of the NH2 group of 100a was weak and reveals 2 
distinct bands between 3100 and 3150 cm
-1
.  The peak appearing at about 3025 cm
-1 
corresponds to CH stretching. 
 
 
 
Isolation and purification of 4-methyl-1-naphthoic amide 101a 
Isolation and purification of 4-methyl-1-naphthoic amide was done in the same way 
as amide 99a with the following exceptions.  Flash column chromatography was 
performed with 70:30 ethyl acetate/40-60: petroleum ether, and the product had an Rf 
= 0.30.   
5 mg was isolated from 180 mg of crude extract, a yield of 5% relative to the added 
acid. 
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LCMS data of 4-methyl-1-naphthoic amide 101a: 
 
 
Figure 3.23: LCMS of purified 4-methyl-1-naphthoic amide.  (X3): LCMS 
chromatograms.  (Y3): Positive ion electrospray mass spectrum for the new peak at Rt 
= 2.6-2.7 min.  
 
Figure 3.23 demonstrates a clear alignment between the HPLC total ion 
chromatogram (TIC), the base peak chromatogram (BPC) and extracted ion 
chromatogram (EIC) for 4-methyl-1-naphthoic amide ion (m/z 186).    EIC peaks for 
m/z 169, 159 and 143 superimpose perfectly with EIC 186 indicating that these peaks 
are fragments of m/z 186.  m/z 128 corresponds to background signal.    
4-methyl-1-naphthoic amide 101a was characterized only by LCMS (Figure 3.23), as 
impurities hampered NMR analysis.  The fragmentation patterns that are shown in 
Figure 3.23 display also strong correlations with those for 1-naphthoic amide in 
Figure 3.1.  As consequence, the fragmentation mechanisms of amide 101a could be 
explained in a similar fashion to that of 1-naphthoic amide 99a in scheme 3.1.   
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Isolation and purification of 2-methyl-1-naphthoic amide 102a: 
 
Isolation and purification of 2-methyl-1-naphthoic amide was done in identical way as 
amide 99a except that TLC exibited an Rf of 0.48.   
3 mg was purified from 74 mg of crude extract, a yield of 3% relative to the added 
acid. 
 
LCMS data for 2-methyl-1-naphthoic amide 102a: 
 
 
 
 
 
 
 
 
 
 
Figure 3.24: LCMS of purified 2-methyl-1-naphthoic amide.  (X4): LCMS 
chromatograms.  (Y4): Positive ion electrospray mass spectrum for the peak at Rt = 
2.3-2.4 min.  
 
Figure 3.24 demonstrates a clear alignment between the HPLC base peak 
chromatogram (BPC) and extracted ion chromatogram (EIC) for 2-methyl-1-
naphthoic amide ion (m/z 186).    EIC peaks for m/z of 169, 143 and 141 superimpose 
perfectly with EIC 186 indicating that these peaks are fragments of m/z 186.   
 
The persistence of impurities was a major obstacle preventing NMR analysis.  
Therefore, amide 102a was characterized only by LCMS (Figure 3.24).  The 
fragmentation patterns that are shown in Figure 3.24 display also strong correlations 
with those seen for the other amides, formed by the same mechanisms (Scheme 3.2).   
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Scheme 3.2: Fragmentation mechanisms of 2-methyl-1-naphthoic amide. 
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Isolation and purification of 2-methoxy-1-naphthoic amide 103a: 
 
Isolation and purification of 2-methoxy-1-naphthoic amide was achieved similarly to 
1-naphthoic amide except that TLC exibited an Rf of 0.41.  
20 mg was purified from 80 mg of crude extract, a yield of 20% relative to the added 
acid. 
 
LCMS results after feeding 2-methoxy-1-naphthoic amide 103a: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25: LCMS of purified 2-methoxy-1-naphthoic amide.  (X5): LCMS 
chromatograms.  (Y5): Positive ion electrospray mass spectrum of the peak at Rt = 
3.1-3.4 min.  
 
Figure 3.25 shows a clear alignment between the HPLC total ion chromatogram 
(TIC), base peak chromatogram (BPC) and extracted ion chromatogram (EIC) for 2-
methoxy-1-naphthoic amide ion (m/z 202).  EIC peak for m/z 224 is the sodium 
adduct of the main amide ion [M+H]
+
 for m/z 202.  The persistence of impurities was 
a major problem preventing NMR analysis.  Hence, amide 103a was characterized 
only by LCMS.   
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Isolation and purification of 3-fluoro-1-naphthoic amide 98a: 
 
Isolation and purification of 3-fluoro-1-naphthoic amide was achieved similarly to 4- 
fluoro -1-naphthoic amide.  The product had Rf = 0.21. 
14 mg was purified from 97 mg of crude extract, a yield of 15% relative to the added 
acid. 
 
LCMS data of 3-fluoro-1-naphthoic amide 98a: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26: LCMS of purified 3-fluoro-1-naphthoic amide.  (X6): LCMS 
chromatograms.  (Y6): Positive ion electrospray mass spectrum of the peak at Rt = 
2.3-2.4 min.  
 
There is clear alignment between the HPLC total ion chromatogram (TIC), the base 
peak chromatogram (BPC) and extracted ion chromatogram (EIC) for 3-fluoro-1-
naphthoic amide ion (m/z 190).    EIC peaks for m/z of 173, 163 and 147 superimpose 
perfectly with EIC 190 indicating that these peaks are fragments of m/z 190.   
3-fluoro-1-naphthoic amide was characterized only by LCMS since the existence of 
impurities hampered NMR analysis.  The fragmentation patterns for amide 98a 
(Figure 3.26) is similar to amides 99a and 100a (Figures 3.1 and 3.12, respectively) 
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and the mechanisms could be explained in a similar fashion to that of 1-naphthoic 
amide 99a in scheme 3.1.  
 
Isolation and purification of 3-methoxy-1-naphthoic amide 97a: 
 
Isolation and purification of 3-methoxy-1-naphthoic amide was achieved similarly to 
naphthoic amide except that TLC Rf was 0.46. 
2 mg was purified from 43 mg of crude extract, a yield of 2% relative to the added 
acid. 
 
LCMS results after feeding 3-methoxy-1-naphthoic amide 97a: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27: LCMS of purified 3-methoxy-1-naphthoic amide.  (X7): LCMS 
chromatograms.  (Y7): Positive ion electrospray mass spectrum of the peak at Rt = 
2.2-2.3 min.  
 
The peak at Rt = 2.2-2.3 min has MS data consistent with 3-methoxy-1-naphthoic 
amide ion with m/z 202 for the MH
+
 ion.    Also the EIC peaks for m/z of 185 and 159 
superimpose perfectly with EIC 202 indicating the fragmentation origin of these ions 
according to the same mechanism as 1-naphthoic amide (Scheme 3.1).  The EIC peak 
 
146 
 
for m/z of 144 could be explained by the loss of the methyl group from fragment m/z 
of 159.  3-methoxy-1-naphthoic amide was characterized only by LCMS (Figure 
3.27), as impurities hampered NMR analysis.   
 
Feeding amine derivatives in conjunction with naphthoic acid 
 
In an attempt to test the ability of S. sahachiroi to biotransform naphthoic acid with 
different amines (other than ammonia), compounds, a series of amine salts (110-114, 
Table 3.4) were added in various concentrations along with 1 mM naphthoic acid, 24 
h after inoculation.  The results are shown on table 3.4. 
 
 
Compound 
 
Result 
Methylamine hydrochloride 
CH3NH2 . HCl 
 
 
No production. 
Hydrazine dihydrochloride 
H2NNH2 .2HCl 
No production. (apparent 
new metabolite of MW = 
792 which, not identified 
yet, was produced instead).   
Dimethylamine hydrochloride 
CH3NHCH3 . HCl 
 
No production. 
Ethylamine hydrochloride 
CH3CH2NH2 . HCl 
 
No production. 
 
Hydroxylamine hydrochloride 
NH2OH . HCl 
 
 
No production. 
 
 
Table 3.4: Evaluation of amine analogues for biotransformation into naphthoic 
amides after 64 h incubation of S. sahachiroi culture. 
 
The chloroform extracts of feeding compounds 110-114 were analysed by LCMS 
method but no peaks consistent with the anticipated amide compounds were seen 
(Table 3.4).  However, new peaks were seen whilst analysing the hydrazine 
dihydrochloride 111 feeding extract suggesting the production of a new metabolite 
(Figures 3.28-3.29). Several reasons might be behind the non-production of amide 
metabolites.  Firstly, it is possible that the added amines were not incorporated into 
110 
111 
112 
113 
114 
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the bacterial enzymatic machinery. Secondly, the bacterial membrane might have 
restricted the diffusion of the fed compounds.  Finally, the fed compounds could be 
degraded by an unknown catabolic pathway. 
 
Isolation and attempted purification of hydrazine feeding extract 
 
Isolation and purification of hydrazine feeding extract was performed the same way as 
naphthoic amide with the following exceptions.   
Flash column chromatography was performed with 75:25 ethyl acetate/40-60 
petroleum ether, with the main product (MW = 792 g.mol
-1
 and [M+H]
+ 
= 793) 
eluting with an Rf of 0.28. 
 
LCMS results after feeding hydrazine dihydrochloride 111: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28: HPLC of crude extract from feeding 1-naphthoic acid and hydrazine 
dihydrochloride to S. sahachiroi.  (X8): HPLC chromatograms.  (Y8): Positive ion 
electrospray mass spectrum. 
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The new metabolite was isolated and purified by flash column chromatography and 
gave the LCMS data presented in Figure 3.29. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.29: HPLC of purified compound from feeding hydrazine hydrochloride to S. 
sahachiroi.  (X9): HPLC chromatograms.  (Y9): Positive ion electrospray mass 
spectrum.  The main ions observed in (Y9) come from the same compound.   
 
The identity of the apparent new metabolite (MW = 792 g.mol
-1
 and m/z (ESI)
 
= 793) 
subsequent to feeding hydrazine dihydrochloride to S. sahachiroi could not be 
confirmed yet as NMR analysis was hampered by impurities. 
 
3.2.2 Antibacterial and antifungal activity tests 
 
Target microorganisms 
 
Disk diffusion (DDA) and spot culture growth inhibition (SCGIA) assays (chap. 2, 
section 2.2.2 Microbiology) were used to assess the antimicrobial activity of the 
methanol extract of S. sahachiroi and the methanol solution (by redisolving the dried 
chloroform extracts) of the purified compounds (97a-103a as well as the purified one 
from feeding hydrazine 111) against several target microorganisms as is shown in 
table 3.5.  In total 8 bacteria (4 Gram-positive and 4 Gram-negative) and 4 fungi 
strains were target for antimicrobial activity.    
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Bacteria strains 
 
Fungi 
Gram
+
 Gram

 
Micrococcus luteus Escherichia coli K1  Trichoderma harzianum T1 
 
Bacillus subtilis Escherichia coli K12 Pyrenophora avenae 
 
Bacillus megaterium Escherichia coli Rhizoctonia solani  
 
Staphylococcus epidermis Pseudomonas diminutus Fusarium oxysporum 
 
 
Table 3.5: Microorganisms used as target to assess the antibacterial and antifungal 
activity of S. sahachiroi’s crude extracts and the purified compounds (97a-103a and 
the purified one from feeding hydrazine 111). 
 
Disk diffusion assay (DDA) and spot culture growth inhibition (SCGIA) assay  
   
During DDA, filter paper disks were firstly soaked either with the purified compound 
at two different concentrations (2 to 1 mg mL
-1
) or impregnated with S. sahachiroi’s 
crude extracts at a range of concentrations (120 to 5 mg mL
-1
).  Then the disks were 
placed on the agar plate already inoculated with target bacteria (Table 3.5).  The 
plates were then incubated for 24 hours at 37 
o
C.   
With fungi, a trimmed colony disk of a precultured fungus was placed in the centre of 
the PDA media.  Then the paper disks were impregnated with the test compounds, 
placed on the agar plates and incubated for 3-5 days at 25 
o
C. 
 
During spot culture growth inhibition assay, the tested compounds were dissolved in 
methanol and two duplicated dilutions (2 mg mL
1
 and 0.2 mg mL
1
) of each 
compound were made in 2 mL eppendorf tubes.  Using a six well plate, a volume of 2 
 5 µL (of each compound) was transferred into a duplicated wells, followed by 2.5 
mL of nutrient agar (NA) in each individual well.  The final dilutions were 4 and 0.4 
µg mL
1
 respectively.  The procedure was the same for the remaining two wells but 
no compound was added because the wells were used as positive control.  After 
bacterial (5 µL) transfer and horizontal shaking, the plates were sealed and incubated 
at 37 
o
C for 48 hours.  
  
150 
 
Results from DDA and SCGIA 
  
In general there were no sign of any inhibition zones around the disks (for DDA) or 
inhibition of growth of the tested microorganisms (for SCGIA) except for the purified 
compound from feeding hydrazine 111 (not identified yet) and against one sole isolate 
strain (M. luteus).  An (average) inhibition zone of about 8 mm was seen at a 
concentration of 2 mg mL
1
 (Figure 3.30).  The same compound (from feeding 
hydrazine 111) has also shown a growth inhibition at minimum inhibitory 
concentration (MIC) of 0.4 µg mL
-1
 during SCGIA (Figure 3.31).  In the same plate 
(Figure 3.31), it was found that 1-naphthoic amide had no effect on M. luteus growth. 
  
Since many data from DDA and SCGIA looked alike, only results from testing 1-
naphthoic amide 99a for DDA (Figures 3.36-3.47, Appendices two and three) and 
results from testing 99a and 4-fluoro-1-naphthoic amide 100a for SCGIA (Figures 
3.48-3.55, Appendix four) are presented in this study.   
 
Results from DDA 
 
 
 
 
 
Figure 3.30: Antibacterial test result of purified compound from feeding hydrazine 
111 against M. luteus.  Inhibition zones (average ~ 8 mm) are seen around all disks 
except control disk (c).  Methanol (MeOH) was used as control.     
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Results from SCGIA 
 
 
 
Figure 3.31: Spot culture growth inhibition assay (SCGIA) of 99a and purified 
compound from feeding 111 against M. luteus: Result showing (a) no growth 
inhibition with increased concentration (wells 1 and 2) of 1-naphthoic amide 99a and 
(b) growth inhibition with the increased concentration (wells 3 and 4) of purified 
compound from feeding 111.  (c) represents methanol (MeOH) control. 
 
The purified compound from feeding hydrazine 111 shows a biological activity 
against M. luteus solely.  There was no activity against the other bacteria or fungi 
when compounds 97a-103a were tested. 
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3.3 Discussion 
 
3.3.1 Bacterial biotransformation 
 
While attempting to discover, by precursor directed biosynthesis, novel azinomycin 
analogues (Chapter 4), additional novel metabolites appeared in some of the 
fermentation broths.  These metabolites were clearly the result of microbial 
modification of the fed chemicals, which were biotransformed into their analogous 
primary amides (Table 3.1). However, no secondary amide metabolites were seen in 
the fermentation broths following the co-feeding of naphthoic acid and amine 
precursors.   
These results suggest that the biotransformed precursors diffused (passively or by 
active transport) through the first bacterial barriers (cell wall and cytoplasmic 
membrane).  Secondly, the enzyme involved in the biotransformation of acids to 
amides shows some degree of flexibility towards a range of substrates (97a-103a).  
On the other hand, there was no production of naphthoic amides after feeding the 
remaining naphthoate compounds (Table 3.1).  That result might be due to the lack of 
diffusion of these compounds through the bacterial cell wall and/or cytoplasmic 
membrane or could be due to their degradation in the fermentation media.  Likewise 
there is a possibility of the non-compatibility of these compounds with the enzyme’s 
active site. 
It is likely that the enzymes involved in the biotransformation of naphthoic acids to 
amides belong to the amide synthases family using ammonia molecules from the 
culture medium or from internal catabolism pathways.  It is difficult to be sure of the 
identity of the enzymes involved in the present biotransformation as no enzymes have 
yet been isolated from S. sahachiroi that are involved in the biotransformation of 
naphthoic acids into amides.  It was reported that both amide synthases (Thiericke & 
Rohr., 1993) and nonribosomal peptide synthetases (Bushley and Turgeon, 2010) 
show low substrate specificity.   
It has been experimentally determined that the AziA1 NRPS di-domain serves to load 
and activate 3-methoxy-5-methyl-1-naphthoic acid as expected for its role in initiating 
azinomycin biosynthesis (Zhao et al., 2008; Ding Zhao et al., 2010).  It was also 
demonstrated that this enzyme could activate unnatural substrates.  However, 
modified naphthoate derivatives were not isolated in these studies.  It is therefore 
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possible that the AziA1 NRPS enzyme activates the naphthoic acids in the formation 
of amides but then fails to pass them on to the hydroxyl group on the epoxide 
fragment, with ammonia acting as an alternative nucleophile (Figure 3.32). 
 
 
 
Figure 3.32: Proposed strategy for the bioconversion of naphthoic acid analogues into 
the corresponding amides by the azinomycin NRPS.   
 
Figure 3.32 shows that naphthoic acid analogues are first activated by the adenylation 
domain of the enzymatic module AziA1 and then transferred to the peptidyl carrier 
protein (PCP) domain of the same enzyme module.  The tethered thioester is then 
transferred to the PCP of the second module AziA2 in order to initiate the assembly of 
azinomycin A analogue fragments.  However, the azinomycin NRPS might have 
failed to catalyse the latter step and instead alternate ammonia molecules, acting as 
nucleophiles, catalyse amidation reactions and consequently bioconvert naphthoic 
acid analogues into corresponding amide products.   
 
It is worth emphasizing that Streptomyces bacteria are not only well known for their 
leading role as important source of bioactive natural compounds, they also offer a 
wide spectrum of enzymes that are useful for microbial biotransformation.  Indeed, it 
is well cited in the literature that Streptomyces’ enzymes cover a wide array of 
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reactions allowing the bioconversion of a broad spectrum of organic substrates into 
useful compounds (Sutherland, 1986; Brunati et al., 2003; Gurram et al., 2009).  They 
are less substrate specific than enzymes of primary metabolism, but may reveal high 
chemo-, regio- and enantioselectivity (Mara et al., 2004).  Examples of some of these 
microbial bioconversions include hydroxylation of aliphatic and cyclic compounds 
(Gurram et al., 2009), demethylation of vanillic acid (Sutherland, 1986), methylation 
of catechin by Streptomyces griseus (Figure 3.33) (Das and Rosazza., 2006) and 
amidation of cinnamic acid (Brunati et al., 2003).  Biotransformation of aromatic 
carboxylic acids to amides is known to occur with many streptomyces strains.  
Examples of these biotransformations are the transformation of mycophenolic acid by 
Streptomyces albidoflavus (Figure 3.34) (Jekkel et al., 2002), and cinnamic acid to 
cinnamamide by Streptomyces halstedii (Figure 3.35) (Mara et al., 2004).  Microbial 
enzymatic machinery can be used in many occasions as an alternative route to 
classical synthetic processes.  Certainly, many difficulties encountered during organic 
synthesis such as protecting functional groups or isomerisation and racemisation 
problems are lessened by the use of biological systems (Gurram et al., 2009).  
 
 
 
Figure 3.33: Methylations of (+)-catechin by S. griseus. 
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Figure 3.34: Bioconversion of mycophenolic acid by Streptomyces albidoflavus. 
 
 
 
Figure 3.35: Amidation of cinnamic acid by Streptomyces halstedii. 
 
3.3.2 Biological activity of the purified compounds 
 
Comparison of DDA and SCGIA 
 
Both DDA and SCGIA are reliable, easy, simple to perform and inexpensive 
compared to many other MIC determination methods (Jorgensen and Ferraro, 1998; 
Gaudreau et al., 2007; Evangelopoulos and Bhakta, 2010).  However DDA shows 
many drawbacks. The results are in general qualitative; the test is unsuitable for 
hydrophobic compounds as their diffusibility through the agar is restricted (Brouwer 
et al., 2005).  Additionally DDA is not generally automated test but could be 
automated sometimes (Hejblum et al., 1993).   
 In contract, SCGIA is a quantitative test, suitable for hydrophobic and large 
molecular weight compounds.  Furthermore, the compounds do not interfere with the 
assay (Evangelopoulos and Bhakta, 2010). 
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Chapter 4: Precursor-Directed Biosynthesis of 
Azinomycin A Analogues 
 
4.1 Introduction 
 
The aim of this part of the project was the discovery of novel azinomycin analogues 
by precursor-directed biosynthesis (PDB).  
On analysis of the chemical structure of the azinomycins, it is difficult to imagine 
how to modify by PDB the 1-azabicyclo[3.1.0]hexane ring system.  The idea of 
feeding any alternative potential precursor analogues to S. sahachiroi culture was 
discarded, since the detailed biosynthetic origin of carbons C10 and C11 of the 
aziridine functional group as well as its biocyclisation remain unidentified.  Also, the 
synthesis of any structural analogues would be very challenging. 
The epoxide moiety is relatively small so there are limited options for structural 
analogues of this fragment.  Another likely approach to PDB of azinomycin analogues 
could be modification of the metabolic precursor aminoacetone.  However, the role of 
this metabolite in azinomycin biosynthesis was published (Sharma et al., 2009) well 
after the start of this project.         
We decided that the most fruitful approach was to attempt to modify the substitution 
of the naphthoate fragment by feeding naphthoic acid analogues to the azinomycin 
producer culture.  There is also the fact that Lowden and co-workers had already 
established that naphthoic acids are taken up by the cells during the feeding of native 
precursors 38-40 (Figure 4.1) (Lowden et al., 2004b). 
 
 
 
 
 
 
 
 
Figure 4.1: Structures of compounds 38, 39 and 40. 
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3-Methoxy-5-methylnaphthoic acid (3-Methoxy-5-methyl-NPA) plays an important 
role in the biological activities of the azinomycins through a non-covalent interaction 
with the double stranded DNA.  A study done by Zang and Gates has shown that 
azinomycin analogue 115 (Figure 4.2) containing both an intact epoxide moiety and 
the naphthoate fragment (but lacking the aziridine residue) intercalates into the DNA 
duplex and retains significant biological activity.  On the other hand non-epoxy 
analogues 116 and 117 (Figure 4.2) that contain the naphthalene ring showed weak 
biological activity.  (Zang and Gates, 2000). 
 
 
 
 
 
 
 
 
 
Figure 4.2: Structures of compounds 115, 116 and 117. 
 
In a later study by Coleman and co-workers, it was shown that the viscosity of the calf 
thymus DNA solution did not rise with the increase of naphthoic acid compound 118 
(Figure 4.3) indicating a failure of an effective intercalation between acid 118 and 
calf thymus DNA (Coleman et al., 2002a).  However, and in a support to the 
significant functional importance of the naphthoate moiety, it was revealed in another 
study done by Coleman and co-authors that compounds lacking the naphthoate 
fragment 119 and 120 (Figure 4.3) react weakly with DNA and show no biological 
activity (Coleman et al., 2002b).   
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Figure 4.3: Structures of compounds 118, 119 and 120. 
 
Modification of the aromatic ring in synthetic azinomycin analogues resulted in a 
change in their biological activity.  A study done by Landreau and co-workers showed 
that the effect of removing either 5’-methyl 121 or 3’-methoxy 122 (or both 123) 
(Figure 4.4) substituent(s) from the naphthalene ring resulted in a significant decrease 
in the efficiency of DNA interstrand cross-linking (Landreau et al., 2004).  
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Structures of compounds 121, 122 and 123. 
 
The direct chemical modification of azinomycins is impeded by difficulties due to the 
chemical instability of the 1-azabicyclo[3.1.0]hexane ring system and the poor 
availability of the natural products.  An alternative approach could be the 
development of novel azinomycin analogues by the PDB method.  PDB has a 
significant advantage as it combines the power of synthetic chemistry and 
biosynthesis.  During the deployment of the method, a range of naphthoic acid 
analogues (Table 4.2, Results) were added to the azinomycin producer fermentation 
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broth, and fermentations analysed for the presence of new metabolites incorporating 
these unnatural naphthoates. 
First, we needed to achieve a consistent production of azinomycin A from S. 
sahachiroi batch cultures.  For that purpose the culture method was optimised using a 
fresh S. sahachiroi strain (instead of the old strain) that was ordered from the 
American Type Culture Collection (ATCC).  The strain was maintained and grown on 
batch cultures as described in section 2.2.2.  The main difference between the 
optimised conditions and the unsuccessful ones lies on the age of the inoculating 
spores.  During the unsuccessful conditions, fresh S. sahachiroi spores (from both, old 
and new strains) that were grown for 5-7 days at room temperature were used for 
initial seed cultures.  However, during the optimised conditions aging spores 
(incubated for 3-6 months at room temperature) were the source for initial seed 
cultures.  Hence a reliable production of azinomycin A was achieved.  
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4.2 Results  
 
4.2.1 Bacterial growth and azinomycin production 
 
The growth of the azinomycin producing organism has been checked in GYM, TSA, 
PDA, SRA and NA solid media.  It was found that S. sahachiroi grows and sporulates 
best in GYM solid medium (Table 4.1).  Therefore this solid medium was used for 
growth and maintenance of S. sahachiroi during the course of this study.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1: Evaluation of solid media for growth and formation of spores of S. 
sahachiroi 
Plate Growth Formation of spores 
GYM Robust, with mature and grey 
spores of S. sahachiroi after 
two weeks incubation at room 
temperature. 
Yes 
 
PDA Rapid growth of S. sahachiroi 
after 48 h incubation at 30 
o
C.   
Grey spore formation after two 
weeks incubation at room 
temperature. 
 
Yes 
 
TSA Rapid growth of S. sahachiroi 
after 48 h incubation at 30 
o
C.  
Then the culture was left at 
room temperature for 2 weeks. 
 
No 
 
SRA Rapid growth of S. sahachiroi 
after 48 h incubation at 30 
o
C. 
 
No 
 
NA Rapid growth of S. sahachiroi  
after 48 h incubation at 30 
o
C.  
Then the culture was left at 
room temperature for 2 weeks. 
(M. luteus and S. epidermis 
bacteria streaked in 
perpendicular line with S. 
sahachiroi) 
No 
 
 
161 
 
Different conditions were attempted for optimisation of production of azinomycins A 
and B as follows:  Starting always with fresh spores for initial seed culture, the 
volume of culture broth was decreased from 50 mL to 40 mL (in the 250 mL 
Erlenmeyer flask) in order to rise the volume of oxygen in the flasks available for the 
culture.  Also the volume of spores’ inoculum was increased gradually from 4 to 8% 
(culture broth was kept constant at 50 mL) so that the competition for nutrients would 
intensify leading to a bacterial stress and possibly to a reliable production of 
azinomycins.  Additionally 1-5% dimethyl sulfoxide (DMSO) was added to the 
fermentation broth 24 h after incubation with the intention of inducing stress among S. 
sahachiroi bacteria and consequent production of secondary metabolites in response 
to this stress.  Finally, commercially available chemicals such as naphthoic acid and 
naphthoic acid analogues (at 1 mM) were fed to the fermentation culture 24 h after 
incubation for the same purpose as for the feeding of DMSO.  However, a consistent 
production of azinomycins was difficult to achieve.  The production of azinomycins A 
and B was seen in some of the fermentation culture extracts for a few weeks then 
disappeared for a few months.  It then appeared again for a short period of time and 
vanished for a lengthy period of time.  During some of these attempts, both 
azinomycins (A and B) were seen in some samples during LCMS analysis (Figures 
4.5 and 4.6).  The final optimised conditions involved three phases, two seed and one 
fermentation cultures.  During the first phase, S. sahachiroi’s spores grown on GYM 
solid plates for 3 to 6 months were used to initiate the first seed culture in Erlenmeyer 
flasks containing GYM liquid medium and then incubated as described in chap. 2, 
section 2.2.2.  Afterward, 4% inoculum from previous seed culture was used to 
inoculate similar flasks but containing PS5 liquid medium and then incubated as 
described in chap. 2, section 2.2.2.  The final fermentation batch culture was 
composed of 4% inoculum from the second stage culture and half litre of PS5 medium 
and then incubated as described also in chap. 2, section 2.2.2. 
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Figure 4.5: LCMS of S. sahachiroi chloroform crude extract from feeding 4-fluoro-1-
naphthoic acid.  (A1): HPLC chromatograms of S. sahachiroi chloroform extract 
showing new peaks at 2.8-2.9 min.  (B1) and (B1a): Positive ion electrospray mass 
spectra.  (B1) is displaying peaks for ions consistent with [M+H]
+
 for m/z = 624, 
[M+Na]
+
 for m/z = 646 and the hydrolysed form [M+Na]
+
 + H2O at m/z = 663.8 
consistent with azinomycin B production.  (B1a) shows peaks for ions consistent with 
naphthoate fragment (m/z = 173) and related ions (m/z = 190, m/z = 163 and m/z = 
147) as previously discussed (Figure 3.12, Chapter 3). 
 
A total ion chromatogram (TIC) represents a measure of the overall intensity of ion 
production as function of time.  An extracted ion chromatogram (EIC) designates the 
signal intensity at selected m/z range plotted against retention time.  A base peak 
chromatogram (BPC) represents the plot of the base peak ion signal obtained from a 
series of mass spectra as a function of retention time (Murray, 2010).  
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Figure 4.6: LCMS of S. sahachiroi chloroform crude extract showing production of 
azinomycin A.  HPLC chromatograms (A2) and (A3) of S. sahachiroi chloroform 
extract and positive ion electrospray mass spectrum (B2) showing peaks respectively 
at [M+H]
+
 = 595.8 and [M+Na]
+
 = 617.9 consistent with azinomycin A production. 
 
Azinomycin B (Figure 4.5) was seen in the intact form [M+H]
+
 = 623.8, as a sodiated 
addut [M+Na]
+
 = 645.7 and as a sodiated adduct in the hydrolysed form M+Na]
+
 = 
663.8.  Similarly, azinomycin A was produced as an intact metabolite, sodiated adduct 
and sodiated adduct in the hydrolysed form.  Figure 4.6 shows only the intact form 
[M+H]
+
 = 595.8 and the sodiated adduct [M+Na]
+
 = 617.9. 
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It is noteworthy to mention that the production of azinomycin B was not seen in any 
of the fermentation broths after optimising the culture growth.  Azinomycin A was the 
only secondary metabolite analogue reliably produced with or without exogenously 
supplemented naphthoic acid analogues as seen in Figures 4.7 and 4.10-4.20 (section 
4.2.3)   
 
 
 
Figure 4.7: LCMS of S. sahachiroi showing the production of azinomyicin A and the 
hydrolysed form.  HPLC chromatograms (A4) and positive ion electrospray mass 
spectra (B3) and (B4) showing the production of azinomycin A as sodium adduct 
[M+Na]
+
 at m/z = 618 and in the hydrolysed form [M+Na]
+
 + H2O at m/z = 636 from 
S. sahachiroi crude extract.   
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A consistent production of azinomycin A was seen in the fermentation extracts 
(Figure 4.7) without feeding any exogenous precursor to the culture broth during this 
experiment. 
 
4.2.2 Time course study of the production of azinomycin A 
 
To characterize the behaviour of the azinomycin producer S. sahachiroi, a time course 
study was conducted to analyse bacterial growth.  The growth was assessed by total 
viable-colony counts (Chap. 2, section 2.2.2 Microbiology) and a detailed growth 
curve was prepared (Figure 4.8).   
 
 
 
Figure 4.8: Growth curve of Streptomyces sahachiroi.  Microbial growth was 
measured every 4 h for a period of 80 h.  Developmental phases: lag phase from 0 to 8 
h, log phase from 8 to 24 h, Transition phase from 24 to 28 h and stationary phase 
from 28 to 80 h.  Error bars indicate ± AVEDEV. 
 
Figure 4.8 demonstrates the growth curve of S. sahachiroi by using bacterial cell 
viable counts.  The cultures grew exponentially with a doubling time of about 1.11 h 
in PS5 medium at 30 
o
C.  The cultures enter stationary phase about 28 hours after 
inoculation.  
In order to establish the time-course production of azinomycin A, the culture 
fermentation broth was harvested after different time periods (each 4 h time interval), 
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extracted with chloroform and concentrated. Quantitative LCMS analysis was 
conducted using reversed-phase silica (C18 column, ACE5, 250  4.6mm) with water 
and methanol solution (45:55) as the solvent.  Azinomycin detection was done with 
UV detection (350 nm) and mass-based identification (Section 2.2.2 Microbiology).  
The time course of azinomycin A production was estimated by integrating the areas 
under the peaks for each HPLC chromatogram consistent with azinomycin A 
production and then plotted as a graph of peak area in arbitrary units (A.U) against 
time (in hours) Figure 4.9. 
 
 
 
Figure 4.9: Time course of the production of azinomycin A.  Microbial production of 
azinomycin A started just after 28 h and reached it maximum at 52 h.  Error bars 
indicate ± AVEDEV. 
 
As shown in Figure 4.9, maximum production of azinomycin A occurred at 52 h and 
started shortly after 28 of incubation.  In comparison with Figure 4.8, the production 
of the secondary metabolite, azinomycin A, occurred during the late transition phase 
and continued throughout parts of the stationary phase.  These conditions enabled us to 
proceed to the feeding studies by PDB.   
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4.2.3 Novel azinomycin A analogues by PDB 
 
Precursor-directed biosynthesis method is a potentially powerful way to generate 
novel metabolites by introducing exogenous materials into biosynthetic pathways of 
S. sahachiroi.  Thus, commercially available and synthetic naphthoic acids were fed 
to S. sahachiroi cultures as shown in scheme 4.1.   
 
Scheme 4.1: General strategy adopted for feeding naphthoic acid analogues to S. 
sahachiroi culture broth. 
 
1 mM of Naphthoic acid analogues were fed to the S. sahachiroi cultures 24 h after 
incubation at a concentration of 1 mM.  Successful results were achieved subsequent 
to feeding naphthoic acids 97 and 99-101 as shown in Table 4.2 and Figures 4.10-
4.20.    
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Table 4.2: Evaluation of naphthoic acid analogues for incorporation into azinomycin 
A biosynthesis pathway. 
Compound  Expected Azinomycin A Analogue 
 
Result 
 
3-methoxy-1-
naphthoic acid  
 
Production of 
azinomycin A 
analogue. 
 
 
3-fluoro-1-naphthoic 
acid 
 
No production. 
 
1- naphthoic acid   
Production of 
azinomycin A 
analogues ( 3-
methoxy one).  
 
4-fluoro-1-naphthoic 
acid  
 
Production of 
azinomycin A 
analogue.   
 
4-methyl-1-naphthoic 
acid  
 
Production of 
azinomycin A 
analogue. 
 
2-methyl-1-naphthoic 
acid  
 
No production. 
 
2-methoxy-1-
naphthoic acid  
 
No production. 
97 
98 
99 
100 
101 
102 
103 
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Compound  
 
Expected amide 
 
Result 
 
1,4-naphthalene-
dicarboxylic acid 
 
No production. 
 
8-bromo-1-naphthoic 
acid 
 
No production. 
 
2-ethoxynaphthoic 
acid 
 
No production. 
 
1-hydroxy-2-
naphthoic acid  
 
No production. 
 
2-hydroxy-1-
naphthoic acid  
 
No production. 
 
1,8-naphthalaldehydic 
acid  
No production. 
 
Table 4.2: Evaluation of naphthoic acid analogues for incorporation into azinomycin 
A biosynthesis pathway. 
 
  
108 
107 
109 
104 
105 
106 
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4.2.4 Azinomycin A and analogues from prep HPLC extracts from 
feeding of 1-naphthoic acid  
 
Three novel azinomycin A analogues incorporating 1-naphthoic acid were discovered 
in the fermentation culture of S. sahachiroi.  The novel metabolites were detected by 
LCMS as sodium and potassium salts and hydrolysed salt adducts m/z (mass-to-
charge ratio) = 574/592/608, 590/606 and 604/622/638 (Figures 4.10-4.14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: LCMS analysis of the extract from feeding of 1-naphthoic acid to S. 
sahachiroi.  (A5): Chromatograms from prep HPLC.  (A5a): magnification of EICs 
for m/z 590/606.  (B5): Positive ion electrospray mass spectrum.  A new peak at Rt = 
39.2-40.0 min has MS data, [M+H]
+
 m/z = 589.8, consistent with incorporation of the 
naphthoic acid into azinomycin A analogue after hydroxylation. 
 
Fig. 4.10 shows a new HPLC peak at 39.2-40.0 mins (A5) that has MS data for m/z = 
590 (M+Na
+
) and 606 (M+K
+
)  consistent with incorporation of the naphthoic acid 
into azinomycin A (Scheme 4.2) after hydroxylation, most likely by the cytochrome 
P450 involved in generating the natural naphthoic acid intermediate.  
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The MS peak at m/z = 530 corresponds to fragment of the main ions at m/z 589.8 
formed by loss of HOAc (Scheme 4.2).    Fragments m/z = 530 and 546 represent the 
same ion as sodium and potassium adducts respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.2: Proposed biosynthesis and fragmentation of the new metabolite.  
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Figure 4.11: LCMS analysis of the extract from feeding of 1-naphthoic acid to S. 
sahachiroi (A6): Chromatograms from prep HPLC.  (B6) and (B6a): Positive ion 
electrospray mass spectra.  A new peak at Rt = 58.1-58.8 min (B6) has MS data, 
[M+Na]
+
 = 573.8, consistent with incorporation of the unmodified naphthoic acid into 
azinomycin A analogue.  The peak at Rt = 62.9-63.4 min (B6a) has MS data, [M+H]
+
 
= 228.9 and might be a metabolite from S. sahachiroi’s extract or simply an artefact 
signal detected by the mass spectrometer. 
 
 
A peak at Rt = 58.1-58.8 min (A6) and m/z = 574 (M+Na
+
) (B6) is consistent with the 
incorporation of 1-napthoic acid into the azinomycin biosynthetic pathway without 
additional modification (Scheme 4.3).  The MS fragment with m/z = 514 is consistent 
with loss of HOAc from the precursor ion at m/z 573.8 (Scheme 4.3).  The MS 
fragment with m/z = 155 is the naphthoate fragment consistent of the loss of m/z = 
419 from ion at m/z 573.8 (Scheme 4.3).   
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Scheme 4.3 Incorporation of 1-naphthoic acid into the azinomycin A biosynthesis 
pathway.  Spontaneous fragmentation results in the production of two fragments at 
m/z = 155 and 514. 
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Figure 4.12: LCMS analysis of the extract from feeding of 1-naphthoic acid to S. 
sahachiroi (A7): Chromatograms from prep HPLC.  (B7): Positive ion electrospray 
mass spectrum.  A new peak at Rt = 53.8-54.9 min has MS data, [M+Na]
+
 = 592 and 
corresponds to the hydrolysed form of ion metabolite  of m/z = 574.  The additional 
peak for MS data, [M+K]
+
 = 608 corresponds to the potassium adduct of the same 
new metabolite. 
 
Data from Figure 4.12 indicate that a substantial amount of hydrolysis of the 
azinomycin A analogue (m/z = 574, Figure 4.11) has occurred leading to the 
formation of the metabolite with m/z 592 and 608 (A7), as outlined in scheme 4.4.    
  
 
175 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.4: A possible biosynthesis pathway for the production of the metabolites 
with m/z = 592 and 608. 
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Figure 4.13: LCMS analysis of the extract from feeding of 1-naphthoic acid to S. 
sahachiroi (A8): Chromatograms from prep HPLC.  (B8): Positive ion electrospray 
mass spectrum.  A new peak at Rt = 60.1-60.7 min has MS data, [M+Na]
+
 = 603.8, 
consistent with incorporation of the naphthoic acid into azinomycin A analogue after 
hydroxylation and methylation. 
 
The peak at 60.1-60.7 minutes has m/z 604 (Figure 4.13), consistent with the sodium 
adduct of the metabolite formed by incorporation of 1-naphthoic acid after 
hydroxylation and methylation (Scheme 4.5). 
The ion at m/z 185 is consistent with the naphthoate fragment formed from this 
metabolite (Scheme 4.6). 
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Scheme 4.5: Incorporation of 1-naphthoic acid into the azinomycin A pathway 
leading to the metabolite with m/z = 604. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.6: Mechanism of formation of fragment m/z = 185 from the azinomycin A 
analogue (m/z = 604). 
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Figure 4.14: LCMS analysis of the extract from feeding of 1-naphthoic acid to S. 
sahachiroi (A9): Chromatograms from prep HPLC.  (B9): Positive ion electrospray 
mass spectrum.  A new peak at Rt = 64.9-65.4 min has MS data, [M+Na]
+
 = 621.9, 
consistent with the hydrolysed ion for m/z = 604 (Figure 4.13). 
The additional peak for MS data, [M+K]
+
 = 608 corresponds to the potassium adduct 
of the same metabolite. 
 
A significant amount of hydrolysis of this metabolite (m/z = 604) is apparent, leading 
to the formation of the metabolite with m/z = 622 and 638 (A9), seen in Figure 4.14, 
and illustrated in scheme 4.7.   
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Scheme 4.7: A possible biosynthesis pathway for the production of the metabolites 
for m/z = 622 and m/z = 638. 
 
In our fragmentation mechanisms, we assume that it is the aziridine ring that is 
hydrolysed.  In fact Salvati et al. managed to isolate and identify the hydrolysis 
product of azinomycin B showing that the hydrolysis took place in the aziridine ring 
(Salvati et al., 1992).  
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4.2.5 Azinomycin A and analogues from prep HPLC extracts from 
feeding of 4-methyl-1-naphthoic acid  
 
Two novel azinomycin A analogues incorporating 4-methyl-1-naphthoic acid were 
discovered in the fermentation culture of S. sahachiroi.  The novel metabolites were 
detected by LCMS as sodium adducts (m/z 588 and 604) or hydrolysed sodium 
adducts (m/z 606 and 622) (Figures 4.15-4.16).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: LCMS analysis of the extract from feeding of 4-methyl-1-naphthoic acid 
to S. sahachiroi (A10): Chromatograms from prep HPLC.  (B10) and (B11): Positive 
ion electrospray mass spectra.  A new peak at Rt = 75.2-76.1 min has MS data, 
[M+Na]
+
 = 587.8 (B10), consistent with incorporation of 4-methyl-1-naphthoic acid 
into the azinomycin A analogue.  The peak at Rt = 93.2-94.8 min has MS data, 
[M+Na]
+
 = 617.9 (B11) consistent with azinomycin A. 
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We observed new HPLC peaks that are consistent with 4-methyl-1-naphthoic acid 
being accepted and incorporated into S. sahachiroi’s enzymatic machinery, resulting 
in the production of new azinomycin A analogues.  The new metabolite shown as 
(B10) in Figure 4.15 with sodium adduct m/z = 588 is consistent with incorporation 
of 4-methyl-1-naphthoic acid.  The MS peak for m/z = 528 is the fragment of the 
main ion (m/z = 588) after the spontaneous loss of the acetyl functional group in the 
MS.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: LCMS analysis of the extract from feeding of 4-methyl-1-naphthoic acid 
to S. sahachiroi (A11): Chromatograms from prep HPLC.  (B12) and (B13): Positive 
ion electrospray mass spectra.  New peak at Rt = 23.5-24.0 min has MS data, 
[M+Na]
+
 = 604.0 (B12), consistent with incorporation of 4-methyl-1-naphthoic acid 
into azinomycin A analogue after hydroxylation.   Peak at Rt = 72.0-73.3 min has MS 
data, [M+Na]
+
 = 605.8 (B13), consistent with metabolite for m/z = 588 (Figure 4.15, 
(B10)) being hydrolysed.  
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Figure 4.16 shows that the peak at 23.5-24 min (B12) has MS data consistent with 
incorporation of 4-methyl-1-naphthoic acid with extra hydroxylation.  Also the peak 
for m/z = 544 (same figure) represents the fragment of the main ion (m/z = 604) after 
the spontaneous loss of the acetyl functional group in the MS.  
In (B13), MS peaks for m/z =606 and m/z = 622 are respectively consistent with the 
hydrolysed form of the new metabolites for m/z = 588 (B10) and m/z = 604 (B12).  
The possible biosynthesis of the new metabolites incorporating the precursor 4-
methyl-1-naphthoic acid is described in scheme 4.8.   
 
 
 
Scheme 4.8: A possible biosynthetic pathway for the production of the new 
metabolites shown in Figures 4.15-4.16. 
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Previous feeding of 4-methyl-1-naphthoic acid resulted in the biotransformation of 
naphthoic acid to amide (Chapter 3) and an additional major product that has MS 
data consistent with additional hydroxylation, perhaps before amide formation by the 
same cytochrome P450 involved in azinomycin biosynthesis (scheme 4.8).   
The production, by S. sahachiroi fermentation culture, of the new metabolites 
incorporating the feeding analogue with and without hydroxylation suggests a 
competition role between the enzymes involved in the azinomycin A biosynthesis 
pathway (details in section 4.3).   
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4.2.6 Azinomycin A and analogues from extracts from feeding of 4-
fluoro-1-naphthoic Acid 
 
Two novel azinomycin A analogues incorporating 4-fluoro-1-naphthoic acid were 
discovered in the fermentation culture of S. sahachiroi.  The novel metabolites were 
detected by LCMS as sodium or hydrolysed sodium adducts (m/z = 592 and 610) and 
with HCl added (m/z = 628 and 630) (Figures 4.17-4.18).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: LCMS analysis of the extract from feeding of 4-fluoro-1-naphthoic acid 
to S. sahachiroi (A12): Chromatograms from prep HPLC.  (B14) and (B15): Positive 
ion electrospray mass spectra.  New peak at Rt = 84.4-85.9 min has MS data, 
[M+Na]
+
 = 591.8 (B14), consistent with incorporation of 4-fluoro-1-naphthoic acid 
into azinomycin A analogue.   Peak at Rt = 79.4-80.8 min has MS data, [M+Na]
+
 = 
609.8 (B15), consistent with metabolite for m/z = 592 (B14) being hydrolysed.  
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4-fluoro-1-naphthoic acid has also been accepted and incorporated by the azinomycin 
A producer.  A new metabolite (m/z = 592) was detected by LCMS analysis ((B14), 
Figure 4.17), corresponding to a fluorinated azinomycin A analogue.  The produced 
metabolite was subject to a spontaneous fragmentation in the MS and a new daughter 
ion has been formed at m/z 532, consistent with the loss of the acetyl functional group 
((B14), Figure 4.17).  A significant amount of the new metabolite has been 
hydrolysed resulting in the formation of an HPLC peak with m/z = 610 ((B15), 
Figure 4.17). 
 
 
 
Figure 4.18: LCMS analysis of the extract from feeding of 4-fluoro-1-naphthoic acid 
to S. sahachiroi (A13): Chromatograms from prep HPLC.  (B16): Positive ion 
electrospray mass spectrum.  New peak at Rt = 116.0-117.9 min has MS data, 
[M+Na]
+
 = 627.8 and 629.7 (B14), consistent with incorporation of 4-fluoro-1-
naphthoic acid into azinomycin A analogue with HCl added.    
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Figure 4.18 shows the presence of a metabolite that may be a chlorinated analogue of 
azinomycin A from the same fermentation culture.  The ions at m/z 628 and 630 are 
present in a 3:1 ratio, corresponding to the relative abundances of 
35
Cl and 
37
Cl.  
When extracted ion chromatograms (EICs) of ions at m/z 628 and 630 were plotted, 
they coincide together.  
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4.2.7 Azinomycin A and analogues from prep HPLC extracts from 
feeding of 3-methoxy-1-naphthoic acid  
 
A novel azinomycin A analogue incorporating 3-methoxy-1-naphthoic acid was 
discovered in the fermentation culture of S. sahachiroi.  The novel metabolite was 
detected by LCMS in the intact form (m/z = 582), as sodium and hydrolysed sodium 
adducts (m/z = 604 and 622 (Figure 4.20), respectively) and as hydrolysed potassium 
adduct (m/z = 638, Figure 4.20).   
 
Initial results using analytical method are shown in Figure 4.19.   
 
 
 
Figure 4.19: LCMS of extract from feeding of 3-methoxy-1-naphthoic acid to S. 
sahachiroi.  (A14): HPLC chromatograms.  (B17) and (B18): Positive ion 
electrospray mass spectra.  A new peak at 3.5-3.7 min has MS data for m/z = 582 
consistent with an azinomycin A analogue incorporating the fed precursor.  The mass 
spectrum (B18) displays azinomycin A. 
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The LCMS data shown in Figure 4.19 are the results of the initial analysis of 3-
methoxy-1-naphthoic acid extract after using a C18 microbore column (ACE3, 100  
2.1 mm).  A significant amount of a new metabolite was produced and was still in the 
native/intact form (m/z = 582).  A less amount was shown as sodium adduct (m/z = 
604).  No hydrolysis has occurred yet.  Similarly azinomycin A was shown only as an 
intact form (m/z = 596) or as sodium adduct (m/z = 618).  MS peaks for m/z = 544 
and m/z = 185 are fragments of the main ions [M+H]
+
 = 581.9.  The first fragment 
(for m/z = 544) has resulted after the loss of the acetyl functional group (-HOAc) 
from the parent ion (for m/z = 582) and the second corresponds to the naphthoate 
fragment.  The fragmentation mechanism for the naphthoate fragment is identical to 
the one shown in scheme 4.6. 
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The results from prep HPLC from feeding of 3-methoxy-1-naphthoic acid are shown 
in Figure 4.20. 
 
 
 
Figure 4.20: LCMS of extract from feeding of 3-methoxy-1-naphthoic acid to S. 
sahachiroi.  (A15): HPLC chromatograms.  (B19): Positive ion electrospray mass 
spectrum showing hydrolysed new metabolite for m/z = 622.  (B20): Positive ion 
electrospray mass spectrum showing hydrolysed azinomycin A for m/z = 636.  (B21): 
Positive ion electrospray mass spectrum showing new metabolite for m/z = 604.   
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A brief comparison between the results from the initial analytical analysis (Figure 
4.19) and the data from prep HPLC analysis of 3-methoxy-1-naphthoic acid extract 
(Figure 4.20) shows that a substantial amount of azinomycin A (for m/z = 636) and 
its analogue (for m/z = 622) has been hydrolysed in solution.  
The analysis of the MS data in (B19) shows another peak for m/z = 638 which is 
consistent with the same new metabolite but as potassium adduct.  The possible 
biosynthesis pathway for the production of the new metabolite with m/z = 582 and its 
salt adducts is described in scheme 4.9.      
In relation to the new metabolite for m/z = 604, there is a strong correlation between 
the MS data from feeding 1-naphthoic acid ((B8), Figure 4.13) and feeding 3-
methoxy-1-naphthoic acid ((B21), Figure 4.20).  In both cases the produced 
metabolites are identical.  The assumption was made based on retention time 
comparison.  In fact, both metabolites had the same retention time when their 
corresponding crude extracts were run under the same LCMS conditions.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.9: Incorporation of 3-methoxy-1-naphthoic acid in the azinomycin A 
biosynthesis pathway and the possible biosynthesis pathway for the production of the 
metabolites for m/z = 622 and m/z = 638. 
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4.2.8 Towards purification of azinomycin A and related analogues by 
prep HPLC 
 
The purification and isolation of azinomycin A and its subsequent analogues was 
performed as described in section 2.2.1 (Chapter 2).  The separation was first started 
on C18 microbore column (ACE3, 100  2.1 mm) since it requires less time and less 
solvent and sample and then optimised on an analytical column (C18, ACE5, 250  
4.6 mm).  The developed method was then transferred to the prep.  HPLC column 
(C18 column (ACE5 250  21.2 mm) with some modifications to the sample 
preparation.  During analytical HPLC, sample from S. sahachiroi’s crude extract (30 
mg) from feeding 3-methoxy-1-naphthoic acid 97 was dissolved in the minimum 
amount of chloroform (2 mL), centrifuged for 5 min at 6000 rpm in an MSE 
MicroCentaur machine and then an aliquot (50 µL) was transferred to an LCMS vial 
containing 950 µL of a pre-degassed mobile phase consisting of a mixture of water 
and methanol (25:75).  Using the microbore column, Azinomycin A and its analogues 
were seen after LCMS analysis but the HPLC peaks were unresolved as shown in 
Figure 4.21.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Microbore HPLC of extract from feeding of 3-methoxy-1-naphthoic 
acid to S. sahachiroi’s culture broth.  (A16): HPLC chromatograms.  (B22): Positive 
ion electrospray mass spectrum.  Peaks at Rt = 2.3-2.5 min for m/z = 604 and 636 are 
not fully separated when using water and methanol at a ratio of 25:75. 
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A more polar mobile phase consisting of water and methanol (35:65) was attempted 
in order to achieve better resolution.  Yet, the HPLC peaks of hydrolysed azinomycin 
A (m/z = 636) and its analogues (m/z = 604 and 622) were still not fully separated 
(Figure 4.22).  However, azinomycin A (for m/z = 618) was well separated from its 
analogues.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22: Analytical HPLC of extract from feeding of 3-methoxy-1-naphthoic acid 
to S. sahachiroi.  (A17): HPLC chromatograms.  (B23): Positive ion electrospray 
mass spectrum.  EIC peaks for hydrolysed azinomycin A and its analogues (m/z = 604 
and 622) are still partially overlapping.  Water and methanol at a ratio of 35:65 were 
used as the mobile phase.  
 
Keeping the same solvent system, the solvent ratio mixture (50:50) was introduced to 
further slowdown the mobile phase by increasing the polarity of the solvent system.  
However EIC peaks for hydrolysed azinomycin A (m/z = 636) and it analogue (for 
m/z = 622) were still partially overlapping as shown in Figure 4.23.  
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Figure 4.23: Analytical HPLC of extract from feeding of 3-methoxy-1-naphthoic acid 
to S. sahachiroi.  (A18): HPLC chromatograms.  (B24): Positive ion electrospray 
mass spectrum.  EIC peaks for hydrolysed azinomycin A (m/z = 636) and its analogue 
(m/z = 622) were still partially overlapping.  Water and methanol at a ratio of 50:50 
were used as the mobile phase.  
 
A further change of the solvent ratio mixture (60:40) was tried towards a good 
separation between the target peaks.  A fairly good separation between azinomycin A 
and its analogues was achieved but with longer elution time as shown in Figure 4.24.  
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Figure 4.24: Analytical HPLC of extract from feeding of 3-methoxy-1-naphthoic acid 
to S. sahachiroi.  (A19) and (A20): HPLC chromatograms.  (B25): Positive ion 
electrospray mass spectrum.  A fairly good EIC peaks separation between hydrolysed 
azinomycin A (for m/z = 636) and its analogues (for m/z = 622 and for m/z = 604).  
Water and methanol at a ratio of 60:40 were used as the mobile phase.  
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Then a clear separation between the target peaks at reasonable eluting time was 
achieved with the same mobile phase at the ratio of 45:55 as shown in Figure 4.25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.25 Analytical HPLC of extract from feeding of 3-methoxy-1-naphthoic acid 
to S. sahachiroi.  (A21): HPLC chromatograms.  (B26): Positive ion electrospray 
mass spectrum.  A clear separation between EIC peaks for hydrolysed azinomycin A 
(for m/z = 636) and its analogue (for m/z = 622).  Water and methanol at a ratio of 
45:55 were used as the mobile phase.  
 
The method was also used to confirm the full separation between the target peaks 
from crude extracts after feeding 1-naphthoic acid, 4-methyl-1-naphthoic acid and 4-
fluoro-1-naphthoic acid compounds.  
After optimisation of the analytical HPLC and before proceeding to prep HPLC 
separation and sample collection, a few changes to sample preparation were required.  
Since a highly concentrated sample was needed, all attempts to dissolve bacterial 
crude extract in the minimum amount of HPLC solvent system had failed.  Therefore 
a mixture of 20% chloroform and 80% HPLC mobile phase was needed for complete 
solubility of the extract.  Then the sample was centrifuged for 5 min at 6000 rpm in an 
MSE MicroCentaur machine.  Aliquots of 200 µL of analyte solution were transferred 
to LCMS vials containing a 200 µL glass insert.  A few crucial technical steps were 
taken in consideration before starting the separation and collection of sample 
fractions:  
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1) As MS method is a destructive identification technique where the sample 
cannot be recovered, only a very small sample amount was needed to reach 
the MS instrument.  Hence a T shaped splitter with a long tube (60 cm) was 
set up to connect to the MS electrode (Figure 4.26).  
2) DAD is a non-destructive detection technique therefore most of the volume of 
the identified target peak should be collected in the Falcon tube.  Hence a 
short tubing (2 cm long) was placed at the opposite site of the splitter for that 
purpose (Figure 4.26). 
3) There was a time lag (2 sec) between sample arrival at the DAD and MS 
detectors.  That was taken into account during the identification and 
collection of the target peaks.  In fact, initial prep HPLC runs using only 5 µl 
as the injection volume of extract were carried out to correlate DAD peaks 
with MS ones.  All other prep HPLC parameters were kept the same as 
described in section 2.2.1 (Prep HPLC). 
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Figure 4.26: Pictures of the LCMS instruments. (a): annotated picture of the LCMS 
instruments used during the course of this study.  (b): magnified region shown with 
blue square in (a). 
 
The separation and sample collection proceeded as described in section 2.2.1. (Prep 
HPLC).  Analytical scale HPLC analyses of the isolated azinomycin A and its 
analogues are shown in Figures 4.27-4.32. 
  
 
 
198 
 
During the course of prep HPLC work, azinomycin A (as sodium and hydrolysed 
adducts) and four novel azinomycin A analogues were separated and isolated.  The 
isolated novel analogues are as follow: m/z = 592 from feeding 1-naphthoic acid, m/z 
= 622 from feeding 1-naphthoic acid and 3-methoxy-1-naphthoic acid, m/z = 610 and 
628/630 from feeding 4-fluoro-1-naphthoic acid to S. sahachiroi.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27: Analytical HPLC of hydrolysed azinomycin A (m/z = 636) after prep 
HPLC purification.  (A22): HPLC chromatograms.  (B27): Positive ion electrospray 
mass spectrum.  
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Figure 4.28: Analytical HPLC of purified azinomycin A (m/z = 618).  (A23): HPLC 
chromatograms.  (B28): Positive ion electrospray mass spectrum.  An impurity peak 
(for m/z = 409) is shown in (A23) in addition to the azinomycin peak at 3.1-3.2 min.  
The MS peaks for m/z = 558 and m/z = 199 are the characteristic of the spontaneous 
fragmentation of the azinomycin parent ion. 
 
The impurity peak shown in Figure 4.28 (A23) could have originated from plastic 
pipette tips (http://www.bmss.org.uk/Docs/MSTG_web_version.pdf). 
 
The results presented in Figures 4.27 and 4.28 represent the LCMS analysis after 
combining all similar azinomycin prep HPLC purified fractions.  Azinomycin A was 
isolated from all the four scaled up fermentation crude extracts from feeding 1-
naphthoic acid, 4-methyl-1-naphthoic acid, 4-fluoro-1-naphthoic acid and 3-methoxy-
1-naphthoic acid.  However, the final yields (~ 1 mg azinomycin A and ~ 200 µg of 
the hydrolysed form) were only enough for MS/MS, TLC analysis and melting point 
calculation.  
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Figure 4.29: Purified azinomycin A analogue (m/z = 592, hydrolysed form) from 
prep HPLC after feeding 1-naphthoic acid.  (A24): HPLC chromatograms.  (B29): 
Positive ion electrospray mass spectrum.  A substantial amount of impurities (m/z = 
676 and 365) is found in (A24).  The amount of isolated product (~ 200 µg) could 
only allow LCMS analysis. 
 
 
 
 
 
 
 
 
  
 
201 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.30: Purified azinomycin A analogue (m/z = 622, hydrolysed form).  (A25): 
HPLC chromatogram.  (B30): Positive ion electrospray mass spectrum. The purified 
prep HPLC fractions from feeding 1-naphthoic acid and 3-methoxy-1-naphthoic acid 
crude extracts were added together hoping to increase the yield.  But, only traces were 
collected allowing only LCMS analysis.  For the peak with m/z = 129 corresponds to 
a common contaminant.  
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Figure 4.31: Towards purified azinomycin A analogue (m/z = 610, hydrolysed form) 
from prep HPLC of feeding 4-fluoro-1-naphthoic acid crude extract.  (A26): HPLC 
chromatograms.  (B31): Positive ion electrospray mass spectrum. The amount of 
isolated product (~ 500 µg) could only allow LCMS analysis. 
   
 
Figure 4.31 shows a perfect alignment between UV chromatogram peak and HPLC 
peak for the new azinomycin analogue (m/z = 610, hydrolysed form) at 25.2-25.7 
min.  On the other hand, the impurity peak (m/z = 409) does not absorb UV light at 
350 nm as shown in (A26).  The EIC for m/z = 409 is seen at two different retention 
times (Rt ~ 26 min and ~ 35 min).  A considerable amount of impurities was detected 
after prep HPLC purification.  The impurities might have originated from plastic 
pipette tips.  
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Figure 4.32: Towards purified azinomycin A analogue (m/z = 628, metabolite with 
added HCl) from prep HPLC of feeding 4-fluoro-1-naphthoic acid crude extract.  
(A27): HPLC chromatograms.  (B32): Positive ion electrospray mass spectrum. The 
final yield of the isolated new compound (~ 300 µg) was only enough for LCMS 
analysis. 
   
Figure 4.32, (A27) shows a total overlap between UV chromatogram peak and HPLC 
peak for the new azinomycin analogue (m/z = 628) at 38.5-39.0 min.  The impurity 
related peak shown here (A27) is identical to the one shown in Figure 4.31 and also 
does not absorb UV light at 350 nm.   
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4.2.9 Tandem mass spectrometry (MS/MS) assignment of azinomycin 
A and related analogues  
 
The yields of the purified azinomycins and related analogues were not enough for full 
NMR analysis.  Therefore, MS/MS was used as an alternative method for structural 
characterisation.  Our analysis looked for correlations between the fragmentation 
patterns of azinomycin A and its analogues (using both purified fractions and crude 
extracts), to provide support for the assumption that the new metabolites are new 
analogues of azinomycin A.  For that purpose, MS/MS was performed in the ion trap 
of the mass spectrometer with helium as collision gas.  In MS/MS, precursor ions are 
accumulated in the ion trap then the precursor ion of interest (azinomycin A for 
example) is mass-selected while other ions are ejected from the ion trap.  An increase 
in the activation energy inside the spectrometer results in collisions between helium 
gas and the selected ion.  This allows the fragmentation of the precursor ion and 
therefore the generation of daughter ions that are then analysed to generate a fragment 
mass spectrum.  
For each successful MS/MS experiment, similar patterns between the purified 
compound and the related feeding crude extract were obtained.  The results are 
summarised in Figures 4.33-4.39. 
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LCMS/MS of azinomycin A (m/z = 636) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.33: LCMS/MS of purified azinomycin A in the hydrolysed form (m/z = 
636).  (A28): HPLC chromatogram.  (B33): Product ion MS/MS spectrum from 
fragmentation of the [M+Na]
+
 parent ion.   
 
The fragmentation pattern shown in Figure 4.33 and summarised in Table 4.3 may be 
explained by the following reactions.  The ion at m/z 576 corresponds to the loss of 
HOAc from the parent ion (path (a), Scheme 4.10).  The ion at m/z 563 corresponds 
to the loss of NH2CH2COCH3 from the parent ion.  The ion at m/z 562 corresponds to 
the loss of a radical proton from ion with m/z = 563.  The first fragment (m/z 563) 
results from the intramolecular rearrangement that precedes fragmentation.  The 
fragmentation mechanism for both fragments is described in scheme 4.10, path (b).  
The ion at m/z 537 corresponds to the loss of CONCH2COCH3 from the parent ion 
after an intramolecular rearrangement (path (c), Scheme 4.10).  The ion with m/z = 
429 corresponds to the loss of AcO, OH, H2COH and H from ion with m/z = 537 by 
radical fragmentations (path (c), Scheme 4.10).  The ion at m/z 504 corresponds to 
the loss of radical NHCH2COCH3 from the ion of m/z 576 following homolytic 
fission of the amide bond (path (d), Scheme 4.10).  The ion of m/z 477 corresponds to 
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the loss of HOAc from the ion of m/z 537 (path (e), Scheme 4.10).  The major ion of 
m/z 463 corresponds to the loss of the sodiated fragment NHCH2CONa
+
CH3 from the 
parent ion with m/z = 636 followed by hydrolysis and then the loss of HOAc group as 
described in path (f), scheme 4.10.  The ion of m/z 347 corresponds to the loss of the 
naphtthoate fragment from the parent ion followed by the loss of radical 
NHCH2COCH3 in a similar mechanism as in path (d) and finally the loss of water.  
 
m/z Ion Groups associated with 
the mass lost 
636 
 
MNa
+
 - 
576 
 
MNa
+  60 HOAc 
563 
 
MNa
+  73 NH2CH2COCH3 
562 MNa
+  74 NH2CH2COCH3 and H (as 
radical proton) 
537 
 
MNa
+  99 CONCH2COCH3 
504 MNa
+  132 HOAc and NHCH2COCH3 
(as radical) 
477 MNa
+  159 CONCH2COCH3 and 
HOAc 
463 MNa
+  173 NHCH2CONa
+
CH3, H2O 
and  HOAc 
429 MNa
+  207 CONCH2COCH3, and 
(AcO, OH, H2COH and H) 
as radicals 
347 MNa
+  289 Naphthoate, 
NHCH2COCH3 (as radical) 
and H2O 
 
Table 4.3: Summary of ions and groups associated with the mass lost during MS/MS 
of purified hydrolysed azinomycin A. 
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Scheme 4.10: Paths (a) and (b). 
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Scheme 4.10: Paths (c) and (d). 
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Scheme 4.10: Paths (e) and (f). 
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Scheme 4.10: Path (g). 
 
LCMS/MS of azinomycin A (m/z = 618) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.34: LCMS/MS of purified azinomycin A (m/z = 618).  (A29): HPLC 
chromatograms.  (B34): Product ion MS/MS spectrum of azinomycin A ion showing 
different fragmentation patterns compared to the hydrolysed form.   
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LCMS/MS of purified azinomycin analogues with m/z = 622 
 
Azinomycin A analogue with m/z = 622 was produced after feeding 1-naphthoic acid, 
and 3-methoxy-1-naphthoic acid and has a retention time, Rt = 64.9-65.4 min (Figure 
4.14).  Another azinomycin A analogue with the same mass (m/z = 622), but different 
retention time [Rt = 22.2-23.3 min; ((B11), Figure 4.16)] was produced after feeding 
4-methyl-1-naphthoic acid.  MS/MS of the purified fractions and crude prep HPLC 
extracts from feeding 1-naphthoic acid and 3-methoxy-1-naphthoic acid compared to  
MS/MS of the crude prep HPLC extract from feeding 4-methyl-1-naphthoic acid 
revealed the same fragmentation patterns as shown in (B35), Figure 4.35.  However, 
their chromatograms appeared at different retention times ((A30) at Rt = 7.1-7.3 min 
for the first two feeding compounds and (M) at Rt = 11.1-13.7 min for the third one).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.35: LCMS/MS of purified azinomycin A analogues (m/z = 622).  (A30) and 
(M): HPLC chromatograms.  (B35): Product ions MS/MS spectrum of azinomycin A 
analogue ions.   
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The fragment ions from m/z = 622 form a similar pattern (Figure 4.35) to that for 
hydrolysed azinomycin A (Figure 4.33), with mass shifts of 14 for certain fragment 
ions. This implies that these fragments contain the naphthoate group, which lacks CH2 
compared to the natural naphthoate, and that the fragments are formed by the same 
mechanisms (Scheme 4.10) as for the hydrolysed azinomycin A. 
Scheme 4.11 (paths (h)-(n)), describe the fragmentation pathways for fragment ions 
from m/z = 622. 
 
  
 
Scheme 4.11: Paths (h) and (i). 
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Scheme 4.11: Paths (j) and (k). 
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Scheme 4.11: Paths (l) and (m). 
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Scheme 4.11: Path (n). 
 
Identical fragmentation mechanisms can explain the same fragment ions that result 
from the metabolite with m/z 622, from feeding 4-methyl-1-naphthoic acid.  The only 
difference resides in the isomeric substitution on the naphthalene ring.  
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The LCMS/MS data for the azinomycin A analogue with m/z = 592 (hydrolysed 
form) formed from feeding 1-napthoic acid are presented in Figure 4.36. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.35 LCMS/MS of purified azinomycin A analogue (m/z = 622).  (A30):  
 
 
 
Figure 4.36: LCMS/MS of purified azinomycin A analogue from feeding 1-naphthoic 
acid (m/z = 592, hydrolysed form).  (A31): HPLC chromatogram.  (B36): Product 
ions MS/MS spectrum from m/z 592 parent ion.   
 
There is a strong correlation between the fragmentation pattern seen in Figure 4.36 
and those in Figure 4.35 and Figure 4.33.  Comparison between fragments in Figure 
4.33 and Figure 4.36 shows a difference of mass of 44 indicating the incorporation of 
1-naphthoic acid into the azinomycin A biosynthesis pathway lacking the methoxy 
group  at C3’ and the methyl group at C5’ of the naphthyl group.  Therefore the 
fragmentation pattern in Figure 4.36 can be explained by the same mechanisms as in 
scheme 4.10, only diverging in the substituents on the naphthoate.  
 
In Figure 4.36 and Table 4.4, the ion at m/z 532 corresponds to the loss of HOAc 
from the parent ion (m/z = 592, sodiated and hydrolysed forms).  The ion at m/z 519 
corresponds to the loss of NH2CH2COCH3 from the parent ion by the intramolecular 
rearrangement that precedes fragmentation.  The ion at m/z 493 corresponds to the 
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loss of CONCH2COCH3 from the parent ion after an intramolecular rearrangement.  
The ion with m/z = 385 corresponds to the loss of AcO, OH, H2COH and H from ion 
with m/z = 493 by radical fragmentations.  The ion at m/z 460 corresponds to the loss 
of radical NHCH2COCH3 from the ion of m/z 532 following homolytic fission of the 
amide bond.  The ion of m/z 433 corresponds to the loss of HOAc from the ion of m/z 
493.  The major ion of m/z 419 corresponds to the loss of the sodiated fragment 
NHCH2CONa
+
CH3 from the parent ion with m/z = 592 followed by hydrolysis and 
then the loss of HOAc.  The ion of m/z 347 corresponds to the loss of the naphtthoate 
fragment from the parent ion followed by the loss of radical NHCH2COCH3 and 
water.   
 
m/z Ion Groups associated with 
the mass lost 
592 
 
MNa
+
 - 
532 
 
MNa
+  60 HOAc 
519 
 
MNa
+  73 NH2CH2COCH3 
493 
 
MNa
+  99 CONCH2COCH3 
460 MNa
+  132 HOAc and NHCH2COCH3 
(as radical) 
433 MNa
+  159 CONCH2COCH3 and 
HOAc 
419 MNa
+  173 NHCH2CONa
+
CH3, H2O 
and  HOAc 
385 MNa
+  207 CONCH2COCH3, and 
(AcO, OH, H2COH and H) 
as radicals 
347 MNa
+  289 Naphthoate, 
NHCH2COCH3 (as radical) 
and H2O 
 
Table 4.4: Summary of ions and groups associated with the mass lost during MS/MS 
of purified hydrolysed azinomycin A analogue with m/z = 592. 
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Figure 4.37 shows the LCMS/MS data for the unhydrolysed azinomycin A analogue 
(m/z 604, M+Na
+
) formed after feeding 3-methoxy-1-naphthoic acid or 1-naphthoic 
acid. The fragment m/z 544 corresponds to loss of the acetyl group from the parent 
ion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.37: LCMS/MS of azinomycin A analogue (m/z = 604) from feeding 3-
methoxy-1-napthoic acid.  (A32): HPLC chromatogram.  (B37): Product ions MS/MS 
spectrum from m/z 604.   
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The LCMS/MS data for the hydrolysed azinomycin A analogue (m/z = 610, M+Na
+
) 
from feeding purified 4-fluoro-1-napthoic acid is shown in Figure 4.38.  The 
fragmentation pattern is in good correlation with the previous ones (Figures 4.33, 
4.35-4.36).  Hence, the fragmentation mechanisms are likely the same and are shown 
in scheme 4.12, paths (o)-(u).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.38: LCMS/MS of the hydrolysed azinomycin A analogue (m/z = 610) from 
feeding 4-fluoro-1-napthoic acid.  (A33): HPLC chromatogram.  (B38): Product ion 
MS/MS spectrum for m/z 610.  
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Scheme 4.12: Paths (o) and (p). 
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Scheme 4.12: Paths (q) and (r). 
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Scheme 4.12: Paths (s) and (t). 
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Scheme 4.12: Path (u). 
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The LCMS/MS data for the presumed chlorinated azinomycin A analogues (m/z = 
628) from feeding 4-fluoro-1-napthoic acid is shown in Figure 4.39. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.39: LCMS/MS of the chlorinated azinomycin A analogue (m/z = 628) from 
feeding 4-fluoro-1-napthoic acid.  (A34): HPLC chromatogram.  (B39): Product ion 
MS/MS spectrum of m/z 628. 
 
There is an association between most of the fragment ions seen in Figure 4.39 and 
those in Figure 4.38, with a difference of 18 mass units between each correlated pair 
of ions (Table 4.5).  This implies replacement of OH by 
35
Cl in each of these 
fragment ions, most likely at the end of the carbon chain of the aziridine component 
as shown in scheme 4.13, paths (v1)-(v6).  The additional ions 4 mass units lower in 
mass may arise from intermolecular reaction of the chlorinated fragment ions with 
MeOH solvent molecules, resulting in substitution of CH3O for Cl. 
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Scheme 4.13: Paths (v1) and (v2). 
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Scheme 4.13: Paths (v3) and (v4). 
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Scheme 4.13: Paths (v5) and (v6). 
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Fragments of chlorinated 
azinomycin A analogue (m/z 
628/630) 
Fragments of azinomycin A 
analogue (m/z 610) 
MNa
+ 
(m/z) MNa
+ 
(m/z) 
365 347 
455 437 
469 451 
496 478 
529 511 
554 536 
555 537 
568 550 
 
Table 4.5: Comparison between the major MS/MS product ions of hydrochlorinated 
and hydrolysed azinomycin A analogues (m/z 628/630 and 610 respectively).  There 
is a correlation between each pair of ions within the same row (difference of 18 mass 
units). 
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The LCMS/MS for the unhydrolysed azinomycin A analogue (m/z = 592) after 
feeding 4-fluoro-1-napthoic acid is shown in Figure 4.40.  The new azinomycin A 
analogue could not be purified as the corresponding UV absorption peak was too 
small, so these data come from the crude extract. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.40: LCMS/MS of azinomycin A analogue (m/z = 592) from 4-fluoro-1-
napthoic acid feeding.  (A35): HPLC chromatogram of MS/MS data only.  (B40): 
Product ions MS/MS spectrum of m/z 592.  The fragment m/z 532 corresponds to the 
loss of the acetyl group from the parent ion. 
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The LCMS/MS for the azinomycin A analogue (m/z = 588) after feeding 4-methyl-1-
napthoic acid is shown in Figure 4.41.  The new azinomycin A analogue was not 
purified as the UV absorption peak was too small to collect fractions during prep 
HPLC purification, so this data is from the crude extract. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.41: LCMS/MS of azinomycin A analogue (m/z = 588) from 4-methyl-1-
napthoic acid feeding.  (A36): HPLC chromatogram of MS/MS data only.  (B41): 
Product ions MS/MS spectrum of m/z 588.  The fragment m/z 528 corresponds to the 
loss of the acetyl group from the parent ion. 
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The LCMS/MS data for the purified hydrolysed azinomycin A analogue (m/z = 606) 
from feeding 4-methyl-1-napthoic acid.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.42: LCMS/MS of azinomycin A analogue (m/z = 606) from feeding 4-
methyl-1-napthoic acid.  (A37): HPLC chromatogram of purified extract.  (B42): 
Product ion MS/MS spectrum of m/z 606.   
 
The fragmentation pattern shown in Figure 4.42 correlates well with that for the 
native azinomycin A derivative.  Hence, the fragmentation mechanisms are similar to 
scheme 4.10 as described in scheme 4.14.  
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Scheme 4.14: Paths (w1) and (w2). 
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Scheme 4.14: Paths (w3) and (w4). 
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Scheme 4.14: Paths (w5) and (w6). 
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Scheme 4.14: Path (w7). 
 
Scheme 4.14 describes the fragmentation patterns of hydrolysed azinomycin A 
analogue (m/z = 606) feeding from 4-methyl-1-napthoic acid. 
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4.3 Discussion  
 
4.3.1 Novel azinomycin A analogues from precursor-directed 
biosynthesis 
 
Our data are in agreement with the conclusion that azinomycin A and its analogues 
were produced after feeding compounds 1-naphthoic acid, 4-methyl-1-naphthoic acid, 
4-fluoro-1-naphthoic acid and 3-methoxy-1-naphthoic acid (section 4.2.3, Table 4.2) 
to S. sahachiroi fermentation cultures.   Prep HPLC isolation of azinomycin A and its 
analogues afforded very low yields that were not enough for NMR characterisation 
(section 4.2.8, Figures 4.27-4.32).  The low yields of native azinomycin A and its 
analogues could be explained by the necessity of further optimisation of the 
incubation temperature and the medium pH, by the requirement of testing S. 
sahachiroi’s growth and azinomycins production in wider range of carbon and 
nitrogen sources and by the need of optimisation of inoculum’s age and size. 
  
Some contaminants were found within the purified fractions and could be of 
exogenous origin.  These contaminants might have been extracted from plastic pipette 
tips during sample preparation using chloroform following prep HPLC isolation 
(Figures 4.28-4.30).  Also they could have come up from the same prep HPLC crude 
extracts.   
 
In the absence of NMR data, we used tandem mass spectrometry to characterise and 
confirm the identities of the purified compounds with m/z 636 and 618 (Figures 4.27 
and 4.28 respectively) as azinomycin A and its hydrolysed derivative.  The results 
shown in Figure 4.33, scheme 4.10 and Figure 4.34 conform to literature data 
(Yokoi et al., 1986 and Zhao et al., 2008) with respect to the loss of acetyl group (C2 
H4O2), naphthoate fragment (m/z 199) and the aminoacetone (NHCH2COCH3).  
Therefore the purified compounds are azinomycin A (m/z 618, M+Na+) and the 
hydrolysed form of azinomycin A (m/z 636, M+Na+).  The fragmentation mechanisms 
of all the fragments in Figure 4.33 are fully described in scheme 4.10.  A comparison 
between the fragmentation patterns of azinomycin A and its hydrolysed derivative 
(Figure 4.33) and the fragmentation patterns of all the novel analogues (Figures 4.35-
4.42) reveals a strong correlation with consistent mass shifts that match the structural 
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changes in the naphthoic acids.  The fragmentation mechanisms of the known natural 
products and these new analogues must be similar and are described in schemes 4.11-
4.14.  Therefore the novel metabolites are most likely analogues of azinomycin A 
differing only in the substituents within the naphthoate region.  
   
Results (Figure 4.11) of prep HPLC from feeding 1-naphthoic acid show a new peak 
at 58.1-58.8 min with m/z 574 for the sodium adduct.  This mass is consistent with 
incorporation of the naphthoic acid analogue into azinomycin A biosynthesis pathway.  
Previous biosynthetic studies (Ding et al., 2010) showed the incorporation and 
adenylation of a range of commercially available naphthoic acid analogues by NRPS 
enzyme AziA1.  By analogy, our results indicate the incorporation and activation of 1-
naphthoic acid by the same adenylation domain of AziA1 and then being transferred 
to  peptidyl carrier protein (PCP) domain of AziA1 for starting the assembly of 
azinomycin A analogue fragments.  Additionally, the azinomycin analogue with m/z 
574 has been produced after incorporation of 1-naphthoic acid directly into the 
azinomycin A biosynthesis pathway without hydroxylation and methylation. This 
implies that the cytochrome P450 processes the unnatural 1-naphthoic acid substrate 
less efficiently than its native substrate.    
Prep HPLC chromatogram (Figure 4.11, (A6)) also reveals the presence of an 
exciting peak at 62.9-63.4 min with m/z 229 (Figure 4.11, B6a) and might be an 
interesting metabolite from S. sahachiroi’s extract or simply a cross contaminant 
encountered during the experimental work. 
   
Results (Figure 4.10) of prep HPLC from feeding 1-naphthoic acid show a new peak 
at 39.2-40.0 min with m/z 590 for the sodium adduct. This mass is consistent with 
incorporation of the naphthoic acid analogue into azinomycin A biosynthesis pathway 
with an extra oxygen atom.  This must be due to hydroxylation of 1-naphthoic acid by 
a cytochrome P450 hydroxylase prior to its incorporation into the azinomycin A 
analogue.  This explanation is in analogy with previous experimental facts established 
by many authors.  In fact, previous biosynthesis studies (Corre and Lowden, 2004a; 
Zhao et al., 2008; Ding et al., 2010) have confirmed similar results.  The authors have 
established and confirmed that the naphthoate fragment (5-methyl-1-naphthoic acid) 
of azinomycins A and B is being hydroxylated and methylated before being 
incorporated into the complete azinomycin skeleton.  
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The precise position of the hydroxylation could be predicted (but not confirmed) to 
have occurred in position C3’ of the naphthalene ring (similar to Azinomycin A 
biosynthesis) (Zhao et al., 2008).  Support for this hypothesis comes from the 
presence in the same fermentation of an analogue with sodium adduct m/z 604 
(Figure 4.13) consistent with the incorporation of 1-naphthoic acid into azinomycin A 
biosynthesis pathway after hydroxylation and then methylation.  Feeding of 3-
methoxy-1-napthoic acid (Figure 4.19, (B17)) forms a new metabolite with m/z 604 
consistent with the incorporation of the fed precursor into the azinomycin A 
biosynthesis pathway.  Both of these metabolites with m/z 604 have the same LCMS 
retention time when run using the same conditions.  It is very likely that the 
incorporation of hydroxyl and methyl groups into 1-naphthoic acid has been done by 
the same tailoring enzymes (cytochrome P450 hydroxylase AziB1 and O-methyl 
transferase AziB2 respectively) as that involved in the modifications to 5-methyl-
naphthoic acid prior to incorporation into the native azinomycin skeleton (Zhao et al, 
2008; Ding et al., 2010). 
  
Results (Figures 4.15) of prep HPLC from feeding 4-methyl-1-napthoic acid show a 
new peak at 75.2-76.1.0 min with m/z 588 for the sodium adduct.  This mass is 
consistent with incorporation of the 4-methyl-1-naphthoic acid analogue into 
azinomycin A biosynthesis pathway.  Additional new peak at Rt = 23.5-24.0 min with 
m/z 604 (Figure 4.16) has MS data consistent with incorporation of the 4-methyl-1-
naphthoic acid analogue into azinomycin A biosynthesis pathway after hydroxylation, 
most probably at C3 position and by the same cytochrome P450 involved in 
azinomycin biosynthesis.  Data (Figure 4.17) from feeding 4-fluoro-1-napthoic acid 
show a new peak at Rt = 84.4-85.9 min with m/z 592 consistent with incorporation of 
the 4-fluoro -1-naphthoic acid analogue into azinomycin A biosynthesis pathway.  
Two extra analogues (4-methyl-1-naphthoic acid and 4-Fluoro-1-naphthoic acid) of 
the natural starter unit, 3-methoxy-5-methyl-naphthoic acid were activated and 
incorporated by AziA1 to produce azinomycin analogues suggesting a potential for 
production by precursor-directed biosynthesis of more new azinomycin analogues 
differing in their naphthoic acid moieties. 
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Together, these results begin to reveal the extent of substrate flexibility of the 
enzymes in the azinomycin biosynthetic gene cluster.  The NRPS-related enzyme 
AziA1 is expected to activate the naphthoic acid intermediate by initial reaction with 
ATP to form an acyl adenylate, which then reacts with the SH group of a 
phosphopantetheinyl cofactor on the peptidyl carrier protein domain of AziA1.  The 
enzyme-bound naphthoate is then combined with the other building blocks by the 
action of the other NRPS enzymes.   
The results presented in this chapter demonstrate that AziA1 is able to activate 
alternative naphthoic acid substrates.  Our results are complementary to those of Ding 
(Ding et al., 2010) who found that AziA1 could activate a variety of substituted 
naphthoic acids in vitro.  Our results also show that the subsequent enzyme reactions 
in azinomycin biosynthesis can also tolerate structural changes in the naphthoate 
group. 
 
4.3.2 Chlorinated metabolites 
 
In previous work conducted by Dr. Jason Taylor, a postdoctoral fellow, it was shown 
that fermentation extracts without adding any naphthoic acids, contained apparently 
chlorinated azinomycins with M+Na
+
 ions at m/z 654/656 consistent with azinomycin 
A analogue and 672/674 consistent with azinomycin B analogue.  
The origin of the chlorine atoms in the azinomycin A analogue for m/z 628/630 
(Figure 4.18) is not known.  It may be just an artefact of sample preparation via 
decomposition of chloroform, or it may arise from a side reaction of the azinomycin 
A analogue with chloride in the fermentation medium.  However, a biosynthetic 
origin of chlorine is possible.  In this case, if the latter was the case, could the new 
chlorinated metabolite act as a biosynthetic precursor to the aziridine or epoxide ring? 
There is a number of well-known examples of chlorinated natural products such as 
vancomycin, chlortetracycline (Vaillancourt et al., 2006) and 593A (Gribble GW, 
2010).  The structure of 593A is shown in Figure 4.43. 
 
240 
 
 
 
Figure 4.43: Chemical structure of 593A. 
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The fragmentation patterns shown in Figure 4.39 correlate closely with those in 
Figure 4.38 with an 18 mass unit difference between each correlated pair of daughter 
ions (Table 4.5) and could be explained by the addition of HCl.  Three chlorinated 
isomers were suggested (F1-F3, Figure 4.44).  Isomer F2 is assumed to be the 
chlorinated metabolite with m/z 628/630 as the presumed structure explains well most 
of the fragmentation patterns shown in Figure 4.39.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.44: Suggestion of possible chlorinated analogues of azinomycin A 
subsequent to feeding 4-fluoro-1-naphthoic acid to S. sahachiroi. 
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Chapter 5: Overall Conclusions and Future Work 
 
The results presented in this project provide evidence that precursor-directed 
biosynthesis is a useful way to prepare azinomycin A analogues not encountered in 
nature.  The successful incorporation of synthetic and commercially available 
unnatural naphthoic acid (NPA) substrates demonstrates convincingly that there is a 
degree of substrate flexibility in azinomycin A biosynthesis (Chapter 4).  The non-
ribosomal peptide synthetase (NRPS) AziA1 that incorporates and activates 3-
methoxy-5-methyl-NPA (the natural start unit for the azinomycin biosynthesis) must 
have flexibility.  
 
We also observed biotransformation of a number of naphthoic acid analogues into 
their corresponding amides by S. sahachiroi (Chapter 3).  This provides more 
evidence on the broad substrate specificity of the enzymes in S. sahachiroi.  
 
Several of the observed azinomycin A analogues were isolated and purified (Chapter 
4) using prep HPLC and then were characterised by diode array detection and 
electrospray tandem mass spectrometry.  The low yields and persistence of impurities 
in the isolated fractions hampered further characterisation by 1D and 2D NMR.  
Biological studies could not yet be conducted for the same reasons.  
 
The substrate flexibility of AziA1 and its tolerance to a range of NPA analogues could 
be extrapolated to other monocyclic substrates.  For example, a variety of 
commercially available benzoic acid analogues (Table 5.1) could be fed to S. 
sahachiroi fermentation culture (in a similar fashion to NPA analogues) and the 
possible recognition, activation (by AziB, a type I iterative PKS) and tolerance (by 
AziA1) could be investigated by LCMS analysis.  
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Benzoic acid 
Compound to be fed to S. sahachiroi General strategy for feeding experiments 
 
 
 
 
 
 
 
 
 
 
Table 5.1: Proposed benzoic acid analogues for future feeding to S. sahachiroi culture 
broth. 
 
All attempts to characterise azinomycin A and its analogues by NMR were 
unsuccessful due to the low yield products isolated by Prep HPLC (Chapter 4).  
Therefore, it is essential to improve S. sahachiroi growth conditions (and may be the 
separation techniques as well) to enable, not only a consistent and reliable production 
of azinomycin A, but production of azinomycin B as well and their respective 
analogues in reasonable yields.  For that purpose and in order to determine the best 
carbon and nitrogen source to provide the maximum yield of azinomycins by S. 
sahachiroi, it is possible to substitute the original glucose and yeast extract in GYM 
medium with other carbon and nitrogen sources.  For example, glucose could be 
substituted with fructose, galactose, ribose, sucrose, maltose or lactose and yeast 
extract with ammonium sulphate, ammonium chloride, sodium nitrate, urea, peptone, 
beef extract or soybean.  Furthermore, bacterial growth conditions may be further 
optimised by increasing the agitation speed to 300 rpm as it will provide higher 
2-hydroxy-3-methoxybenzoic 
acid 
3-(trifluoromethoxy)benzoic 
acid 
2-bromo-5-methoxybenzoic 
acid 
3-methoxy-4-methylbenzoic 
acid 
3-methoxybenzoic acid 
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oxygen concentrations in S. sahachiroi fermentation flasks which, is essential for 
achieving a better production performance (Loptanev et al., 1973; Chen and Wilde, 
1990).   
 
Precursor-directed biosynthesis (PDB) proved to be a promising approach to generate 
novel analogues of azinomycin A (Chapter 4).  This technique may be extended to a 
mutant strain of S. Streptomyces by inactivating aziB, the gene encoding for the 
enzyme AziB, a type I iterative PKS responsible for the production of 5-methyl-NPA.  
Therefore, it would be possible to biosynthesise only the required azinomycin A 
analogues by supplementing the resultant mutant with analogues of 5-methyl-NPA as 
illustrated in Figure 5.1.   
 
 
 
Figure 5.1: Mutasynthesis of azinomycin A analogues using NPA analogues 
supplement.   
 
Mutasynthesis utilises a mutant strain of S. sahachiroi Wild type in conjunction with 
feeding of chemically modified 5-methyl-NPA intermediates.  The implementation of 
this technique will enable the production of azinomycin analogues exclusively with a 
possible improvement in the final yield production.    
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Appendices: 
 
Appendix one: 1D NMR and FTIR Figures 
 
 
 
Figure 2.2: Attempt 
1
H-NMR in CDCl3 of azinmycin A 3.  A brief comparison with 
the literature data (Sharma et al., 2009) shows that the assignment of azinomycin’s 
protons could not be deduced from this spectrum.  Peaks are due to the presence of 
contaminants in the NMR sample.  
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Figure 3.2: 
1
H-NMR in CDCl3 of 1-naphthoic amide 99a.  The expected 
1
H signals 
are seen in the aromatic region at 7.4-8.5 ppm. The amine NH2 signal is at 5.98 ppm.  
Some impurities labelled with X are detected up field (between 0.8-2.0 ppm) and 
could be due to solvents from the purification procedure.  
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Figure 3.6: 
13
C-NMR in CDCl3 of 1-naphthoic amide 99a.  The spectrum shows 
persistence of impurities in the purified target compound 99a.    
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Figures 3.11: The Figure shows the acquire FTIR spectrum of 1-naphthoic amide 
99a dissolved in chloroform along with the assignment of the main absorption 
frequencies. The sample was contained in KBr plates. 
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Figure 3.13: 
1
H-NMR in CDCl3 of 4-fluoro-1-naphthoic amide 100a.  The expected 
1
H signals are seen in the region at 7-8.5 ppm. The amine NH2 signal is at 5.96 ppm.  
Some impurities labelled with X and solvent residue are detected up field (0.6-2.4 
ppm).  
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Figure 3.17: 
13
C-NMR in CDCl3 of 4-fluoro-1-naphthoic amide 100a.  An impurity 
peak appears at 31 ppm.  
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Figure 3.22: FTIR spectrum of 4-fluoro-1-naphthoic amide 100a in chloroform.  The 
sample was contained in KBr plates. The annotated peaks illustrate the assignment of 
main absorption frequencies.  
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Appendix two: Antifungal disk diffusion assay results 
 
 
 
Figure 3.36: DDA for 1-naphthoic amide 99a at a concentration of 2 mg mL
-1
 against 
T. harzarium T1.  The compound has no inhibition growth effect at the tested 
concentration.  MeOH was used for control disk (c).  
 
 
 
 
Figure 3.37: DDA for 1-naphthoic amide 99a at a concentration of 2 mg mL
-1
 against 
R. solani. The compound has no inhibition growth effect at the tested concentration.  
MeOH was used for control disk (c). 
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Figure 3.38: DDA for 1-naphthoic amide 99a at a concentration of 2 mg mL
-1
 against 
F. oxysporum. The compound has no inhibition growth effect at the tested 
concentration.  MeOH was used for control disk (c). 
 
 
 
 
Figure 3.39: DDA for 1-naphthoic amide 99a at a concentration of 2 mg mL
-1
 against 
P. avenea. The compound has no inhibition growth effect at the tested concentration.  
MeOH was used for control disk (c). 
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Appendix three: Antibacterial disk diffusion assay results 
 
 
 
Figure 3.40: DDA for 1-naphthoic amide 99a at a concentration of 2 mg mL
-1
 against 
B. megaterium. The compound has no inhibition growth effect at the tested 
concentration.  MeOH was used for control disk (c). 
 
 
 
 
Figure 3.41: DDA for 1-naphthoic amide 99a at a concentration of 2 mg mL
-1
 against 
M. luteus. The compound has no inhibition growth effect at the tested concentration.  
MeOH was used for control disk (c). 
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Figure 3.42: DDA for 1-naphthoic amide 99a at a concentration of 2 mg mL
-1
 against 
E. coli. The compound has no inhibition growth effect at the tested concentration.  
MeOH was used for control disk (c). 
 
 
 
 
Figure 3.43: DDA for 1-naphthoic amide 99a at a concentration of 2 mg mL
-1
 against 
E. coli K1. The compound has no inhibition growth effect at the tested concentration.  
MeOH was used for control disk (c). 
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Figure 3.44: DDA for 1-naphthoic amide 99a at a concentration of 2 mg mL
-1
 against 
E. coli K12. The compound has no inhibition growth effect at the tested 
concentration.  MeOH was used for control disk (c). 
 
 
 
Figure 3.45: DDA for 1-naphthoic amide 99a at a concentration of 1 mg mL
-1
 against 
S. epidermis. The compound has no inhibition growth effect at the tested 
concentration.  MeOH was used for control disk (c). 
 
 
 
Figure 3.46: DDA for 1-naphthoic amide 99a at a concentration of 2 mg mL
-1
 against 
B. subtilis. The compound has no inhibition growth effect at the tested concentration.  
MeOH was used for control disk (c). 
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Figure 3.47: DDA for 1-naphthoic amide 99a at a concentration of 2 mg mL
-1
 against 
P. diminitus. The compound has no inhibition growth effect at the tested 
concentration.  MeOH was used for control disk (c). 
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Appendix four: Spot culture growth inhibition assay results 
 
The labelling followed for Figures 3.48-3.55: 
  
Top wells from right to left: MeOH control, 0.4 and 4 µg mL
1
 of 1-naphthoic acid 
respectively.  Bottom wells from right to left: MeOH control, 0.4 and 4 µg mL
1
 of 4-
fluoro-1-naphthoic acid respectively.  
 
 
 
Figure 3.48: SCGIA for 1-naphthoic amide 99a and 4-fluoro-1-naphthoic amide 100a 
against P. diminitus.  
 
 
 
Figure 3.49: SCGIA for 1-naphthoic amide 99a and 4-fluoro-1-naphthoic amide 100a 
against S. epidermis.  
 
 
 
Figure 3.50: SCGIA for 1-naphthoic amide 99a and 4-fluoro-1-naphthoic amide 100a 
against M. luteus.  
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Figure 3.51: SCGIA for 1-naphthoic amide 99a and 4-fluoro-1-naphthoic amide 100a 
against B. megaterium.  
 
 
 
Figure 3.52: SCGIA for 1-naphthoic amide 99a and 4-fluoro-1-naphthoic amide 100a 
against E. coli.  
 
 
 
Figure 3.53: SCGIA for 1-naphthoic amide 99a and 4-fluoro-1-naphthoic amide 100a 
against E. coli K1. 
 
 
  
274 
 
 
 
Figure 3.54: SCGIA for 1-naphthoic amide 99a and 4-fluoro-1-naphthoic amide 100a 
against E. coli K12. 
 
 
 
Figure 3.55: SCGIA for 1-naphthoic amide 99a and 4-fluoro-1-naphthoic amide 100a 
against B. subtilis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
